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Abstract 
 
Merkel cell carcinoma (MCC) is a highly aggressive skin cancer of neuroendocrine 
origin with a high propensity for metastasis through the dermal lymphatic system.  
In 2008, Merkel cell polyomavirus (MCPyV) was discovered monoclonally integrated 
within the host genome of more than 80% of MCC tumours.  MCPyV is known to 
contribute to the transformation and maintenance of MCC tumour cells through 
the expression of the Large and Small Tumour (LT and ST) antigens.  To date, a 
number of mechanisms by which MCPyV T antigen expression promotes cell 
transformation and viral replication have been elucidated.  Although, no studies 
have addressed the molecular mechanisms associated with MCPyV T antigen 
expression and the highly aggressive, metastatic nature of MCC. 
Herein, a quantitative proteomic approach has been used to identify cellular 
proteins and gene ontology pathways that are differentially expressed upon MCPyV 
ST expression.  This highlighted that MCPyV ST expression promotes the 
upregulation of cellular proteins involved in microtubule-associated cytoskeletal 
organisation and dynamics. 
Further analysis, has demonstrated that MCPyV ST promotes cell motility, migration 
and invasion and that MCPyV ST-induced microtubule destabilisation is 
fundamental for this phenotype.  Bioinformatical analysis highlighted the 
upregulation of stathmin, a microtubule destabilising protein, which is required for 
MCPyV ST-induced cell motility.  Furthermore, through protein interaction studies 
and cell motility assays, the cellular phosphatase catalytic subunit PP4C has been 
implicated in the regulation of this process.   
Herein, these findings present the first study into the metastatic nature of MCC and 
the underlying mechanisms by which MCPyV T antigen expression can promote cell 
migration.  This in turn should allow for enhanced therapeutic studies and 
chemotherapy regimes, in order to improve current treatments of MCC.   
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1.1 Viruses and Cancer 
 
Worldwide cancer deaths account for 13% of deaths worldwide1,2 and is a major 
public health concern, both in terms of logistics and medical treatment.  More 
people die from cancer each year than AIDs, tuberculosis and malaria combined 
and it is likely the death toll will remain high, due to inadequate diagnosis and 
treatment in developing countries. In the developed world cancer accounts for 20% 
of all deaths and is the highest cause of death after cardiovascular disease.  In the 
United Kingdom alone, 2 million people live with cancer and this number is set to 
increase by 3.2% each year2. 
In the second half of the 20th century it became increasingly apparent that viral 
infection played a significant role in cancer formation and maintenance.  In 1911, 
Peyton Rous discovered the first tumour virus, Rous sarcoma virus (RSV) which 
causes tumours in chickens3.  From here intensive research began and in the 
subsequent years multiple mammalian tumour viruses were identified, including 
murine polyomavirus (MPyV) and simian vacuolating virus 40 (SV40)4-6.  Through 
intensive research it has been shown that most cancer associated viruses express 
specific oncoproteins which facilitate cell growth, proliferation and transformation 
of the host cell.   
The International Agency on Cancer has estimated that 20% of cancer cases 
worldwide are caused by chronic infections7.  The known human tumour associated 
viruses include Human papilloma virus (HPV), Hepatitis B virus (HBV), Hepatitis C 
virus (HCV), Human T-lymphotrophic virus (HTLV-1), Kaposi’s sarcoma associated 
herpes virus (KSHV), Merkel cell polyomavirus (MCPyV) and Epstein-Barr virus 
(EBV).  These are believed to account for 10-15% of human viral-associated cancers 
(Table 1.1). 
In general, upon infection the host suffers little or no symptoms, but a percentage 
of those infected will later develop a cancer intrinsically linked to the initial 
infection.  Human tumour viruses have been widely studied and represent a wide 
range of different virus types from RNA viruses to retroviruses (Table 1.1), thus a 
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variety of different infectious routes, target sites and life cycles.  While the current 
estimate stands at 20%, other reports speculate that the percentage of cancers 
caused by virus involvement may be much higher at 30%8.  With the rapid 
progression of deep sequencing technologies it is likely that more oncogenic viruses 
will be discovered.  For example, these new sequencing technologies have allowed 
the discovery of nine new polyomaviruses in the last six years, although none have 
been implicated in cancer. 
 
Virus Family/Genome Examples of 
Oncoproteins 
Associated cancers 
Merkel Cell 
Polyomavirus (MCPyV) 
- 2008 
Polyomaviridae - 
dsDNA 
T antigens -
namely, LT and 
ST 
80-95% Merkel cell carcinoma 
cases 
Kaposi’s scarcoma 
associated herpesvirus 
(KSHV) - 1994 
Herpesviridae - 
dsDNA 
LANA, vflip, vBcl-
2 and others 
Kaposi’s sarcoma, primary 
effusion lymphoma and some 
multicentric Castleman’s 
disease 
Hepatitis C Virus (HCV) 
- 1989 
Hepaciviridae - 
(+)ssRNA 
NS5A Some hepatocellular 
carcinomas and lymphomas 
Human 
papillomaviruses (HPV) 
16 and 17 - 1983 and 
1984 
Papillomaviridae - 
dsDNA 
E5, E6, E7 Cervical cancer and most 
penile cancers 
Human T-
lymphotrophic virus-1 
(HTLV-1) - 1980 
Retroviridae - ssRNA Tax Adult T cell lymphoma 
Hepatitis B Virus (HBV) 
- 1965 
Hepadnaviridae - 
ssDNA and dsDNA 
HBx Some hepatocellular 
carcinomas 
Epstein-Barr Virus 
(EBV) - 1964 
Herpesviridae - 
dsDNA 
LMP1 Burkitt’s lymphoma, 
nasopharyngeal carcinoma, 
most lymphoproliferative 
disorders 
 
Table 1.1.  Human tumour viruses. A list showing the 7 known human tumour viruses, date of 
discovery, virus family, genome structure and the viral-associated cancer.   
 
1.2 Polyomaviruses 
 
The polyomaviridae family are composed of non-enveloped, small double stranded 
DNA viruses with icosahedral capsids capable of infecting multiple different species 
including humans, birds, primates and rodents9,10.  While the number of possible 
species susceptible to polyomavirus infection is high, the host range for each 
specific polyomavirus in highly restricted and productive viral infections do not 
occur in non-native hosts11.   
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In the late 1950s and early 1960s, the first polyomaviruses were identified.  In 1958 
the murine polyomavirus (MPyV) was shown to induce tumours in newborn mice12.  
A further two years later in 1960, the simian vacuolating virus 40 (SV40) was 
isolated as a contaminant in Salk’s inactivated poliovirus vaccine, however its 
natural host is the rhesus macaque13,14.  These two polyomaviruses have been 
excellent models to study viral-induced cancers, oncogenic processes and have 
highlighted fundamental cell biology processes12.   
 
1.2.1         Human polyomaviruses 
1.2.1.1      JCPyV and BKPyV   
Despite the identification of polyomaviruses in the late 1950s, human 
polyomaviruses were first identified in 1971.  JC polyomavirus (JCPyV) was isolated 
in 1971 from a patients’ brain tissue who was suffering from the CNS demyelinating 
disease, progressive multifocal leukoencephalopathy (PML)15.  JCPyV is now 
established as the causative agent in PML and is thought to be a common infection 
contracted during childhood and early adolescence with a seroprvalence of 70-90% 
in the adult population16,17.  The virus is prevalent in urban sewage systems 
suggesting that the virus is contracted and spread through the faecal-oral route18.  
The initial site of infection is in the tonsils, followed by spread and replication 
within lymphoid cells and then infection in the gastrointestinal tract and kidneys, 
where it establishes a latent infection19-21.  PML mainly occurs in patients with 
compromised immune systems, such as AIDS and transplant patients, under these 
conditions virus reactivation can occur and lytic infection is established in 
oligodendrocytes, resulting in focus formation and demyelinated areas, symptoms 
of PML22.   
Besides its role in PML, JCPyV has also been shown to induce human and rodent cell 
transformation in vitro and in animal models23.  However, this phenotype has only 
been demonstrated in neural cells, which are non-permissive for JCPyV infection.  
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Glial cell specific regulation of JCPyV large T (LT) antigen expression results in higher 
T antigen protein levels which facilitates transformation23.  Similar to SV40, JCPyV 
DNA has been detected in paediatric medulloblastomas24, however there is no 
conclusive evidence linking JCPyV infection with human tumours. 
BK polyomavirus (BKPyV) was also identified in 1971 from a urine sample of a 
kidney allograft patient presenting with chronic pyelonephritis and advanced renal 
failure25.  Both JCPyV and BKPyV share 75% sequence identity and have similar 
infection routes21.   
Similar to JCPyV, BKPyV is an asymptomatic ubiquitous infection among the adult 
population with a seroprevalence of approximately 80%, however under immune 
suppression BKPyV can reactivate and enter a lytic replication cycle26.  In the case of 
kidney transplantations, lytic BKPyV infection can result in polyomavirus-associated 
nephropathy (PVAN) and is the highest cause of graft loss at 10%27.  Similar to 
JCPyV, BKPyV is capable of inducing transformation in vitro and in animal models28.  
However, no data has indicated a causal role of BKPyV in human tumour 
formation29.   
 
 
1.2.1.2     Other human polyomaviruses 
Since the discovery of JCPyV and BKPyV in 1971, a renaissance in human 
polyomavirus research began in 2007, and is a direct result of new genomic 
amplification technologies, such as digital transcriptome subtraction and rolling 
circle amplification.   In the past eight years 12 further human polyomaviruses have 
been identified, as described below. 
KIPyV and WUPyV were identified from respiratory tract samples and are present in 
approximately 1-10% of nasopharyngeal aspirates30-32, however they have not been 
associated with any disease pathology33.  Furthermore, neither KIPyV or WUPyV 
seem to follow the route of infection and viral life cycle typical of JCPyV and BKPyV, 
as the viruses have not been identified from either urine or blood samples30,31.   
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The fifth human polyomavirus, Merkel cell polyomavirus (MCPyV), discovered in 
2008 will be discussed in Section 1.4.  Following this in 2010, two human 
polyomaviruses (HPyV) were isolated from human skin: HPyV6 and HPyV7, but 
show no clinical symptoms34.  Later in 2012, trichodysplasia spinulosa-associated 
polyomavirus (TSPyV) was isolated from the inner root sheath cells of hair 
follicles35.  Lytic reactivation in immune-compromised individuals result in a rare 
skin disease called Trichodysplasia Spinuloas (TS).  Following this a novel human 
polyomavirus (HPyV9) was isolated from kidney transplant patients36.  In 2012, the 
tenth HPyV was isolated from healthy stool samples and termed Malawi 
polyomavirus (MWPyV)37, followed by identification of HPyV10 from a patient 
presenting with warts, hypogammaglobulinemia, infections and myelokathexis 
(WHIM) syndrome38.   
Also identified in 2012, from acute diarrheal samples of children, was the MX 
polyomavirus (MXPyV)39.  This was followed by two further discoveries in 2013, 
starting with HPyV12 which was isolated from resected liver samples and infects 
between 10-20% of the population40, and by STLPyV isolated from human faeces41.  
The role of human polyomaviruses in disease is now under intense investigation, as 
it is clear that they are important in human pathology, as viral reactivation under 
specific circumstances can be associated with pathology. 
 
1.2.2     SV40 – The polyomavirus model 
The natural host for permissive SV40 infection is the rhesus macaque and the 
resulting infection is generally asymptomatic. However in immune-compromised 
hosts a demyelinating disease can occur, similar to the human condition PML42-44.  
Furthermore, infection in non-permissive hosts, such as rodents, can cause 
transformation of host cells leading to tumour establishment and growth. 
The ability of SV40 to replicate in human cells in vitro is low and both SV40 and 
MPyV infection can result in transformation of the host cells12.  In the years since 
the discovery of SV40, its tumour antigens (T antigens) have been widely studied for 
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their contribution to cellular transformation which is thought to only occur in      
non-permissive cells45-48.  Non-permissive cells are those that lack the correct 
cellular machinery required for viral-induced replication, thus expression of T 
antigens interferes with cellular signalling pathways resulting in increased cell 
proliferation and eventual transformation45,48.   
Between 1955 and 1963, the polio vaccination programme resulted in millions of 
people being exposed to SV40 and later on SV40 DNA has been detected in certain 
human cancers including mesotheliomas49.  However, despite extensive study the 
role of SV40 in human tumour formation remains inconclusive and to date SV40 
infection has not been conclusively associated with in vivo human tumour 
formation50,51.  However, there are a number of other human viruses that are 
capable of inducing cellular transformation, including the recently identified Merkel 
cell polyomavirus (MCPyV). 
 
1.2.2.1     Genetic Organisation 
The polyomavirus family are composed of a small non-enveloped virus with a 
circular double-stranded DNA genome of approximately 5.3 kilobase pairs (kbp).  
There are three distinct genomic regions: a non-coding control region (NCCR), an 
early and late coding region52.  The NCCR contains the viral bi-directional origin of 
replication and transcriptional control elements, while the early and late coding 
regions are encoded on opposite strands of the template DNA. 
Transcription of the early and late coding regions produces one primary transcript 
respectively, which undergoes differential splicing to produce multiple mRNA 
species for production of distinct proteins.  This is an evolutionary mechanism 
which maximises protein coding capacity due to the limited genomic size 
constraints.  The early region is transcribed in a clockwise fashion and generally 
encodes three T antigens, the large T antigen (LT), the small T antigen (ST) and the 
middle T antigen (MT). Other splice variants have also been observed, and are 
discussed in Section 1.2.4.8. 
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The late region is transcribed in a counter-clockwise direction and encodes three 
structural proteins required for viral capsid formation: VP1, VP2 and VP3.  
Interestingly, SV40, BKPyV and JCPyV encode an additional protein, VP4, termed 
agnoprotein which may function as a viroporin52-54.   
 
1.2.2.2    Viral life Cycle 
Using SV40 as a model, the life cycle of polyomaviruses has been well characterised 
from viral attachment and entry to viral replication and virion release.  Moreover, 
the life cycle of JCPyV has also been fairly well characterised and provides a good 
human model for polyomavirus infections, as other human polyomaviruses are 
poorly understood.  Figure 1.1 represents the main stages in the polyomavirus life 
cycle.   
To initially infect animal cells, viruses must first attach to specific receptor 
molecules on the cell surface, which are commonly proteins or carbohydrates, but 
in some cases lipid molecules. With SV40, initial viral infection is mediated by 
binding to sialic acids.  A crucial cell surface receptor required for initial attachment 
for SV40, is the ganglioside GM1, however SV40 can also infect most cell types by 
virion attachment to the major histocompatibility complex (MHC)55-57.  JCPyV has 
also demonstrated tropism for α2-6-linked sialic acids on cell membrane 
glycoproteins and glycolipids58.  The well characterised MPyV and the human 
polyomavirus BKPyV have also been shown to bind sialylated glycans, such as 
GT1B59-61. 
Endocytosis is the main mechanism by which polyomaviruses enter and are 
transported from the cell surface to the nucleus.  However various types of 
endocytosis mechanisms have been identified between different polyomavirus 
species.  SV40 virion entry is fully dependent on caveolin-mediated endocytosis, 
whereas JCPyV depends on a clathrin-dependent mechanism62,63.  Following entry 
into the cells, the virus must be transported to the nucleus in order to replicate its 
DNA.  Recent evidence has demonstrated that JCPyV VP1, the structural capsid 
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protein, contains a nuclear localisation signal (NLS), allowing binding of cellular 
importins and entry into the nucleus via the nuclear pore complex (NPC)64.   
Once the virion has entered the nucleus by one of these mechanisms, the viral DNA 
is uncoated from the capsid and viral DNA transcription begins. SV40 LT 
transactivates the early promoter region and LT is capable of promoting viral DNA 
replication by directly binding the viral origin of replication within the NCCR65.  Viral 
DNA synthesis in polyomaviruses depends on the host cell machinery, enzymes and 
co-factors expressed during S-phase, this is crucial to the viral life cycle, hence both 
ST and LT modify specific signalling pathways to promote entry into S-phase.  
Furthermore, once LT protein levels reach a certain concentration, LT acts to inhibit 
early viral promoter activity and alternatively binds the late viral promoter to drive 
production of structural proteins required for virion assembly66,67.  Upon synthesis 
of the structural proteins these are then imported back to the nucleus where virion 
assembly begins.  Assembled virions are most commonly released from the cell 
through cell lysis, although other modes of escape have been documented, such as 
cell membrane fusion exocytosis48.   
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Figure 1.1.  Polyomavirus life cycle.  A schematic representing the major steps during lytic SV40 
infection including, viral attachment, entry, transport to the nucleus, gene transcription and 
translation and virion assembly. 
 
 
1.2.2.3     Genome integration 
A fairly common phenomena during polyomavirus infection in non-permissive cell 
lines is the integration of the viral genome into the host chromosomal DNA. This 
has been demonstrated for MPyV, SV40, JCPyV and BKPyV with up to six copies of 
the viral genome being integrated into one host cell68-70.  Interestingly, the pattern 
of integration seems to occur at random sites within the host genome, and has 
recently been confirmed using MCPyV as a model, where integration was seen to 
be random but localised in fragile sites within the host genome71-73.  While Martel-
Jantin and colleagues concluded that integration occurred at random sites in 
MCPyV, they also identified specific cellular genes involved in carcinogenesis, at the 
site of integration72. These included X-ray defective repair in Chinese hamster cells 
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4 (XRCC4) and phospholipase A2, group IVA (9PLA2G4A), indicating that these 
genes may play a role in MCC pathology, and warrant further study. 
 
With regards to the viral integration junction, no specific patterns have been 
demonstrated however in MCPyV this seems to be located within the LT antigen, 
and in all samples, occurs after the pRB binding domain72.  It is thought that 
integration may result in MCPyV LT tumour specific truncations, removing the 
helicase binding domain, thus inhibiting viral replication and in turn facilitating 
transformation71,74,75. Literature regarding the mechanism of polyomavirus 
integration is sparse, although it has been suggested that integration occurs by a 
double-crossing over event, or homologous recombination event76. 
 
1.2.2.4     Polyomavirus early proteins 
All polyomaviruses encode the regulatory LT and ST antigens, which are transacting 
factors required for viral replication.  It has also been demonstrated that the T 
antigens are oncogenic proteins with the ability to transform cells in vitro and in 
mouse models77,78.   
The central polyomavirus dogma concludes that LT is the more oncogenic, with ST 
playing an accessory role, however there is also an emerging role for ST in 
transformation.  Currently, most human polyomaviruses are discussed in terms of 
the known functions of other better characterised polyomaviruses, such as SV40 
and MPyV.  Polyomavirus regulatory proteins are crucial for viral DNA replication 
and stimulate quiescent host cells into S phase52,79.  This ensures the virus has all 
the necessary host cell machinery required to synthesise its DNA, as 
polyomaviruses themselves do not encode the required replicative proteins to 
synthesise their own DNA12.  This is the driving force behind polyomavirus-induced 
cellular transformation as early gene expression in non-permissive cells results in 
aberrant cell cycle stimulation and interference with host cell signalling pathways48.   
There exists a high degree of sequence homology between the regulatory proteins 
of HPyV and other polyomaviruses (PyV).  Differential splicing of the early transcript 
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allows for the production of both LT and ST, both of which share a common region 
(first 80-82 residues of the N-terminal), and a unique region at the C-terminal52.   
 
1.2.2.4.1       Small T antigen 
1.2.2.4.1.1   Structure and domains 
 
The coding region of ST is approximately 500 base pairs (bp) in length and codes for 
a 17 kDa protein of approximately 170 amino acids in length.  ST localises to the 
nucleus and cytoplasm and is highly conserved across PyV species, with JCPyV 
sharing 96% sequence homology with BKPyV ST and 79% identity with SV40 ST52.   
The common region, termed the J domain is present at the N-terminus of all T 
antigens and is thought to have similar functions within host cells.  The J domain 
contains a conserved Cr1 domain and a conserved DnaJ (HPDKGG) binding domain 
for the cellular heat shock protein, Hsc70, which acts as a chaperone protein to 
prevent protein aggregation during viral invasion and stress23,80, as shown in Figure 
1.2.   
 
Figure 1.2. Diagrammatic representation of the polyomavirus ST antigen.  The common J domain 
(residues 1-90) contains conserved DnaJ and Cr1 motifs.  The unique region contains a binding 
domain for PP2A and two cysteine rich motifs for Zinc binding. 
The latter portion of ST, is distinct from MT and LT and is referred to as the unique 
region. While the N-terminal region shows a high degree of sequence homology 
across the polyomavirus family, the C-terminal region is more divergent23. This may 
enable species and tissue specific tropism of each polyomavirus and may influence 
viral replication and tissue specific transformation.   
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The unique region of the SV40 ST antigen contains a conserved motif (CxxP/CxC) at 
97-103 residues which is required for binding protein phosphatase 2A (PP2A), the 
major serine/threonine phosphatase in mammalian cells81,82.  A consensus among 
polyomavirus literature maintains that the main functional roles of ST within the 
host cell are PP2A-dependent and through this interaction ST aids viral replication 
and cellular transformation. 
 
 1.2.2.4.1.2    ST interacts with PP2A 
 
PP2A is a family of serine/threonine phosphatases that are widely expressed 
throughout the cell and are highly conserved among species46.  PP2A is a 
heterotrimeric holoenzyme, composed of three subunits with varying functional 
roles.  Subunit A (approximately 65 kDa) functions as a scaffold protein and its        
C-terminus binds Subunit C (approximately 32 kDa), which acts as the catalytically 
active phosphatase and together they form the core heterodimer83. 
Subunit B provides the regulatory specificity of this complex and binding results in 
the predominant cellular form of PP2A as a heterotrimeric complex.  Binding occurs 
through the Subunit B N-terminus which directly binds Subunit A84,85.  There are 
numerous B subunits all with variability within the N-terminal region, allowing for 
distinct substrate specificity81.   
Due to this diverse range of possible substrates, PP2A is an important regulator of 
multiple downstream signalling pathways and can affect signal transduction, 
apoptosis, cell cycle regulation and proteolysis pathways86. De-regulation of this 
system has been associated with multiple disorders and cancer types, and is a 
critical cellular regulator through which ST can interact, as shown in Figure 1.3. 
The PP2A A subunit is present as two isoforms within the cell, namely alpha (α) and 
beta (β), however SV40 ST has only been shown to interact with the Aα subunit not 
Aβ87.  Crystallisation studies have determined that the SV40 ST J domain and the 
unique region are important for ST binding to PP2A87.  Both SV40 and JCPyV ST have 
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been shown to directly bind the A subunit and via this interaction ST is able to make 
contact with the C subunit88-90.   
 
 
Figure 1.3.  Polyomavirus ST antigen binds and affects the inherent functions of PP2A.  ST acts as a 
competitive inhibitor for the B subunit binding site on the A subunit of PP2A. The A subunit is 
present as two isoforms with ST binding only the Aα subunit.  The J domain of ST is required for 
binding PP2A A subunit and this can alter the specificity and/or inhibit PP2A activity.  This can affect 
cell signalling pathways and promote cell proliferation and transformation.  
 
Ruediger et al demonstrated that the SV40 ST-PP2A binding site responsible for 
binding subunit A, does so in a manner that overlaps the B subunit binding site91.  
This is important as ST can therefore act as a competitive inhibitor and compete 
with B subunits for A subunit binding. SV40 ST has been shown to inhibit the activity 
of PP2A both in vitro and in vivo and prevent binding of multiple different 
substrates to PP2A78,88,92. 
Using this information, there are two distinct theories to explain how downstream 
pathways are regulated by the PP2A complex upon subversion by the ST antigen.  
Firstly, ST may function as a negative inhibitor of the PP2A complex and 
competitively replace the B subunit, thereby inhibiting dephosphorylation of 
specific downstream cellular targets.  Secondly, ST could act in a positive manner, 
whereby ST facilitates the selection of specific substrates and may redirect PP2A 
activity towards different cellular targets.  Interestingly, ST has been shown to act 
by both mechanisms. SV40 ST can increase PP2A-mediated histone H1 
dephosphorylation and at the same time inhibit dephosphorylation of substrates, 
such as relA88.  Through this interaction, ST is capable of affecting a wide range of 
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cellular signalling pathways which could aid in viral replication or in non-permissive 
cells may induce transformation. 
 
1.2.2.4.1.3   The role of ST in the viral life cycle 
 
There is substantial evidence to conclude that the polyomavirus LT is important for 
viral DNA replication, however emerging data indicates that ST is also required for 
this function. Both MCPyV and SV40 ST have trans-acting regulatory functions in 
vitro on promoters transcribed by RNA polymerase II and III93,94, and while ST is not 
essential for viral DNA replication, it is capable of enhancing LT-mediated DNA 
replication.  This is supported by mutational studies rendering SV40 ST defective 
which results in diminished viral growth in vitro compared to wild type95.  
Moreover, expression of SV40 ST increases early viral promoter activity and 
enhances LT-mediated late promoter activity65,96.  Although ST is not essential for 
LT-mediated viral replication, it is clear that ST plays a significant role in the viral life 
cycle and in the efficiency of viral DNA replication.   
The J domain contains specific residues required for binding to Hsc70, which is 
important for the correct and timely folding and transport of cellular proteins97.  
Hsc70 acts through its inherent ATPase activity and binding of the J domain results 
in ST acting as a chaperone97.  Interestingly, studies involving chimeric constructs 
have demonstrated that the SV40 ST J domain is crucial for ST-mediated 
enhancement of viral replication98.  However, studies have not yet concluded 
whether this is a direct result of ST binding Hsc70 or possible uncharacterised 
indirect effects of the J domain within the host cell.   
One of the major functional roles of ST involves the interaction with PP2A, as 
mentioned previously. The ST-PP2A interaction is thought to contribute to virus 
replication in an indirect manner through disrupting the cell cycle and driving cells 
into S-phase, thus allowing recruitment of the host cell machinery required for virus 
DNA replication99.  Furthermore, MPyV ST has been implicated in promoting 
progression of the cell cycle by activating the MAP kinase cascade in a               
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PP2A-dependent manner82.  Phosphorylation of serine/threonine kinases, such as 
ERK and MEK, within this signalling cascade result in increased binding of 
transcription factors, such as AP-1, which stimulate the transition from G1 to           
S-phase82. 
In addition, ST has been shown to affect cell cycle progression through decreasing 
cellular levels of p27/kipI23.  Cyclin dependent kinases (cdk) inhibitors are key 
components regulating cell cycle progression, and increased levels of one such 
inhibitor - p27/kipI – prevent efficient complex formation between cyclin 
dependent kinase 4 (CDK4) and its substrate pRB resulting in pRB-mediated cell 
cycle arrest100,101.  While the mechanism by which ST mediates this decrease is 
unknown, it is possible that the ST-PP2A interaction could result in a decrease in 
dephosphorylation of cyclin E/cdk2 which regulates p27/kipI, thereby stimulating 
cell cycle progression.  ST expression also upregulates other cell cycle progression 
factors including cyclin D1 and B and thymidine kinase102, indicating other possible 
mechanisms of ST-mediated cell cycle progression.  
 
1.2.2.4.1.4    The Role of ST in transformation 
 
Several studies have demonstrated that LT and ST J domain deletions inhibit T             
antigen-mediated transformation23.  Therefore, it is conceivable that the J domain, 
through its functions in promoting S-phase entry, may promote both replication in 
permissive cells and transformation in non-permissive cells.  In addition, the J 
domain contains a conserved Cr1 domain which functions in a similar manner to 
that of the adenovirus E1A protein which binds p300, the cellular transcriptional  
co-factor103,104, both of which have been shown to induce cellular transformation89.    
As previously discussed, the ST-PP2A interaction is essential for stimulating cell 
entry into S-phase, thereby promoting viral replication in permissive cells.  
However, in non-permissive cells, aberrant stimulation and entry into S-phase can 
result in cellular transformation.  Both SV40 ST and LT are required for cellular 
transformation in rodent cells, although ST is only required when LT expression is 
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low96.  However, in human cells full transformation requires expression of both 
SV40 T antigens in combination with oncogenic ras and hTERT, whose expression is 
dependent of ST78.  Hahn et al also demonstrated that using SV40 ST as a model, ST 
is essential for cell cycle progression, anchorage independent growth and 
transformation.78 
 
The ST-PP2A interaction has been shown to play a role in cellular transformation 
and can affect the levels of transcription factors within the host cell.  C-myc is an 
important transcription factor and is activated by phosphorylation which promotes 
binding to more than 15% of human gene promoters and enhancer sequences105.  
The ST-PP2A interaction inhibits dephosphorylation of C-myc and promotes C-myc 
stabilisation106, thereby altering cell proliferation, growth and apoptosis signalling 
and can directly induce cell transformation90.  ST also activates other cellular 
transcription factors, such as AP-1, Sp1, CREB and NF-KB, all important in cell 
proliferation and growth and all have been implicated in tumourigensis52,107-109.   
Furthermore, SV40 ST has been shown to induce aberrant activation of the  
phosphatidylinositol 3-kinase (PI3K) pathway, which is implicated in tumourigenesis 
in multiple human cancers and results in phosphorylation of cellular targets, such as 
Akt110.  Akt is a serine/threonine kinase important in cell survival, metabolism and 
angiogenesis, and inhibition of PI3K activity can inhibit ST-mediated 
transformation82. 
Interestingly, the ST-PP2A interaction has also been implicated in promoting cell 
immortalisation, both in vitro and in vivo111.  It has been demonstrated that 
telomerase is upregulated upon SV40 ST expression112 and it has been suggested 
that inhibition of Akt desphosphorylation, at conserved Akt phosphorylation 
sites113, may promote an increase in telomerase phosphorylation and activity. 
Furthermore, upregulation of Bub1 (a mitotic spindle checkpoint protein) is thought 
to lead to aneuploidy within the host chromosomes, and this has been 
demonstrated in MCC tumour cells114. The SV40 ST-PP2A interaction has been 
implicated in hyperphosphorylation of Bub1 through activation of the MAP kinase 
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signalling pathway, and has previously shown to induce tumourigenesis and 
aneuploidy in transgenic mice52,115.   
 
1.2.2.4.2       Large T antigen 
1.2.2.4.2.1    Structure and domains 
 
Transcription and alternative splicing of the polyomavirus early gene transcript 
results in production of a protein of approximately 700 amino acids in length 
referred to as LT.  LT contains the common J domain at its N-terminal and a unique 
C-terminal region (Figure 1.4).  The J domain contains the characteristic protein 
binding domain for Hsc70 and the conserved Cr1 domain.  However, within its 
unique region the LT protein contains multiple distinct protein binding domains, 
such as the LxCxE motif required for binding pRB116.  Furthermore, LT contains a 
DNA binding domain within the mid-region of the protein (~350-450) and a             
C-terminal bipartite region (~530-630), which facilitates an interaction between LT 
and the tumour suppressor protein p53117,118.  LT also contains a nuclear 
localisation signal which is required for localisation to the nucleus in mammalian 
cells119.   
 
Figure 1.4  Diagrammatic representation of the polyomavirus LT antigen.  Taken from 
23
.  The 
common J domains contains the DnaJ and Cr1 motifs (residues 1-90).  The unique region contains 
binding domains for pRB, and p53.   
 
1.2.2.4.2.2    The Role of LT in the viral life cycle 
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Similar to ST, the LT antigen promotes cell cycle dysregulation by driving the host 
cell into S-phase and is thought to be the major T antigen responsible for this 
function52.  This is aided by the LT helicase and ATPase activity which promotes DNA 
unwinding, along with specific domains required for binding cellular replication 
proteins, such as DNA polymerase-α, replication protein A, topoisomerase I and 
nucleolin48,120-122.   
 
1.2.2.4.2.2.1    DNA binding capabilities 
 
SV40 LT acts as an essential factor in early viral DNA replication and binds to the 
viral origin of replication, through its DNA binding domain thus promoting double 
helix unwinding and recruitment of DNA replication machinary121,122.  SV40 and 
JCPyV LT  also facilitate DNA transcription and recuit cellular component to both the 
early and later promoter regions.  Late promoter activity requires suppressing early 
gene transcription through an origin binding dependent mechanism67,123,124.   
 
1.2.2.4.2.2.2    Recruitment of cellular proteins 
 
As discussed previously, the ability of LT to stimulate viral DNA replication depends 
upon the recruitment of cellular proteins required for efficient viral replication 
complex formation at the viral origin (ori).  The NCCR contains the viral ori, 
promoter and enhancer sequences and the TATA box, this facilitates recruitment of 
cellular proteins required for transcription, such as RNA polymerase II and various 
other cellular transcription proteins122.  During lytic infection, transcription of the 
early and later regions is temporally regulated.  Transcription of the early regions 
results in the production of LT and ST, which stimulate the cell to enter S phase, 
thus facilitating viral DNA synthesis and replication of the viral genome, required for 
progeny virion formation.   
Initiation of viral replication occurs within the ori, and proceeds bidirectionally until 
the two replication forks terminate at approximately 180 degrees from the ori.  
Both the J domain and the ATPase domain of SV40 LT are necessary for direct 
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binding of LT to the catalytic subunit of DNA polymerase-α in vitro125.  Furthermore, 
SV40 LT is capable of binding the cellular replication protein A which enables the 
activity of DNA polymerase and stimulates replication of the viral genome126.   
The DNA helicase activity of SV40 LT is required for efficient viral DNA replication as 
the circular double stranded DNA helix must first be unwound to allow replication 
fork formation127. Through this activity SV40 LT recruits nucleolin and 
topoisomerase I to form components of the holoenzyme required for DNA 
unwinding127.   
 
1.2.2.4.2.3       The Role of LT in transformation  
LT alone is sufficient to induce transformation of rat fibroblast cells and is thought 
to be a result of LT binding to the tumour suppressor proteins, p53 and pRB48,128,129.  
Despite this, mutations within LT (that do not affect its ability to bind either pRB or 
p53) can inhibit LT-mediated transformation, demonstrating that other LT functions 
must contribute to tumourigenesis130.  An alternative explanation may be due to 
ability of BKPyV and SV40 LT to induce mutagenic effects in the host DNA by more 
than 100 fold, through SV40 LT binding to Mre11, a double stranded break 
response component48,52. 
 
1.2.2.4.2.3.1    Binding pRB 
 
All polyomaviruses studied to date contain a highly conserved LxCxE motif within 
LT, required for binding the cellular tumour suppressor protein pRB.  Importantly, 
LT binding mutants defective for pRB binding are all incapable of inducing cellular 
transformation48,116,131-133.   
In phenotypically normal cells, binding and sequestration of E2F transcription factor 
proteins inhibit expression of E2F responsive genes, such as C-fos and C-myc134,135.  
Phosphorylation of pRB allows the release of E2F, thus progression from G1 to S-
phase136,137.  SV40 LT binds and sequesters pRB and pRB family proteins, such as 
p130 and p107, and inhibits binding to E2F, allowing transcription of E2F responsive 
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genes and progression to S-phase52,132.  In addition, SV40 and BKPyV LT can also 
downregulate the expression of pRB proteins by promoting proteolysis of p130 and 
other pRB family members in mouse fibroblast cells138.  Furthermore, evidence 
suggests that the Hsc70 binding domain has cis-acting activities that aid in 
dissociation of pRB-E2F in an ATPase dependent manner139.  This suggests that LT 
has a redundancy mechanism by which to subvert the pRB signalling pathways in 
order to promote S-phase entry. 
 
1.2.2.4.2.3.2     Binding p53 
 
Aberrant p53 regulation is the most common feature of human cancers, due to its 
crucial role as a regulator of the cell cycle, apoptosis and DNA damage repair140.  
JCPyV, BKPyV and SV40 LT all bind p53, a mechanism dependent on two ATPase 
domains within the C-terminal region117,132.  Polyomavirus regulation of p53 is 
required as inhibition of pRB activity by LT binding results in the transcription of E2F 
responsive genes and activates p14ARF, whose downstream effect results in 
activation of p53 and transcription of p53-regulated genes 141.  This would result in 
cell growth arrest and apoptosis, however LT binding renders p53 transcriptionally 
inactive, as p53 can no longer access promoters142,143.  LT expression alone is 
sufficient to downregulate the expression of p53 responsive genes which allows 
viral replication to proceed in permissive cells but in non-permissive cells can lead 
to transformation12,144.   
 
1.2.2.4.2.3.3     Binding Cullin 7 
 
More recently, studies have demonstrated that SV40 LT is able to interact with 
cullin7 (cul7), a core protein in the E3 ubiquitin ligase protein degradation 
complex145,146.  This interaction is able to prevent cell growth arrest in low serum 
conditions and deficiencies in anchorage dependent growth146.  The mechanism 
behind this phenotype is poorly understood but demonstrates the importance of 
this interaction in tumourigenesis. 
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1.2.2.4.2.3.4     IRS I 
 
It has been demonstrated that polyomavirus LT expression results in inhibition of 
the homologous recombination-direct DNA repair (HRR) response147.  Both JCPyV 
and SV40 LT have been shown to induce translocation of insulin receptor substrate I 
(IRS I) to the nucleus, resulting in an interaction between IRS I and Rad51 (a DNA 
repair component), thus inhibiting HRR148-150.  Furthermore, the expression of a 
dominant negative IRS I mutant inhibits anchorage independent growth of JCPyV LT 
transformed cells149.  This demonstrates that there may be multiple mechanisms by 
which LT mediates anchorage independent growth of transformed cells.  
 
1.2.2.4.2.3.5      Binding β-catenin 
 
β-catenin is a crucial component of the Wnt signalling pathway, which is able to 
form complexes with transcription factors in order to activate transcription of 
specific target genes, such as C-myc and cyclin D1151,152.  Constitutive activation of 
the Wnt signalling pathway has been associated with tumour formation and 
progression in various cancer types69,153.  Several studies have demonstrated that 
LT can directly bind β-catenin, thereby increasing its stability and thus enhancing 
activation of its target genes.  This is another contributing mechanism by which LT 
can induce tumour formation151,152. 
 
1.2.2.4.2.3.6      Other transcription factors 
 
Studies have demonstrated that SV40 LT can alter the mRNA transcript levels of a 
number of transcription factor genes, such as AP-1, C-myc, TFIIC and Sp152.  These 
transcription factors regulate a wide range of gene families involved in cell 
proliferation, DNA repair, angiogenesis and apoptosis, as such SV40 LT regulation of 
transcription factors has wide ranging downstream effects on the mRNA levels of a 
wide range of effector proteins involved in these processes. 
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Furthermore, the transcription factor thyroid embryonic factor-1 (TEF-1) has been 
identified as a binding partner of SV40 LT, and through this interaction LT is able to 
inhibit TEF-1-mediated repression of the late viral promoter, thereby stimulating 
DNA replication154.  Interestingly, this may also play a role in transformation as LT 
mutants unable to bind TEF-1 showed reduced numbers of foci in transformation 
assays, implicating TEF-1 inhibition in viral induced transformation155.  
 
1.2.2.4.3       Middle T antigen 
 
1.2.2.4.3.1   Structure and domains 
 
Alternative splicing of rodent polyomavirus primary early transcript results in 
production of a 421 residue protein with a molecular weight of 55 kDa, known as 
the middle T (MT) antigen156.  MT is very similar in structure to ST and is composed 
of all but the final 4 C-terminal amino acids from ST, thus sharing the J domain and 
PP2A binding domains (Figure 1.5).  The remaining 230 amino acids at the                
C-terminal portion of MT are unique and contain multiple phosphorylation sites 
which are crucial for the ability of MT to recruit or activate specific cellular 
components156. 
 
Chapter 1 
24 
  
 
Figure 1.5.  Diagrammatic representation of the polyomavirus MT antigen.  MT shares the N-
terminal region with ST and contains the J domain and PP2A binding site, along with a Src binding 
domain.  The unique region contains multiple phosphorylation sites and a transmembrane binding 
domain.   
 
MT is able to span the lipid bi-layer through its long hydrophobic region within its                  
C-terminus, and the inherent functions associated with MT expression are a result of its 
association with the cellular membrane157,158.   
 
1.2.2.4.3.2    The Role of MT in the viral life cycle 
 
Similar to ST and LT, the MPyV MT antigen can bind the viral origin of replication 
thereby regulating viral DNA replication.  It facilitates this through activation of the 
AP-1 transcription factors, Ets protein families and C-jun promoters159-163.  In 
addition, MT is pivotal for maturation of the viral capsid, as the absence of MT 
expression results in aberrant phosphorylation of VP1 which impedes viral capsid 
assembly164,165. 
Clearly MT is important in regulating cell cycle entry to enable efficient viral DNA 
replication, as such in non-permissive cells MT also contributes to tumourigenesis.  
It is interesting to note, that the transcripts encoding MT have not been identified 
in human specific polyomaviruses, such as MCPyV.  Thus human polyomavirus LT 
and ST may compensate for or encode alternative proteins, such as ALTO, that may 
function in a similar manner as MT, as discussed in Section 1.4.5.3.4. 
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1.2.2.4.3.3    The Role of MT in transformation  
 
In rodent polyomaviruses it has been shown that the MT is the major transforming 
protein and its expression alone is sufficient to induce transformation in cell 
culture158.  The C-terminal hydrophobic region is pivotal for viral-mediated 
transformation and deletion of a six amino acid C-terminal of this region fully 
ablates the ability of MT to induce transformation166-169.   It has also been 
demonstrated that both the N-terminal and C-terminal regions are pivotal for MT 
binding to cellular protein kinases, and while MT membrane binding is required for 
this activity it is not sufficient167.  
Interestingly, recent analysis has demonstrated that MT is important during the 
early stages of transformation. Initial expression of MT correlates with host cell 
morphological changes resulting in altered actin filament organisation168.  
Furthermore, perinuclear localisation of MT was consistent with condensation of 
tubular endosomes in the perinuclear region, thus this may contribute to the 
morphological changes seen during early transformation of host cells by SV40 T 
antgens168.   
 
1.2.2.4.3.3.1    Binding PP2A 
 
As mentioned previously, ST and MT share a large proportion of their coding 
sequence including the J domain and the PP2A binding motif.  To this end, MT is 
capable of binding PP2A in the same manner as described for ST170.  However, in 
contrast to ST, MT can bind both isoforms of PP2A (Aα and Aβ), although the 
functional significance of this has yet to be addressed.  Mutations in the PP2A Aβ 
isoform are associated with multiple cancers87,  hence there may be precedence for 
MT-mediated transformation through binding PP2A Aβ.  In addition, MT has been 
shown to activate tyrosine kinases and C-jun, similar to ST, through binding PP2A171. 
 
1.2.2.4.3.3.2      Src family sequestration 
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MT is able to associate and sequester Src family tyrosine kinases (TKs) at the cell 
membrane in a PP2A dependent manner172.  The N-terminal region (residues        
185-210) is responsible for binding TKs and mutations within this site abolish the 
interaction172,173.  Upon binding of MT to the TK proteins, MT is phosphorylated at 
specific tyrosine residues (250, 315 and 322), subsequently enhancing MT 
transforming capabilities174,175.   
 
1.2.2.4.4            Other alternative early proteins 
In addition to the three previously described T antigens, SV40 also produces an 
additional protein by alternative splicing of the early transcript, termed 17kT, 
composed of 131 amino acids (from the LT N-terminus) and an addition A-L-L-T at 
the C-terminus176.  The role of 17kT in the viral lifecycle is relatively unknown, 
however phosphorylation of 17kT can affect the inherent functions of SV40 LT52.  In 
addition, 17kT is capable of immortalising rat fibroblasts (when co-expressed with 
H-ras)176,177. 
JCPyV encodes three addition early proteins – T135, T136 and T165.  The first two are 
composed of the 132 amino acids at the N-terminus of LT and 3 or 4 additional 
amino acids at the C-terminus, respectively.  T165 contains the same N-terminus as 
its predecessor, but combines the last 32 amino acids from the C-terminus of 
LT177,178.  These alternative proteins are highly expressed during JCPyV lytic 
infection and are fundamental for viral DNA replication, as demonstrated by 
mutational studies which result in reduced viral replication in glial cells178. In terms 
of transformation, it has been suggested that they may act in a similar manner as 
MT, as co-expression of the T’ proteins and H-ras can induce immortalisation of rat 
embryo fibroblasts177,178. 
 
1.3            Merkel cell carcinoma 
 
1.3.1        Merkel cells 
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The Merkel-cell neurite complex, is one of the four main classes of mammalian 
sensory receptors and is an important complex for sensing light touch, shape, 
texture and curvature179.  As seen in Figure 1.5 this receptor complex consists of 
Merkel cells situated at the epidermal/dermal border and the afferent 
somatosensory fibers that stimulate them180.  Merkel-cell neurite complexes are 
located in touch sensitive regions of the skin, such as glabrous skin surfaces of the 
hands and feet, whisker follicles and touch domes (specialised epithelial structures 
in hairy skin)181.  Merkel cells are oval shaped and approximately 10-15 µm in 
diameter with spinous projections on the surface of the cells182.  The exact function 
and mechanism of action of Merkel cells is still undetermined, however evidence 
suggests that neuropeptides that accumulate near the nerve fibre junctions are 
required for synaptic transmission via voltage gated ion channels183.  Moreover, the 
use of histochemical markers indicate that Merkel cells may also act in a paracrine 
fashion183.   
Since the discovery of Merkel cells in 1875, there has been debate as to whether 
they are derived from the skin lineage or the neural crest180,181,184,185.  However in 
2009, using neural crest and epidermal Cre-driver lines which specially delete 
Atoh1, it was shown that deletion of the Atoh1 protein in the skin lineage resulted 
in complete loss of Merkel cells from all skin regions, while deletion from the neural 
crest lineage had no effect179, clearly indicating that Merkel cells arise from the skin 
lineage (Figure 1.6). 
Chapter 1 
28 
  
 
Figure 1.6.  Diagrammatic representation of the location of Merkel cells within the skin.  All skin 
layers shown, with Merkel cell neurite complex at the epidermal/dermal border with veins, arteries 
and lymph systems.   
 
 
1.3.2      Merkel cell carcinoma  
Merkel cell carcinoma (MCC) is a rare and highly metastatic neuro-endocrine 
tumour which originates from mammalian Merkel cells186 and has been classed as 
the most aggressive form of skin cancer due to its propensity to spread through the 
dermal lymphatic system187.   
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1.3.3     MCC histology and presentation 
 
MCC primary tumours present as small pink nodules which are less than 2 mm in 
diameter or as a mass which is more than 2 mm in diameter (Figure 1.7)188.  Primary 
MCC tumours can be located on any region of the body, however more than 90% 
appear on sun-exposed regions of the body such as the head and neck189. 
Historically, identification of MCC tumours has been particularly difficult and was 
often mistaken for small-cell carcinoma of the lung and Ewings sarcoma which 
present as visibly similar tumours190.  MCC tumours are visualised as a lesion of 
nested or stranded small round cells, with an oval/round nucleus, inconspicuous 
nuclei, dispersed granular chromatin and scanty cytoplasm, in a bed of vascular and 
infiltrating cells (Figure 1.7)191,192.  It is only recently that a robust detection system 
has been established; MCC cells display a specific arrangement of cytokeratin (CK) 
20 filaments and is a specific and highly sensitive MCC biomarker which can clearly 
distinguish MCC from other tumours193. 
It has been shown that most MCC tumours are CK20 positive and CK7 negative, 
however a few CK20 negative and CK7 positive MCC tumours have been 
characterised194.  Other MCC neuro-endocrine biomarkers include chromatogranin 
and somatostatin along with neuron-specific enolase191,195.  Despite the rare 
differences in cytokeratin reactivity, clinical MCC diagnosis usually includes 
reactivity to CK20, a thyroid transcription factor and leukocyte common antigen, in 
addition to the presence of one of the above neuro-endocrine markers190.  
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Figure 1.7.  MCC appearance and histology.  (A) A typical primary MCC tumour nodule present on 
the leg (Image kindly provided by Howard Peach, Leeds Teaching Hospital NHS Trust, UK). (B) MCC 
tumour cells characterised by dispersed granular chromatin, scanty cytoplasm and large nuclei
186
. 
 
1.3.4     Epidemiology 
 
The reported cases of MCC have tripled in the past 20 years to 1500 new cases 
being diagnosed each year in the United States of America8,190.  In the UK, a similar 
trend has been recorded, with the age standardised incidence rate of MCC at 0.9 
per 100,000 population196. This increase in incidence is partially due to recent 
advances in MCC diagnostic techniques, such as CK20 staining.  Melanoma and non-
melanoma are the most common causes of skin cancer in the US with 76 thousand 
cases being diagnosed each year.  While MCC is thirty times rarer than melanoma, it 
is twice as lethal.  These numbers suggest that MCC is as prevalent as HTLV-induced 
cancers and is likely to affect similar numbers as those affected by KSHV-induced 
cancers (4,100 new KSHV cases are diagnosed in the developed world each year)8. 
Studies have highlighted that MCC incidence is highest in white-caucasians, and 
intermediate incidence in other ethnic groups and an extremely low incidence in 
dark-skinned ethnic groups197.  Furthermore, those of European descent have a 
higher risk of developing MCC, due to UV light being a strong co-factor associated 
with MCC development.  This is likely due to the degree of melanin present in the 
skin which confers protection against DNA damaging UV exposure and 
development of MCC192,198. 
A B 
Chapter 1 
31 
  
Interestingly, the incidence of MCC is higher in males than females with a 2:1 ratio 
for white-Caucasians and 5:1 ratio in other ethnic groups197, however the reason for 
this observed difference in incidence due to sex has yet to be established.  
Furthermore, age poses a significant co-factor in developing MCC, which is very rare 
in those under 50 years of age190.  This indicates the need for accumulation of 
oncogenic mutations within the host genome for MCC development and suggests 
that the increase in MCC incidence is in part due to an ageing population. 
 
1.3.5     Clinical Staging 
 
Before 2010 the clinical staging system for MCC used a four tiered arrangement.  
Stage I disease was classified as ‘localised tumour with a nodule of less than 2 mm’, 
Stage II disease defined as ‘localised tumour with a mass of more than 2 mm’, Stage 
III disease ‘regional metastasis’ and Stage IV disease defined as ‘distant 
metastasis’192.  While this system is still in use, it has been redefined to include 
differences in regional metastasis for patients with inconsistencies in pathological 
and clinical appearances199. 
 
1.3.6     Prognosis and treatment 
 
As mentioned previously MCC is highly aggressive, with 28% of patients dying 
within the first 2 years of diagnosis and a 5 year survival rate less than 45% due to 
the high rate of metastasis197,200.   The cancer is associated by significant incidence 
of local recurrence (45%), early involvement of local lymph nodes (70%) and distant 
metastasis (50%) and of those patients with distant metastasis an 80% mortality 
rate200. 
The high mortality rate associated with MCC is due directly to the metastatic nature 
of the tumour201,202.  As such management of MCC is presently a concerning issue 
and there are unfortunately no specific therapeutic regimes available for treatment.  
Current clinical therapeutic regimes are those used for small-cell carcinoma of the 
lung, however no chemotherapeutic regimes have shown an increase in survival203.  
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As a result MCC is treated aggressively, with a wide surgical excision of the primary 
tumour with pathological verification of complete tumour removal, followed by 
ionising radiation therapy to decrease the incidence of local recurrence190,204.  After 
metastasis of the tumour to local lymph nodes, the patients will undergo extensive 
surgical removal of tumours including lymphadenectomy followed by radiation 
therapy at the excision sites and lymph nodes192.  While distant metastasis is 
treated with chemotherapy regimes such as cyclophosphamide, anthracyclines and 
etoposide, while half of MCC patients respond to chemotherapy, prognosis is very 
poor with a median survival of 21.5 months205.   
 
1.3.7     Infectious origin of MCC 
 
Interestingly, it has been established that the risk of developing MCC is higher in 
immune compromised individuals such as AIDs patients (8 fold increase), transplant 
recipients (10 fold increase) and chronic lymphocytic leukaemia patients (48 fold 
increase)188.  The associated incidence of immune suppression is similar to the 
cancer caused by Kaposi’s sarcoma-associated herpesvirus (KSHV)206, indicating that 
MCC may have an infectious aetiology.   
 
1.4        Merkel cell polyomavirus 
 
1.4.1     MCPyV discovery  
In 2008, a novel human polyomavirus was discovered and first isolated from MCC 
tumours71. Digital transcriptome subtraction (DTS) was employed, whereby mRNA 
was extracted from primary MCC tumour cells followed by cDNA library preparation 
and pyrosequencing.  The subsequent cDNA data was analysed and all known 
human transcripts were removed.  This then identified foreign transcripts of 
unknown origin, which were compared to pathogen sequence databases, 
highlighting sequence similarity to other polyomaviruses71.  3’-RACE was then 
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performed followed by viral genome walking to generate a complete circularised 
MCPyV genome.  
Identical RACE products were generated from both the primary MCC tumour and 
from metastatic tumours derived from the lymph nodes, indicating that clonal viral 
integration occurred prior to tumour formation and metastasis71.  This suggests that 
MCPyV is unlikely to be a passenger virus and that MCPyV is a contributing factor 
for MCC development and progression.  Furthermore, analysis demonstrated that 
80% of MCC tumours analysed were positive for a clonally integrated MCPyV 
genome.  This finding has been confirmed by others in the field71,207, once again 
supporting the finding that MCPyV is a contributing factor for development of MCC.  
Furthermore, a new report using sensitive antibody staining techniques has 
suggested that MCPyV may be present in 97% or more MCC tumour samples208.  
This demonstrates the need for multiple MCPyV screening methods and eludes to 
the fact that MCPyV may be ubiquitous among the MCC tumour population.   
MCPyV is the first human polyomavirus to date that has been conclusively shown to 
be associated with a human malignancy.  Despite this, the role of MCPyV in the 
pathogenesis of MCC is still poorly understood highlighting the importance for 
studying the molecular biology and life cycle of the virus. 
 
1.4.2      Seroprevalence  
 
Until recently, the seroprevalence of MCPyV, was unknown.  However new 
serological data detecting MCPyV VP1 and VP2 in patient blood has determined 
that the majority of the general population is seropositive, with 50% of children 
under 15 years infected and approximately 80% of the adult population209.  As such 
this virus is thought to be a common ubiquitous childhood infection of the skin and 
a common skin commensal.  Furthermore, there was no age-related waning of 
antibody titre indicating a persistent MCPyV infection possibly through latent 
infection209. 
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1.4.3      MCPyV present in non-MCC samples 
 
Evidence exists to suggest that MCPyV may play a role in other non-MCC related 
cancers, as MCPyV DNA has been isolated from Kaposi’s sarcoma210, small cell lung 
carcinoma211 and various melanoma skin cancers212.  However these findings are 
inconclusive and have not as of yet demonstrated MCPyV involvement in any of 
these malignancies.   
Furthermore, replication-deficient MCPyV genomes have been isolated from a 
subset of patients with Chronic lymphocytic leukemic (CLL) and MCPyV-positive 
MCC patients have a greater risk factor of developing CLL than MCPyV-negative 
MCC patients213,214.   While most CLL tumours do not show any particular pattern 
concerning MCPyV infection, there may be precedence for MCPyV involvement in a 
small subset of CLL cases.   
In addition, squamous cell carcinoma (SCC) has also been highlighted as having a 
potential link to MCPyV infection, with studies indicating the presence of MCPyV in 
40% of cutaneous SCC cases215.   Perhaps the most important finding in this study is 
that nearly all MCPyV–positive SCC tumours have a mutation in exon 2 of LT, 
theoretically producing a truncated LT216. This mutation could produce a similarity 
truncated LT protein that is present in MCPyV-positive MCC tumours.  However 
further characterisation is required to identify if a truncated LT protein is expressed 
in these cases, helping to confirm the role of MCPyV in SCC.  Due to the recent 
discovery of the virus, detection and confirmation of MCPyV in other clinical 
samples is ongoing, but it is possible that MCPyV may have a causal role in other 
malignancies.    
 
1.4.4       Phylogeny 
 
MCPyV is closely related to the other known polyomaviruses and phylogenetic 
studies using VP1, VP2 and LT sequences from all known human polyomaviruses 
have been conducted (except HPyV10 and after) (Figure 1.8)37.  Initially studies just 
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after the discovery of MCPyV concluded it was most closely related to the African 
Green Monkey lymphotrophic polyomavirus217.  However more recent analysis has 
indicated that MCPyV is more closely related to MPyV and Chimpanzee 
polyomavirus (ChPyV), due to the high degree of sequence homology between the 
VP2 coding region and LT genes37.  Furthermore MCPyV VP1 coding sequence 
resembles ChPyV and also shares a high degree of homology with one of the 
recently discovered human polyomaviruses, HPyV937.   
Currently, MCPyV resides in the Orthopolyomavirus genus of the Polyomaviridae 
family218.  Interestingly, MCPyV VP1, VP2 and LT all share a high degree of sequence 
homology with trichodysplasia spinulosa-assocaited polyomaviruses (TSV)35,37.  TSV 
was first isolated from patients with a rare skin disorder, while the role of TSV in 
this disease has not yet been elucidated, it suggests that both MCPyV and TSV are 
common skin commensals.   
Recent findings also suggest that there is distinct variability within the MCPyV 
genome.  Phylogenetic analysis of MCPyV strains present in the GenBank database 
clearly indicate that the Japanese and Asian strains form a distinct dominant clade 
from the Caucasian clade219.  This suggests that MCPyV genotypes are 
geographically related and that further characterisation of MCPyV genomes from 
distinct human descents will illuminate the distinct differences between clades 
which perhaps affect MCPyV pathogenesis and tumourigenesis.     
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Figure 1.8. Phylogenetic study of the relationships of human polyomaviruses.  Taken from
220
. Each 
human polyomavirus is highlighted in red and those associated with human disease in bold and 
genera within the polyomavirus family are indicated in italics.  Whole genome nucleotide sequence 
analysis was performed using a maximum likelihood phylogenetic analysis.  Phylogenetic analysis 
suggests MCPyV is most closely related to TSV, HPyV9, HPyV10 and AGMPyV.  Abbreviations are as 
follows: AGMPyV (African Green Monkey polyomavirus; BKV (BK polyomavirus); GHPyV (goose 
haemorrhagic polyomavirus; HPyV6 (human polyomavirus 6); HPyV7 (human polyomavirus 7); JCV 
(JC polyomavirus); KIPyV (KI polyomavirus); MCV (Merkel cell polyomavirus); HPyV9 (human 
polyomavirus 9), MWHPyV (Malawi polyomavirus); TSV (trichodysplasia spinulosa-associated 
polyomavirus) and WUPyV (WU polyomavirus). 
 
 
1.4.5        Genetic Organisation 
 
1.4.5.1    MCPyV Genome 
 
The MCPyV genome is similar to the genetic organisation of other polyomaviruses, 
with a genomic size comprising 5387 base pairs, split into three distinct regions; the 
non-coding control region (NCCR) contains viral promoters and the bi-directional 
origin of replication and the early and late coding regions.  The latter two are 
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present on opposite strands of the viral genome and are transcribed in opposing 
directions, as shown in Figure 1.9. 
 
 
Figure 1.9.  Genome organisation of MCPyV.  Taken from
221
.  Genetic organisation of the MCPyV 
genome, including three distinct regions.  Non-coding control region (NCCR), containing the bipartite 
origin of replication.  The early coding region containing the large T antigen (LT), small T antigen (ST), 
57 kT antigen (57kT), alternative T antigen open reading frame (ALTO), microRNA (miRNA).  The late 
coding region comprises structural genes, the capsid proteins, VP1, VP2 and VP3. 
 
 
1.4.5.1.1      MCPyV Origin of Replication 
The MCPyV non-coding control region (NCCR) contains the origin of replication 
which is 71 base pairs in length.  Similar to other well characterised polyomaviruses 
the NCCR contains an AT rich region, a LT binding domain (to initiate viral 
replication) and an early enhancer domain.  This binding site is comprised of eight 
repeating guanine-rich pentanucleotide sequences, very similar to the 
polyomavirus consensus sequence: 5’-GAGGG-3’.  However, the other two 
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pentanucleotide sequences are distinct from other polyomaviruses (5’-GAGCC-3’ 
and 5’-GGGGC-3’), and the proximity of these sequences and the number are also 
clearly distinct222. 
 
1.4.5.1.2         MCPyV T antigen locus 
Similar to other PyV, MCPyV T antigens (ST, LT an 57kT) are trans-acting factors 
required for viral genome replication and tumourigensis52,71,79 and their structure 
and protein binding domains are depicted in Figure 1.10. 
 
Figure 1.10.  MCPyV T antigen structure and domains.  Taken from
221
.  The schematic shows the 
relative locations of each gene that encode specific protein binding domains and splicing patterns 
associated with differential splicing of the primary early transcript.  The ST binding domains for PP2A 
Aα are at R7 and L142 and for a PP2A Aβ/PP4C at 97-11.  
 
1.4.5.1.2.1     Large T antigen 
 
The MCPyV LT protein comprises 816 amino acids and is transcribed across two 
exons.  As mentioned previously, the J domain comprises the first 80-82 residues; 
however the remaining C-terminal region is unique, with distinct protein binding 
domains required for its interaction with the host cell (Figure 1.10).  The MCPyV LT 
comprises all the major functional domains associated with other polyomaviruses, 
such as a highly conserved pRB binding domain (LXCXE), an origin binding domain 
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(OBD) and a nuclear localisation signal (NLS)74.  The NLS encoded by MCPyV LT is 
responsible for nuclear localisation of LT when expressed in mammalian cells119.  
However truncation of the LT, as seen in tumour samples, may result in loss of this 
signal and hence some cytoplasmic localisation (general consensus from several 
abstracts at the DNA Tumour Virus Meeting 2013, Birmingham). 
MCPyV LT is a highly multifunctional protein and is involved in viral genome 
replication as well as manipulation of host pathways through numerous protein-
protein interactions and described in Section 1.2.4.6.   
Similar to SV40, MCPyV LT has DNA binding and helicase features within its                 
C-terminus and can also interact with p53223.  The inherent helicase activity of PyV T 
antigens is important for viral DNA unwinding, facilitating the loading of cellular 
complexes required for transcription117,118.  Despite MCPyV sharing many similar 
protein binding domains inherent in SV40 LT, they share only 30% sequence 
identity224, clearly indicating novel regions may be present within MCPyV LT.  One 
such unique region has recently been identified – MCPyV unique region (MUR) – 
and is a 200 amino acid sequence located between the OBD and the first exon119.  
In addition, MCPyV LT has also been shown to encode a viral miRNA important in 
regulating early gene expression119,225.   
 
1.4.5.1.2.2     Small T antigen  
 
Similar to LT, the ST antigen (186 amino acids) has roles in both viral DNA 
replication and cellular transformation.  MCPyV ST shares a common J domain, 
however the unique C-terminal is produced by transcriptional read-through of the 
exon splice site used by both 57kT and LT and has been shown to localise to both 
the nucleus and the cytoplasm52.   Similar to other polyomaviruses, MCPyV ST 
contains a protein binding domain for PP2A71 (Figure 1.8). In addition, the MCPy ST 
protein encodes a binding site for another cellular phosphatase, PP4C226, as shown 
in Figure 1.10. Moreover, the novel LBD (LT-binding domain) has been identified 
and prevents LT proteolysis227.   
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1.4.5.1.2.3     57 kiloDalton T antigen  
 
While 432 residues of the 57kT protein shares the J domain of LT and ST, with 
similar protein binding domains (Hsc70, Cr1 epitope, MUR and pRB domain) very 
little is known regarding the role of MCPyV 57kT in the viral life cycle.  SV40 17kT 
has been shown to be homologous with 57kT, thus it could play a role in promoting 
host cell proliferation176,228.   
 
1.4.5.1.2.4      Alternative T antigen open reading frame  
 
The MCPyV early region encodes the three previously discussed T antigens, 
however recently an overprinting gene within the T antigen locus was 
discovered229.  Overprinting results in production of two unrelated proteins which 
are encoded as overlapping ORFs within the same stretch of DNA and is an 
interesting mechanism by which viruses can maximise protein coding capacity 
under genome size constraints230.  The alternative T antigen open reading frame 
(ALTO) is located within the 200 amino acid MUR region encoded by LT229.  
Phylogenetic analysis has demonstrated that while ALTO is evolutionarily related to 
murine polyomavirus MT they share next to no sequence similarity229 (Figure 1.11). 
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Figure 1.11.  A schematic to represent the de novo gene birth of ALTO by overprinting.  ORFs 
corresponding to the LT and ALTO/MT alternative frame and blue shows ALTO/MT region.  Stop 
codons are denoted by asterisks. 
 
Carter and colleagues have demonstrated that the start codon of ALTO overlaps 
exactly with the YGS/T motif of LT located near the pRB binding domain, while the 
function of the YGS/T motif is unknown, it may be required for the correct and 
timely folding of the DnaJ domain229.  Furthermore, ALTO has a hydrophobic            
C-terminus (similar to MT) which is required for the subcellular localisation of ALTO 
when expressed in mammalian cells229.  While the functional significance of ALTO, 
in terms of MCPyV biology, has yet to be determined, this data suggests that ALTO 
may be the twin protein of other PyV MT antigens.   
 
1.4.5.1.3     MCPyV Late Proteins 
MCPyV, like other PyV encodes three structural proteins, VP1, VP2 and VP3.  Both 
the major capsid protein (VP1) and the minor capsid protein (VP2) have been 
shown to self-assemble into virus-like particles in vitro231,232.  However, while there 
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is an open reading frame for VP3 it does not form part of the native MCPyV capsid 
and actually may not be expressed at all233.  The capsid structure of MCPyV forms 
an unenveloped, icosahedral capsid composed of 72 pentamers of VP1.  The overall 
capsid size is similar to other polyomavirus capsids at approximately 40-55 nm, with 
a VP1:VP2 ratio of 5:2233.  Using crystallography techniques the VP1 monomer 
structure has been shown to be composed of two antiparallel β sheets, forming a    
β-sandwich structure with a jelly-roll topology234.  The overall shape of the VP1 
monomer is classed as a symmetrical, ring-shaped homopentamer arranged around 
a central axis, and variable loops have been shown to create unique interaction 
surfaces possibly involved in viral attachment234. 
Interestingly, the current function of VP2 in the MCPyV lifecycle is unknown as the 
protein is not required for entry mechanisms in most cell lines currently studied, 
nor does it affect viral DNA packaging into the capsid, trafficking of viral proteins 
nor is it responsible for binding cellular receptors233.  One possible role of VP2 is 
through VP2 myristoylation, which may enable cellular membrane disruption, 
however this has yet to be characterised233.  Co-expression of both VP1 and VP2 
result in redistribution of VP2 from the cytoplasm to the nucleus, as VP2 does not 
encode a NLS signal233, therefore it would seem that VP1 is crucial for the function 
of VP2. 
 
1.4.5.1.4      MCPyV microRNA 
SV40, BKPyV and JCPyV have all been shown to encode microRNAs (miRNAs) which 
function to regulate early gene transcription235,236.  Similarly, MCPyV encodes a 
miRNA within the late region, MCPyV-miR-M1-5p, and is transcribed from the 
antisense DNA strand encoding the LT gene sequence225. Recent evidence suggest 
that this miRNA is required to regulate early gene transcript levels and expression 
of the MCPyV miRNA acts in a negative feedback loop, whereby expression results 
in a decrease in T antigen expression, thus facilitating the switch from early to late 
gene transcription225.   
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1.4.6      Viral Life Cycle 
The cellular tropism for MCPyV infection has yet to be identified, however MCPyV 
virions are shed from the skin of healthy adult patients34, indicating that the natural 
host cell may reside within the epidermis. Only a few human skin-derived primary 
keratinocytes and transformed melanocytes have been shown to be susceptible to 
infection, while more than sixty others demonstrated no MCPyV cell tropism237.  
Recently, several groups have established a MCPyV genome capable of productive 
viral infection233,238.  Schowalter et al were able to isolate full-length wild-type 
MCPyV genomic DNA from surface skin swabs taken from healthy adult volunteers.  
The DNA extracted from these skin forehead swabs underwent random        
hexamer-primed rolling circle amplification (RCA)233.  While Neumann et al 
generated a synthetic MCPyV genomic clone using sequence data of MCPyV 
genomes from MCC tumour samples, accessible from the NCBI database238. Both of 
these systems have resulted in the production of plasmids, such as pR17b, which 
contain the full recircularised MCPyV genome. 
Presently, the most successful way to recapitulate efficient replication of the 
MCPyV viral genome, both early and late gene expression and viral particle 
formation, is by transfection of the pR17b plasmid in HEK-293 cells that overexpress 
the MCPyV LT and ST in trans239, also known as 293-4T cells.  Five days after 
transfection, 293-4T cells are lysed to release pseudovirions, and these are 
subsequently allowed to mature overnight at 37 oC prior to purification.  Samples 
are then clarified and layered over an Optiprep gradient, followed by centrifugation 
and fraction collection.  These fractions can then be analysed for the presence of 
infectious virus particles by Quant-iT Picogreen dsRNA Reagent and/or by western 
blot analysis for viral capsid proteins such as VP1, VP2 and VP3.  This viral 
replication system is key in the pursuit of understanding MCPyV biology and the 
specific viral-host interactions that contribute to MCC pathology.   
 
 
Chapter 1 
44 
  
1.4.6.1      Attachment and Entry  
SV40, BKPyV and MPyV are well characterised in terms of host cell attachment 
mechanisms and use either ganglisosides or sialic acid-containing glycolipids to 
initially attach to the host cell membrane240,241. Unlike most other PyV, MCPyV 
displays a preference for glycosaminoglycans (GAGs) (Figure 1.12), in particular 
heparan sulphate and chondroitin sulphate as initial attachment receptors239.  
Interestingly, MCPyV is capable of initial attachment to cells deficient in sialylated 
glycans, however this results in impairment in MCPyV transduction of genes using 
reporter vectors239.  This demonstrates that while the siaylated glycans are not 
strictly necessary for initial attachment, lack of them severely restricts MCPyV 
downstream entry processes. 
 
Figure 1.12.  Attachment and entry receptors for MCPyV.  A two-step attachment and entry 
mechanism, MCPyV binds glycosaminoglycan (GAG), specifically heparan sulphate as the initial 
mode of attachment.  MCPyV the binds a ganglioside with a Neu5Ac-α2,3-Gal motif to facilitate viral 
entry. 
 
MCPyV can also bind gangliosides, specifically the GT1b receptor, which contains 
three different sialic acids and is important for entry of the virus after initial 
attachment242.  More recently, X-ray crystallography has confirmed that the MCPyV 
VP1 protein structure contains a binding site that is consistent with binding to host 
glycans which specifically contain sialic acid with a Neu5Ac motif234.  Furthermore, 
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MCPyV shows specificity for binding carbohydrates with a Neu5Ac-α2,3 motif, 
however mutational studies rendering the binding site defective has no discernable 
effect on virus attachment234.   Taken together, these results suggest that MCPyV is 
capable of binding two distinct cell membrane receptors with a separate 
mechanism for both initial virus attachment and post-attachment entry into the 
host cell.   
 
1.4.6.2         Replication 
MCPyV is a ubiquitous infection of the skin and can complete a full replication cycle 
in permissive cells without inducing transformation.  As with other small viruses, 
MCPyV relies upon multiple host cell factors to successfully replicate its genome 
and expression of viral T antigens is essential for this function.  Feng et al 
demonstrated that upon transfection of the MCPyV full circularised genome an 
ordered gene expression profile occurs, with LT and 57kT being the first proteins to 
be transcribed, followed by ST then VP1, 3 days after transfection243. 
Similar to other PyV, the early genes are required to promote G1-S phase 
progression to allow viral replication to occur.  It is thought that after sufficient 
levels of the T antigens have been expressed, transcription of a MCPyV encoded 
miRNA results in a negative feedback loop to inhibit further T antigen expression225.  
This is an important switch between early and late viral gene transcription and 
allows the late encoded capsid genes to be transcribed for viral capsid assembly.   
 
1.4.6.2.1     The role of LT 
The LT antigen is highly conserved among the polyomaviruses, as such is thought to 
act in a similar manner and initiate viral genome replication.  However, there are 
several unique features of the MCPyV LT protein that affect viral replication which 
have recently been characterised.  Liu et al characterised a novel virus-host 
interaction between MCPyV LT and the cellular cytoplasmic vacuolar sorting protein 
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hVam6p119. Mutation studies demonstrated that MCPyV LT binds to hVam6p via its 
unique MUR region adjacent to the pRB binding domain119.  hVam6p is part of the 
HOPS (homotrohpic fusion and protein sorting) complex, and MCPyV LT expression 
results in a redistribution of hVam6p from the cytoplasm to the nucleus, disrupting 
lysosome clustering.  Interestingly, overexpression analysis of hVam6p suggests an 
inhibitory role, as overexpression leads to a reduction in MCPyV virus formation by 
more than 90%243.  Furthermore, mutation studies abrogating the LT-hVam6p 
binding domain significantly increases infectious virion production between 4-6 
fold119,243.  This clearly demonstrates that hVam6p, not only inhibits viral replication 
and particle formation, but highlights the possible role of hVam6p as a novel 
MCPyV anti-viral cellular response factor.   
Another critical factor in MCPyV LT-mediated viral replication is the chromatin-
associated bromodomain containing protein 4 (Brd4).  Brd4 is part of the BET 
protein family and plays a role in recruitment of cellular replication factors required 
for viral replication. The LT-Brd4 interaction facilitates recruitment of cellular 
replication factor C (RFC) to MCPyV replication complexes244.  RFC facilitates loading 
of PCNA clamp and DNA polymerase δ, both of which are required for elongation of 
MCPyV DNA243.  In line with this notion, viral DNA replication can be inhibited by 
expression of a dominant negative Brd4 inhibitor244, highlighting the important role 
of the LT-Brd4 interaction in facilitating successful viral DNA replication.   
DNA damage response (DDR) factors also play a role in MCPyV LT-mediated DNA 
replication245.  The two DNA damage response pathways, ATM and ATR are both 
involved in LT-mediated replication.  MCPyV LT expression redistributes such 
factors to the nucleus, specifically replication foci where they co-localise with LT 
activity245.  HPV has also been shown to induce DDR activation and recruitment of 
these factors to sites of viral replication246.  This indicates the importance of the 
DDR pathways across multiple viral families, however the implication of DDR 
activation and redistribution in MCPyV DNA replication have yet to be fully 
determined.  
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1.4.6.2.2       The role of ST 
The mechanism by which MCPyV ST enhances viral replication does not rely upon 
binding to either PP2A or Hsc70, as specific mutations within these domains do not 
affect viral genome replication247.  This is in stark contrast to other polyomavirus ST 
proteins, as SV40 ST co-expression has minimal effect on SV40 LT-mediated viral 
genome replication and despite SV40 ST having conserved PP2A and Hsc domains is 
unable to cross-enhance MCPyV LT-mediated viral replication247.  This suggests that 
MCPyV ST acts through novel mechanisms, distinct from the well characterised     
ST-PP2A interaction.  
Furthermore, MCPyV ST is able to prevent proteasomal degradation of LT by 
specifically targeting the cellular SCF ubiquitin E3 ligase complex, of which Fbw7 
serves as the recognition component227,248.  Fbw7 is deregulated in multiple cancers 
and loss of Fbw7 can result in tumourigenesis and genetic instability249-252.  SV40 LT 
is a pseudosubstrate for Fbw7 and recognition by Fbw7 results in                  
phospho-dependent degradation of many cellular proto-oncogenes, including c-
Myc, mTOR and Notch248,252,253. 
Both ST and LT readily bind Fbw7 and through the use of chimeric proteins 
composed of various SV40 and MCPyV ST domains and mutation analysis, an 
important region was identified (aa 91-95), termed the LT stabilisation domain 
(LSD)227. The ST LSD region is crucial for binding Fbw7 and this interaction inhibits 
Fbw7 targeting of LT, thereby increasing LT stability and half-life (by approximately 
18 hours), enabling efficient viral replication227. 
 
1.4.6.3      Assembly and egress 
Little is known regarding the mechanisms MCPyV employs during virion assembly 
and egress from the host cell.  A permissive host cell line has yet to be established, 
adding to the complexity of studying the MCPyV life cycle, especially at the latter 
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stages. Though the recent advances in recapitulation of virus replication using 
engineered MCPyV genomes will aid in this endeavour.    
Polyomavirus infection studies demonstrated that endosomal and lysosomal 
trafficking are important for viral transit from the cell membrane to the nucleus.  
Furthermore, the SV40, BKPyV and JCPyV agnoprotein is important in polyomavirus 
virion assembly and SV40 VP4 is required to trigger lytic virion release254,255.  MCPyV 
encodes neither of these proteins, therefore it must utilise other mechanisms to 
facilitate virus capsid assembly, maturation and egress and it has been suggested 
that MCPyV may utilise hVam6p for egress, via lysosomal processing pathways119.  
 
Interestingly, cell lysis and shedding have also been shown to be important for 
polyomavirus escape and this may be a plausible mechanism as MCPyV infection 
resides in the skin256.  The natural human skin cycle requires keratinocyte 
desquamation and this may facilitate MCPyV virion release.  This area of MCPyV 
biology is poorly understood and will benefit from the generation of MCPyV 
genomic clones capable of recapitulating virus particle formation. 
 
1.4.7       MCPyV and the immune response 
Innate immunity is an obstacle that viruses must overcome in order to establish a 
persistent infection, and microorganisms have developed multiple mechanisms by 
which to subvert or evade the host immune response.  Griffiths et al demonstrated 
that the MCPyV ST is able to disrupt the NF-κB pathway, thus downregulating the 
host innate immune response226.  Activation of NF-κB is stimulated by recognition 
of pathogen associated molecular patterns (PAMPs), recognised by pattern 
recognitions receptors (PPRs). PAMPS include foreign proteins and nucleic acids and 
recognition results in the production of antimicrobial peptides, cytokines and 
chemokines capable of clearing microbial infections257.   
Recognition also results in a coordinated signalling cascade leading to the activation 
of the IKK complex257,258.  Activation results in phosphorylation of IκB and thus its 
degradation, allowing for the release of NF-κB from the IKK complex (Figure 1.13).  
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Upon release, NF-κB is free to translocate to the nucleus where it can stimulate 
gene transcription of proinflammatory cytokines and type 1 interferons257,258.  An 
important component of the IKK complex is the NF-κB essential modulator (NEMO), 
which is a non-catalytic regulatory subunit and acts as an essential molecular 
scaffold to allow the recruitment of upstream signalling components258. 
Recent evidence suggests that through an interaction with NEMO, MCPyV ST is able 
to inhibit IKKα/IKKβ phosphorylation, thus rendering NF-κB incapable of 
translocating to the nucleus due to its association with the IKK complex226.  This 
function is dependent on ST binding the cellular phosphatases, PP2A Aβ and/or 
PP4C, which promote the dephosphorylation of the IKK complex226.  This is the first 
characterised mechanism by which MCPyV can interact with the NF-KB complex and 
provides insights into possible immune evasion strategies employed by MCPyV.   
Other viruses have also demonstrated the ability to prevent NF-κB-mediated 
signalling259.  HPV E7 and HCV core protein both inhibit IκB degradation thus 
rendering NF-κB unable to translocate to the nucleus, while cytomegalovirus (CMV) 
disrupts NF-κB activation through a direct interaction with NEMO260-263.  
Interestingly, SV40 has been shown to act in the opposite manner and promotes 
NF-κB activation in a PP2A dependent manner102.   
Furthermore, MCPyV ST has also been shown to downregulate the expression 
involved in the innate immune response such as CCL20, IL-8, TANK and CXCL-9e102.  
This suggests that MCPyV is capable of mediating the immune response to allow 
the virus to establish a persistent and lifelong viral infection.   
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Figure 1.13. NF-κB mediated gene transcription. Taken from
221
.  Recognition of PAMPS by PRRs 
facilitates activation of the IKK complex and subsequent degradation of IκB.  NF-κB is thereby free to 
translocate to the nucleus and stimulate transcription of genes involved in mounting an innate 
immune response. 
 
MCPyV LT also facilitates immune evasion strategies by inhibiting Toll-like receptor 
9 (TLR9) in both MCC and epithelial cell lines264. Inhibition of TLR9 is an important 
factor in immune evasion, as TLRs are subset of PRRs that specifically detect 
viral/bacterial dsDNA and can activate the IKK complex and production of 
inflammatory molecules265.  This feature is not uncommon among viruses, as EBV 
and HPV have been shown to act in a similar manner266,267.  MCPyV LT reduces the 
mRNA levels of C/EBPβ, a positive regulator of the TLR9 promoter, thus decreasing 
TLR9 transcription264. Interestingly, ST may also play a role, as MCPyV ST expression 
alone is able to inhibit TLR9 production264, however the underlying mechanisms 
have not yet been addressed. 
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Recently, a study has implicated the role of prokineticins, particularly prokineticin 2 
(PROK2) in MCPyV infection268.  Prokineticins are chemokine-like factors that 
mediate inflammatory reactions and are mainly present on innate immune cells, 
such as macrophages, monocytes and neutrophils. The results indicate that MCPyV 
infection can alter the expression profiles of prokineticins and may contribute to 
MCPyV immune evasion strategies268, however the specific pathways utilised and 
the mechanism by which MCPyV contributes to this phenotype are unknown and is 
an area currently under investigation.  
Altogether, these results indicate that MCPyV T antigens affect various innate 
immune response pathways in a multifaceted manner, preventing host clearance of 
MCPyV infection, thus allowing persistent and lifelong MCPyV infection.   
 
1.4.8     MCPyV in the pathogenesis of MCC 
 
MCPyV is a common childhood infection however development of MCC is rare, as 
such it is important to understand the predisposing factors which contribute to the 
tumourigenic potential of MCPyV. An acronym has been used to clearly address the 
predisposing factors of MCC – AEIOU – Asymptomatic, Expanding rapidly, Immune 
suppression, Older than 50 years, Ultraviolet light188.   
Broadly speaking, infectious agents that contribute to tumour formation have been 
divided into two categories.  Direct carcinogens that express viral oncoproteins that 
directly cause transformation or indirect carcinogens which cause tumour 
formation through infection and inflammation, resulting in accumulation of 
mutations that lead to tumour formation29. MCPyV can be considered a direct 
carcinogen as the expression of tumour antigens directly contribute to 
transformation of the host cell.   
There are several key stages to MCPyV-induced carcinogenesis as seen in Figure 
1.14.  The first step is rare and involves integration of the MCPyV genome into a 
host chromosome in a monoclonal integration pattern71,208.  Integration results in 
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activation of the MCPyV T antigens, facilitating DNA replication.  This is detrimental 
to the host cells as DNA strand breaks occur, leading to replication fork collisions 
and cell death74,210.  Therefore a second truncating mutation has to occur, only in 
neoplastic cells, leading to premature truncations of the T antigen, eliminating its 
OBD and helicase activity; thereby preventing MCPyV viral replication212. This 
feature is essential for cell survival and is a strong selective pressure for elimination 
of MCPyV viral replication activities.     
The truncating mutation removes the helicase and p53 binding activity but the pRB 
protein binding domain remains intact, thus retaining the transforming ability 
associated with pRB74. 
 
Figure 1.14. The molecular mechanism associated with MCPyV-induced tumour formation.  Taken 
from
4
.  Illustrates the common evolutionary features required for MCPyV ability to induce 
transformation through integration, truncating mutations and loss of immune surveillance through 
aging, AIDs and immune suppression drugs.     
 
Interestingly, a deletion mutation within the promoter region of integrated VP1 has 
also been identified and is linked with decreased viral replication efficiency and 
virion assembly222,238,243, suggesting another process that may contribute to    
MCPyV-mediated transformation.   
To support the role of MCPyV as a direct carcinogen, MCPyV positive MCC cells 
lines (MKL-1 among others) demonstrated growth arrest and cell death upon 
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knockdown of both the LT and ST proteins75.  This demonstrates the importance of 
these proteins in MCPyV-mediated tumour formation and maintenance of the 
tumour state.   
 
1.4.8.1        The role of ST in transformation 
Initially, the tumourigenic potential of MCPyV T antigens was compared to the well 
established role of other polyomavirus T antigens, however in the last few years 
novel mechanisms of MCPyV action have been identified. Most literature concludes 
that the polyomavirus LT, rather than ST, is more oncogenic, with ST providing a 
supporting role78,96.  However, it has been demonstrated that MCPyV ST is more 
commonly expressed in MCC tumour samples than LT, indicating the importance of 
ST in MCC pathology247.  Shuda et al demonstrated 92% of MCPyV-positive MCC 
tumours stained positive for MCPyV ST expression whereas only 75% stained 
positive for LT247. Furthermore, lentiviral knockdown of ST induced growth arrest of 
MCPyV-positive MKL-1 cell lines247.  Moreover, only MCPyV ST, not LT, is sufficient 
to induce rodent fibroblast transformation, loss of contact inhibition,        
anchorage-independent and serum independent growth247.  These are key 
hallmarks of an oncogenic viral protein and there is a substantial body of evidence 
to suggest that MCPyV ST is more oncogenic, which is in stark contrast to other 
polyomaviruses.  
 
1.4.8.1.1     A role for 4E-BP1 
SV40 ST is capable of activating the Akt pathway by preventing PP2A-mediated 
dephosphorylation of Akt82,269.  However evidence suggests that MCPyV ST acts 
downstream of the Akt-mTOR pathway247.  Interestingly, recent studies have 
highlighted a role of the PI3K-AkT-mTOR signalling pathway in the regulation of  
cap-dependent translation in MCPyV tumourigenesis270,271. A key stage in             
cap-dependent translation involves binding of the eukaryotic translation initiation 
Chapter 1 
54 
  
factor 4E (eIF4E) to specific mRNA molecules272.  Loading of the multisubunit eIF4E 
complex at the cap of mRNA molecules allows for initiation of ribosome 
recruitment and translation. 
The chief regulator of this process is the eukaryotic translation initiation factor      
4E-binding protein 1 (4E-BP1), which can inhibit eIF4E complex formation by 
binding and sequestering eIF4E273.  Aberrations within this pathway are significant, 
as eIF4E overexpression induces rodent cell transformation274,275.  4E-BP1 is 
phosphorylated by mammalian target of rapamycin (mTOR), realising eIF4E from 
4E-BP1, thus stimulating cap assembly and cap-dependent translation276, as shown 
in Figure 1.15. 
In 2011, a novel interaction between MCPyV ST and 4E-BP1 was identified which is 
both PP2A and Hsc70 independent247. MCPyV ST has been shown to reduce 
hyperphosphorylated 4E-BP1 turnover, which in turn promotes eIF4E activity and 
cap-dependent translation.  To support this, a constitutively active 4E-BP1 mutant 
was able to both inhibit and reverse ST-mediated transformation247.  In contrast, 
SV40 ST has been shown to diminish 4E-BP1 phosphorylation in a PP2A dependent 
manner92.  These findings demonstrate the significance of MCPyV ST in regulating 
cap-dependent translation and the importance of this mechanism in tumour 
development. 
Chapter 1 
55 
  
 
Figure 1.15. MCPyV ST promotes cell proliferation downstream of the Akt pathway.  MCPyV ST 
targets the translational regulator 4E-BP1, and reduces hyperphosphorylated 4E-BP1 turnover. This 
promote eIF4E activity and cap-dependent translation.  Alternatively, SV40 ST promotes Akt activity 
by preventing PP2A-mediated Akt dephosphorylation.   
 
1.4.8.1.2     The LSD domain 
The MCPyV ST LSD domain is important for inhibition of LT proteolysis and is crucial 
in promoting viral DNA replication227.  However, recent evidence indicates that the 
LSD domain is also important for rodent cell transformation. Mutations within      
the LSD domain inhibit MCPyV ST-mediated transformation in both focus formation 
and soft agar colony growth assays, and is PP2A independent227. However, targeting 
of Fbw7 by ST is not sufficient to induce transformation, demonstrating that MCPyV 
ST utilises multiple mechanisms to induce transformation in a PP2A independent 
manner. This, once again confirms that MCPyV is distinct from other 
polyomaviruses. 
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1.4.8.1.3     MCPyV ST, a dichotomy of functions 
Although MCPyV is closely related to SV40 and shares similar gene structure, it is 
increasingly apparent that they differ drastically in terms of their dependency on 
PP2A binding to facilitate viral replication and transformation.  The SV40 ST-PP2A 
interaction is critical for SV40-mediated transformation and cell proliferation78,170. 
However, mutations within the MCPyV ST-PP2A binding domain which ablate this 
interaction, are still capable of inducing both rodent cell transformation and 
anchorage-independent colony formation247.  Clearly indicating that while these 
viruses may contain similar protein structures and binding domains their mode of 
action is distinct. 
On the contrary, a recent study has concluded that MCPyV LT is more oncogenic 
than ST and is crucial to proliferation and maintenance of established MCC cell 
lines.  Houben et al demonstrated that knockdown of MCPyV ST by lentiviral shRNA 
expression inhibited the growth of three MCPyV-positive cell lines and one    
MCPyV-negative cell line75.  Furthermore, T antigen knockdown induced growth 
inhibition is completely rescued by expression of a LT insensitive to T antigen 
shRNA277. This data indicates that MCPyV ST is not essential for proliferation and 
survival of MCC MCPyV-positive cell lines, however this data also suggests possible 
off-target effects of these shRNA as a MCPyV-negative cell line also exhibited 
growth inhibition.  Houben and colleagues suggest that LT shows true oncogenic 
addiction75,277, however multiple studies have demonstrated that only MCPyV ST 
can induce rodent fibroblast transformation247,277.   
Consequently, this may suggest that while MCPyV ST is essential for initial 
transformation it may no longer be required once transformation has taken place 
and that MCPyV LT becomes necessary for tumour cell maintenance.  Despite this, 
there is a large robust body of evidence that indicates MCPyV ST is crucial for 
tumourigenesis and maintenance of the tumour state. This remains a controversial 
topic and requires further investigation to determine the role of ST and LT in terms 
of oncogenic potential and tumour cell survival.  However, what is clear is that 
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MCPyV is the only known human tumour-associated polyomavirus suggesting that 
there are novel functions of MCPyV that set it apart from its counterparts.  
 
1.4.8.2          The role of LT in transformation 
Despite this controversy, neither full-length or truncated MCPyV LT has been shown 
to be capable of initiating cellular transformation247. However, LT is highly 
expressed in 75% of MCPyV-positive MCC tumour samples278, clearly indicating a 
role for this protein in the tumour environment.  One possible explanation for this 
diminished transforming ability, when compared to the SV40 homologue is that 
truncated MCPyV LT does not interact with p53279. Although, the LT truncated form 
is more effective at inducing cellular proliferation compared to its full length 
counterpart.  This is due to the C-terminal 100 amino acids which possesses growth 
inhibitory effects279.  
 
1.4.8.2.1       DNA damage response 
Recent evidence has highlighted that MCPyV infection results in activation of the 
cellular DNA damage response (DDR) pathway in a LT-dependent manner, requiring 
the C-terminal interaction with p53 223.  Similarly, SV40 infection has also been 
shown to activate the DDR pathway, specifically the ATM DNA damage response280.  
However, while SV40 LT inhibits downstream activities of p53 to promote 
tumourigenesis, cell proliferation is not affected.  Therefore, it is likely that MCPyV 
LT tumour specific truncations removing the C-terminal region are required to 
prevent activation of the host DDR in the absence of p53 activation, in order to 
prevent apoptosis.    
 
1.4.8.2.2        Survivin 
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The SV40 and MCPyV LT-pRB interaction interferences with pRB-E2F binding and 
promotes cell proliferation281.  Survivin is a member of the inhibitor-of-apoptosis 
protein family and its proteins levels are elevated in lymphoma and metastatic 
melanoma and contributes to chemotherapy resistance282.  Interestingly, survivin 
mRNA levels are elevated more than seven-fold in MCPyV-positive MCC cell lines 
compared to MCPyV-negative lines, and MCPyV LT alone is sufficient to induce an 
upregulation of survivin in human fibroblasts281.  Arora et al also demonstrated that 
knockdown of MCPyV T antigens in MCPyV-positive MCC cell lines results in a 
decrease in both mRNA and protein levels of survivin and results in cell        
death281-282,283.  This demonstrates that MCPyV LT-mediated upregulation of 
survivin is critical for the survival of MCPyV-positive MCC cell lines.   
Therefore, this may present a unique avenue for therapeutic intervention and 
chemotherapy.    The small molecular inhibitor of survivin, YM155, was identified 
and can initiate selective and irreversible non-apoptotic cell death of              
MCPyV-positive MCC cells281. Furthermore, this inhibitor has been shown to stop 
the growth of MCPyV-positive xenograft tumours.  Other compounds tested, such 
as bortezomib (Velcade), were just as potent however non-selective in killing 
MCPyV-positive cells281. Despite this, YM155 has been shown to be cytostatic rather 
than cytotoxic in vivo, with xenograft tumour resuming growth after YM155 
treatment was halted281.  Survivin presents an exciting avenue by which to treat 
MCC patients, however the underlying molecular mechanisms involved in inhibition 
of survivin require further identification in order to design drug candidates capable 
of cytotoxic effects.   
 
1.5       Cancer and Metastasis 
 
The spread of malignant cells from a primary solid tumour to remote sites within 
the body is one of the biggest problems facing cancer treatment, resulting in more 
than 90% of cancer associated-deaths284.  Despite the clinical importance of 
metastasis, the molecular mechanisms by which this phenotype is acquired have 
yet to be fully elucidated285.  This poses a significant problem in real terms, for 
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cancer prognosis and treatment of patients and is an area of cancer biology that 
needs much research.   
Concurrent with this, MCC is regarded as the most aggressive form of skin cancer 
and is associated with a poor patient prognosis with quick progression to distant 
metastases201.  Recently, novel interactions have been identified that implicate 
MCPyV in the transformation of Merkel cells, however to date no studies regarding 
the mechanisms by which MCC tumour cells acquire a metastatic phenotype have 
been addressed.   
 
1.5.1        Steps to achieve metastasis 
 
The genetic diversity of the tumour cell population and the tumour 
microenvironment results in environmental selective pressures that dictate cell 
behaviour.  This explains, why despite millions of tumour cells being released from 
the primary tumour into the vasculature daily, only a small percentage of those 
cells are capable of surviving and colonising distant organs.  There are several 
discrete steps in the metastatic cascade that are required for metastases to form 
and include loss of cellular adhesion, acquisition of cell motility, entry and survival 
in the vasculature and colonization of distant sites286.  At each discrete step the 
process of metastasis encounters numerous physiological barriers and in order to 
achieve metastasis tumour cells must overcome all of them286,287.   
 
1.5.1.1      Loss of cell adhesion 
Most solid tumours originate from epithelial tissue, which is composed of rigid cell 
sheets that are separated from the basement membrane by stroma forming highly 
organised structures, requiring cell-cell adhesion complexes and cell-matrix 
components.  In order for epithelial cells to detach, deregulation of the cell 
adhesion complexes must occur, as such carcinoma cells show distinct loss of 
intracellular adhesive properties288.  An important feature of malignant epithelial 
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cells that allows for an invasive phenotype is the loss of E-cadherin289.  The cadherin 
family is composed of multiple members each showing specific tissue specificity and 
are required to maintain tissue integrity290,291. Cadherins are transmembrane 
glycoproteins which localise to specialised cell junctions, termed zonula adherens 
and are responsible for calcium-dependent cell adhesion and cell signalling290,291.  
‘Cadherin switching’ – a loss of E-cadherin and increased expression of N-cadherin 
(mesenchymal tissue specificity) correlates with increased invasiveness of multiple 
carcinomas, reviewed in289, invasiveness of tumour cells in mouse models292 and 
can be represented under a broader program known as the                           
epithelial-to-mesenchymal transition (EMT).  EMT is characterised by a loss of cell 
polarity and epithelial proteins such as E-cadherin, occludins, claudins, catenins and 
cytokeratin among others, which are responsible for maintaining cell-cell 
junctions292.  Thus cells acquire a more mesenchymal phenotype allowing invasion 
into neighbouring tissues292, as shown in Figure 1.16. 
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Figure 1.16.  Steps required for escape from the primary tumour site. Upon transformation, some 
primary carcinoma cells will acquire the capabilities to escape from the primary tumour site into the 
vasculature.  This process involves epithelial-to-mesenchymal transition (EMT) where cells become 
more motile and express specific integrins and MMPs required to invade local tissue and escape 
through the basement membrane into blood and/or lymph vessels. 
 
There are multiple cellular signalling pathways that control E-cadherin loss/EMT 
and include Receptor Tyrosine Kinases (RTKs), the transforming growth factor β 
(TGFβ) family, Notch, WNT and hedgehog292.  Many of these signalling pathways are 
deregulated in tumour cells with a metastatic phenotype, through transcriptional 
repression (promoter methylation), proteolytic degradation or cleavage of the 
extracellular domain288,289. Increased expression of N-cadherin also functions 
towards promoting tumour invasion as it can bind and activate fibroblast growth 
factor receptor (FGFR), stimulating cell survival, migration and invasion293. 
Interestingly, DNA tumour viruses have also been shown to be actively involved in 
promoting loss of cell adhesions.  HPV E6 expression promotes degradation of 
epithelial cell tight junctions through an interaction with E6AP (a ubiquitin-protein 
ligase) allowing for proteosomal degradation of cell adhesion molecules in a 
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manner similar to EMT294,295.  More specifically, HBV HBx protein downregulates     
E-cadherin expression (frequently found in HCC), which results in morphological 
alterations that render cells incapable of forming aggregates in cell culture, 
reflecting the loss of intracellular adhesion molecules296-298. 
In addition, the SV40 ST antigen has the ability to promote redistribution and 
downregulation of proteins involved in tight junction complexes such as E-cadherin, 
Zo-1, claudin-1 and occludin, in a PP2A dependent manner299.  Moreover, analysis 
of MCC tumours demonstrate a pronounced redistribution of E-cadherin from the 
cell membrane adhesion complexes to the nucleus300.  This suggests that MCC cells 
possess mesenchymal-like qualities which may promote an invasive phenotype 
seen in MCC. 
 
1.5.1.2     Acquisition of motility 
A critical parameter in tumour cell metastasis is the ability for cells to acquire a 
motile phenotype to allow dissemination286,301. Extensive studies have been carried 
out to visualise cell motility in vitro using 2D and 3D matrices and advanced in vitro 
imaging techniques292.  Motility analysis demonstrated that there are three broad 
categories of cell migration: mesenchymal, amoeboid and collective motility.  The 
best categorised of these is mesenchymal motility, as 10-40% of carcinomas 
undergoing EMT use this mechanism302.  It is characterised by a polarised, 
elongated cell body and requires degradation of extra cellular matrix components 
(ECM) and is generally initiated by activation of RTKs, such as c-Met (ECM), 
reviewed in302.  Together these changes result in directional movement with 
extended protrusions at the leading edge and retraction at the rear302, as seen in 
Figure 1.17. 
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Figure 1.17.  The process of mesenchymal, directional cell motility.  Key components of directional, 
polarised cell motility using the actin cytoskeleton to form protrusions and extracellular matrix 
degradation to invade local tissue. 
 
Amoeboid motility is similar to leukocyte movement and is generally a feature of 
malignant cells that do not undergo EMT302. Receptors on the cell surface sense 
chemokine gradients which can stimulate the Rho-ROCK signalling pathway, which 
promotes rapid actin remodelling and cortical actin contraction allowing the 
invading cells to ‘squeeze’ between other cells and change direction rapidly292.  In 
contrast to mesenchymal motility, amoeboid movement does not require 
degradation of the ECM due to the ability of cells to ‘squeeze’ through gaps, thus no 
formation of large actin-based protrusions are observed, characteristic of 
mesenchymal motility302.   
The final form of motility relies on similar mechanisms to mesenchymal motility and 
is termed as collective migration which involves whole sheets of cells moving as one 
and has been demonstrated in breast, colon and ovarian carcinomas302.  This 
requires the cells at the leading edge of movement to generate proteases that 
degrade the ECM thereby creating a path for lagging cells to follow303.  The main 
difference between these two forms of motility is that collective motility requires 
active adhesion complexes, whereas mesenchymal motility requires the loss of 
these complexes304.  This method is less widely understood due to the lack of in 
vitro techniques capable of modelling this movement. 
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1.5.1.3       ECM degradation and entry into the vasculature 
The epithelial basement membrane is important for epithelial structure and 
integrity and is composed of a dense network of glycoproteins and proteoglycans, 
including laminin and type IV collagen.  The basement membrane poses a barrier to 
invading tumour cells, as they must first degrade the ECM and invade through the 
basement membrane in order to circulate within the body.   
Extracellular matrix proteases are under strict regulatory control through 
localisation, tissue secreted inhibitors and autoinhibition289,305.  Malignant cancer 
cells utilise multiple mechanisms to activate these proteases and degrade the ECM, 
and is a key feature of mesenchymal motility.  Furthermore, proteolysis of ECM 
components can result in production of bioactive cleaved peptides which can 
further mediate migration, proliferation, angiogenesis and survival of tumour cells, 
reviewed in302.     
Another important family in mediating invasiveness and signalling in tumour cells 
are the ADAM (A disintegrin and metalloproteinase) protein family306-308.  ADAMs 
are membrane-anchored glycoproteins and regulatory enzymes associated with cell 
adhesion and shedding/cleavage of extracellular bound proteins, such as 
integrins307,309.  ADAM proteins themselves are catalytically inactive until 
autocatalysis, however upon activation are capable of cleaving the ectodomain of 
membrane proteins307.  ADAM proteins are important for sensing external stimuli 
and provide an important regulatory component of numerous cell signalling 
pathways, such as anchorage dependent growth and cell adhesion complex 
formation306-308.  Deregulation of ADAMs has been associated with progression of 
multiple cancers and ADAM10 has been shown to activate the HER2 receptor by 
cleaving the extracellular portion in breast cancer and is associated with poor 
patient prognosis310.   
Multiple DNA tumour viruses have demonstrated the ability to promote matrix 
degradation and a subsequent increase in the invasive potential of tumour cells.  
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Both HPV E7 and HBV HBx induce the expression of matrix transmembrane 
metalloprotease 1 (MT1-MMP), a transmembrane protein crucial for degradation of 
the ECM and facilitates activation of pro-MMP2 (matrix metalloprotease 2)311,312.  
MT1-MMP expression promotes tumour growth and angiogenesis through an up-
regulation of vascular endothelial growth factor (VEGF) which correlates with 
invasiveness and poor prognosis in cervical cancer, reviewed in313.   This 
demonstrates that there is precedence for human tumour viruses to promote 
invasive properties through ECM degradation which allows escape through the 
basement membrane into the vasculature.  
 
1.5.1.4       Integrin expression and motility 
During the last 20 years there have been dramatic changes in our understanding of     
integrin-mediated cell migration.  Integrins are the most widely characterised 
transmembrane receptors and are composed of αβ heterodimers that facilitate 
interactions between the ECM and the actin cytoskeletal network during cell 
motility.  Integrins bind to specific motifs and can recognise a large repertoire of 
ECM components such as fibronectin, collagen, and laminin amongst others.  
Importantly, nine different integrins are capable of mediating interactions with 
fibronectin through an RGD motif (Arg-Gly-Asp). Through this interaction, integrins 
can mediate matrix-induced adhesions which affect cell motility and migration and 
have been associated with tumour invasiveness, reviewed in314,315.  It is therefore 
important to note that changes in cell signalling pathways that affect the integrin 
profile can facilitate changes in cell motility and thus migratory potential. 
In line with this, human tumour viruses have demonstrated the ability to induce 
changes in the integrin profile to those that favour increased cell motility.  For 
example, EBV LMP1, LMP2 and EBNA2 have been shown to promote expression of 
αv integrins, which are predominantly expressed on highly migratory cells and 
metastatic melanomas and have been shown to promote invasion316-318. 
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1.5.1.5      Colonisation of remote sites 
One of the inherent steps in tumour growth is the ability to induce the outgrowth 
of the vasculature, a process known as ‘angiogenesis’, this prevents hypoxia and 
necrosis within the growing tumour from lack of oxygen and other nutrients, 
reviewed in302,305. In order for tumour cells to successfully gain access to remote 
sites within the body they must infiltrate the vasculature as a form of 
transportation.   Specific tumour-associated virus antigens, such as EBV LMP1 have 
demonstrated the ability to induce expression of vascular endothelial growth factor 
(VEGF) and hypoxia-inducible factor 1 alpha (HIF-1α), reviewed in Morris313.  Both 
these proteins are pivotal in promoting neo-vascularisation and sensing hypoxic 
conditions in tumour cells. Not only is this important in tumour cell survival and 
growth but it also facilitates metastasis to distant sites.  
The process of intravasation – entry into the vasculature – begins with tumour cells 
orientating themselves towards the vasculature vessels, followed by directional cell 
motility292.  Some studies concluded that the majority of tumour cells are ‘trapped’ 
in the capillary bed due to their size, while others suggest the vast majority of 
tumour cells rapidly die upon entry into the circulatory system292.  Despite this, only 
a minority of tumour cells that manage to travel within the body will have the 
capabilities to exit the vasculature and even less have the ability to establish 
metastases.   
Extravasation – escape from the vasculature – largely depends on the same 
principles involved in intravasation, with integrin profiles playing a pivotal role 
along with platelets and selectin proteins, reviewed in292.  Establishment of tumour 
cells in niche sites and eventual macrometastasis formation is not a random process 
as has been demonstrated by breast cancer preferentially spreading to the liver but 
not the spleen and bone cancer targeting breast tissue.  This has led to the ‘’seed 
and soil hypothesis’ that concludes that the microenvironment (organ) must be 
compatible with the specific migrating tumour cell292,319. 
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Another layer of complexity has been added to this model and was revealed by an 
eloquent mouse study demonstrating that bone-marrow derived cells are mobilised 
and colonize a small section within the lung to establish a microenvironment 
suitable for secondary tumour formation, before the migrating tumour cells reach 
the site320.  The timing associated with the establishment of the pre-metastatic 
niche is unknown but represents an intriguing mechanism that not only facilitates 
metastasis but may also directly promote cell motility and migration.   
The findings demonstrate that DNA tumour viruses have a range of mechanisms 
that can promote metastasis of viral-induced tumour cells at all stages of the 
metastatic cascade and presents viable therapeutic targets in order to prevent this 
occurrence in a clinical setting.   
 
1.5.2        Cell cytoskeleton and motility 
 
Despite the clinical importance of metastasis, the exact molecular mechanisms by 
which tumour cells acquire the ability to move and migrate from the solid tumour 
have yet to be fully elucidated.  What is known is that the actin cytoskeletal 
network is important for this process321 and recent evidence highlights the 
emerging role of the microtubule network in regulating and facilitating cell 
motility322. 
 
1.5.2.1      Actin cytoskeletal network 
Directional or polarised cell motility is a fundamental cell biology process and is 
pivotal for wound healing, immune responses, embryonic and tissue development. 
Furthermore, several studies have implicated the actin network in facilitating cell 
motility in metastasis323.  The key molecular components of the actin cytoskeleton, 
including the regulatory components have been conserved across the species and 
date back approximately 1 billion years.  Directional movement, as seen with 
mesenchymal motility involves protrusion of the leading edge, adhesion to the 
substratum, retraction at the rear and then de-adhesion from the ECM. 
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The actin network is the main component of cellular protrusions, of which there are 
several types; lamellipodia (flat), pseudopods (cylindrical/round) and filopodia 
(spike-like)305.  Other protrusions such as invadepodia, have been named however 
there are difficulties in clearly distinguishing these protrusions from others.  After 
formation of these protrusions, integrin-mediated focal adhesion complexes attach 
the new protrusion to the ECM components, to facilitate movement through the 
ECM305.   
Receptors are activated upon extracellular signals which result in activation of 
downstream signalling cascades, leading to active Rho-family GTPases and an 
increase in PIP2 (phosphatidylinositol 4,5-bisphosphate), which are crucial for actin 
filament formation. Through the activity of Rho-GTPases activation of WASp and 
Scar proteins occurs, recruiting the Arp2/3 complex and initiating new filament 
branch forming from existing filaments. Actin polymerisation and depolymerisation 
is controlled by profilin which catalyses the exchange of ADP to ATP, thereby 
facilitating depolymerisation and returning the actin monomers to the free pool of 
ATP-actin bound to profilin305,321, as shown in Figure 1.18.   
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Figure 1.18.  Actin cytoskeletal dynamics in cell motility.  Arp2/3 facilitates building of actin 
structures by binding to the sides of existing actin filaments, thereby nucleating growth of further 
filaments.  Actin polymerisation and depolymerisation is controlled by profilin, which catalyses the 
exchange of ADP to ATP, thus facilitating depolymerisation.  Free actin monomers can then be 
hydrolysed and used for further filament formation.  This process if controlled by internal and 
external stimuli.  During cell motility, actin polymerisation occurs at the leading edge and actin 
filaments are built in such a ways as to extend the cell membrane in the direction of movement. 
 
Cell directionality is coordinated by Cdc42, which facilitates actin polymerisation at 
the leading edge along with MT filaments302.  Through formation of these 
protrusions, cells are able to move by actin-mediated physical forces as the 
filaments grow beneath the plasma membrane321. 
 
1.5.2.2        Microtubule cytoskeletal network 
The microtubule (MT) cytoskeletal network is pivotal for cell maintenance and also 
plays an important part in cell functions such as, intracellular vesicle transport, 
organelle positioning and mitotic spindle formation for segregation of 
chromosomes during mitosis324-327.  In recent years it has also been established that 
MTs play an important role in the control of cell shape and polarised cell 
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motility322,328.  All these functions require specific MT arrays with different MT 
densities and geometry and is a tightly regulated process.  
Microtubules form a dense cytoplasmic network and are dynamic structures 
composed of hollow tubes composed of αβ-tubulin heterodimers. The tubulin 
heterodimer is polarised, thus the MT structure is also polarised and orients with    
β-tubulin exposed at the plus end and α-tubulin exposed at the minus end.  
Formation of the MT requires nucleation at organising centres, known as the MTOC 
(microtubule organising centre)329,330.  Tubulin heterodimers can self-assemble and 
disassemble, a process known as dynamic instability329.  Dynamic instability results 
in slow plus end growth of the main MT structure and rapid depolymerisation, also 
known as shrinkage or ‘catastrophe’, followed by subsequent rescue329,330.  The 
minus end of the main MT structure is usually capped and does not generally 
participate in MT dynamics as it is anchored at the MTOC.   
New MT structures can be formed by two main types of mechanisms, either by de 
novo MT nucleation or by mechanical/enzymatic disruption of pre-existing MT 
structures331.  The overall MT state is largely determined by four specific 
parameters, the speed of MT growth, speed of MT shrinkage, catastrophe 
frequency and the rescue frequency.  Maintaining a balance between periods of 
growth (stable) and shrinkage (unstable) is highly regulated by proteins capable of 
binding either tubulin dimers or the assembled MT structures.  These are generally 
divided into two classes of MT-associated proteins (MAPs) known as either MT 
stabilising or MT destabilising proteins324,329.   
Recent research into the properties of MAPs have identified multiple different 
mechanisms by which they can stabilise or destabilise MT structures.  MAPs such as 
the tau protein, MAP2 and DCX are able to bind and stabilise the MT lattice, 
thereby strongly suppressing catastrophe and also promoting growth332-334.   
Similarly, the end-binding 1 (EB1) can prevent catastrophe by directly binding 
growing MT tips and facilitating growth335.  Whereas the MT plus-end tracking 
proteins (+TIPs) form a large group of evolutionary unrelated MAPs that specifically 
bind to growing MT plus ends and are able to stabilise MT structures, promoting 
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MT rescue.  Such proteins include CLASPs (cytoplasmic linker protein-associated 
proteins), which act as stabilising factors at the cell cortex and APC (adenomatous 
polyposis coli) which reduces the MT catastrophe rate of MTs present in cell 
protrusions336-338. 
Other proteins that induce MT catastrophe/disassembly and inhibit MT 
polymerisation include non-motile kinesins from the kinesin-13 family.  These are 
one of the most widely characterised subset of MT destabilising proteins and have 
both ATP-dependent catastrophe-promoting activity and ATP-independent     
tubulin-sequestering abilities339.   One such kinesin, MCAK (mitotic centromere-
associated kinesin), is thought to act through binding the MT ends and accelerating 
catastrophe by destabilising the lateral interactions which exist between MT 
protofilaments339.  In terms of regulation, both tubulin heterodimers and MAPs 
undergo post translational modification including phosphorylation, acetylation, 
polyglutamylation and poly-glycylation, all of which can affect the binding of MAPs 
to MT structures, thus altering the structure of MTs.   
 
1.5.2.2.1     Stathmin, a MT-associated protein 
Stathmin, also known as oncoprotein-18, is the original member of a conserved 
family of proteins that play an important role in microtubule dynamics and is a key 
regulator of the mitotic spindle during cell progression340-342. 
Stathmin is a 17kDa, soluble cytosolic protein whose function relies on its ability to 
bind tubulin dimers340. Characterisation of the amino acid structure of stathmin 
reveals that stathmin has a strong bias towards small polar residues (more than 
66% of stathmin’s sequence composition) and a low preference for bulky 
hydrophobic amino acids343.  As a result, stathmin itself lacks a stable tertiary 
structure in isolation and its conformational behaviour marks stathmin as an 
intrinsically disordered protein343. 
In recent years the action of stathmin in MT destabilisation has been hotly debated 
and controversy exists regarding the exact molecular mechanism by which stathmin 
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can promote microtubule catastrophe; either through direct or indirect 
mechanisms.  The indirect sequestrating ability of stathmin has long since been 
established and has been demonstrated by electron micrograph analysis344, a 
schematic of stathmin function ca be seen in Figure 1.19. Stathmin possess two 
binding sites of equal affinity for tubulin heterodimers, and one stathmin molecular 
(S) is capable of sequestering two α/β-heterodimers (T), giving rise to a stable, 
microtubule assembly incompetent T2S complex
346.  Sequestration of tubulin 
heterodimers reduces the substrate required for growing MT polymers, thereby 
promoting MT destabilisation and catastrophe346.  Analysis of the binding 
equilibrium between tubulin heterodimers and stathmin by nucleotide dissociation 
studies and sequestration assays has demonstrated that the dissociation constants 
can vary by three orders of magnitude345.  Further analysis is required to determine 
the nature of this difference and its relevance to the biological function of stathmin.  
More recently, several studies have demonstrated that stathmin can directly 
promote MT catastrophe, involving other functions that do not rely on its tubulin 
sequestering abilities343.  It has been demonstrated that the T2S binding interface 
may be able to directly bind the MT plus ends and the lattice wall344.  This activity 
results in stathmin specifically binding protofilaments present at the growing MT 
tips, thus abolishing the interaction to maintain its structure and function346,347.  
While more work is required to understand the thermodynamics involved in 
stathmin ability to bind growing MT structures, it is becoming clear that stathmin 
promotes MT destabilisation and catastrophe through indirect and direct methods. 
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Figure 1.19.  Microtubule dynamics and the action of stathmin.  Stathmin, when unphosphorylated, 
binds αβ-tubulin heterodimers to form a T2S complex.  This decreases the pool of free heterodimers 
required for microtubule polymerisation and destabilises the microtubule structures, resulting in 
catastrophe. Upon stathmin phosphorylation, stathmin can no longer bind the tubulin heterodimers, 
thereby promoting microtubule stability and growth.  Furthermore, the exchange of GTP to GDP in 
the tubulin heterodimer promotes dissociation of the microtubule filaments, thereby increasing the 
pool of free tubulin heterodimers, required for microtubule growth.   
 
Stathmin is a phosphoprotein and it is well established that the ability of stathmin 
to sequester tubulin heterodimers relies upon multisite phosphorylation at four 
specific serine residues (Ser16, Ser25, Ser38, Ser63)343,347.  Phosphorylation of 
stathmin at one or more of these serine residues weakens stathmin’s tubulin 
binding ability, thereby increasing the free pool of tubulin heterodimers required 
for MT polymerisation343.  While stathmin dephosphorylation promotes stathmins 
tubulin binding ability, resulting in MT destabilisation and catastrophe343. 
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Interestingly, these four serine residues display differing degrees of effect on 
stathmins tubulin binding ability.  It has been demonstrated that isoforms of 
stathmin, phosphorylated at either Ser16 or Ser63 show a significant decrease in 
the tubulin binding ability of stathmin345,348. However, phosphorylation of either 
Ser25 or Ser38 results only in a slight but non-significant decrease in tubulin binding 
affinities345.  Furthermore in vivo data indicates that stathmin phosphorylation is 
sequential and that phosphorylation of Ser25 and Ser38 facilitate the 
phospshorylation of Ser16 and Ser63348.   
This data suggests that Ser16 and Ser63 are the dominate phosphorylation residues 
within stathmin and explains the reduce activity/inactivation of stathmin in vivo, 
upon phosphorylation of these residues.  Furthermore, dephosphorylation at either 
Ser16 or Ser63 have been shown to be important in tumour formation and 
progression346.  This can be explained by recent evidence indicating the position of 
these residues within the tertiary structure of stathmin.  Circular dichroism 
spectroscopy has demonstrated that Ser63 phosphorylation significantly reduces 
the helical content and the thermal stability of stathmin346.  While Ser16 is located 
within the T2S tight turn of the β-hairpin turn, which has been shown disrupt the 
intramolecular interactions within the backbone349.  This demonstrated that 
phosphorylation of theses serine residues compromises the formation and integrity 
of the tubulin-interacting β-hairpin and a helical segment, resulting in significant 
differences in the tertiary structure of stathmin which affect its tubulin binding 
capabilities. 
One of the major documented functions of stathmin is its important role in cell 
cycle progression and its effects on mitotic spindle formation350.  It was observed 
that the phosphorylation levels of stathmin significantly increased upon entry to 
erythroleukemia cells into the mitotic cycle350, and this has been further 
demonstrated in HeLa cells and Jurkat T cells351.  The exact molecular mechanism 
by which stathmin controls cell cycle progression has yet to be fully elucidated but 
it is known that its ability to promote MT depolymerisation is essential352. 
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Upon entry into mitosis, stathmin is inactivated by phosphorylation, thus allowing 
MT to polymerise and assemble into MT lattices that form the mitotic spindle353.  
To further support this, Marklund and colleagues demonstrated that 
overexpression of wild-type stathmin and phosphorylation deficient stathmin 
mutants promoted depolymerisation of interphase MTs.  This resulted in randomly 
arranged chromosome (rather than those arranged at the metaphase plate), no 
chromosome segregation and cell cycle arrest in the early stages of mitosis353.  In 
contrast, stathmin inhibition at later mitotic stages prevents the timely exit from 
mitosis, such as spindle disassembly which requires MT depolymerisation facilitated 
by statmin dephosphorylation341.   
Importantly, stathmin overexpression is a feature of multiple cancer types and has 
been shown to correlate with tumour growth, poor patient prognosis and a high 
metastatic/invasive potential340,354.  Furthermore, RNA interference studies have 
demonstrated that reducing stathmin levels can drastically reduce the motility 
potential of various tumour cells355-358.  This is supported by studies addressing the 
role of phosphorylation on stathmin MT destabilising activity and transforming 
potential359.  Taken together this suggests that stathmin deregulation in various 
cancers can facilitate alterations in the microtubule network that contribute to cell 
motility and increased cell migration.  Thus stathmin may play a crucial role in 
cancer cell metastasis.   
 
1.5.3      DNA tumour viruses and cell motility 
Interestingly in 2006, Grossmann and colleagues demonstrated that the KSHV vFLIP 
protein can promote remodelling of the actin cytoskeletal network through 
activation of the NF-KB signalling pathway
360.  Similarly SV40 ST, through an 
interaction with PP2A, can promote alterations in the cytoskeletal network299. 
Moreover, there is increasing evidence to suggest that PP2A suppression alone can 
promote cell motility and invasiveness of multiple cancers361.  SV40 ST has been 
shown to induce F-actin remodelling resulting in membrane ruffling, lamellipodia 
and filopodia formation299.  Furthermore, actin remodelling is associated with loss 
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of cell polarity and increased tumour invasion thus contributing to ST-mediated 
actin disorganisation and thus cell transformation and invasiveness299.   
In terms of MT-destabilising proteins, transgenic expression of the PyV MT (under 
the control of the mouse mammary tumour virus (MMTV) promoter) in mouse 
prostate cells,  results in an increase in stathmin mRNA levels, this was conducted 
as part of a large screening process which identified 360 differentially expressed 
genes and has yet to be further studied362,363.   
This clearly demonstrates a precedence of DNA tumour virus promoting alterations 
in the host cell cytoskeleton that facilitate and promote motile phenotypes.  In the 
viral-induced cancer context these interactions could aid in cells establishing 
migratory patterns and facilitate metastasis to remote sites.  Thus this could 
identify exciting new therapeutic targets for clinical treatment of viral-associated 
cancers in the endeavour to reduce the metastatic potential of these tumours.  
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Thesis Aims 
 
Upon commencing this study, very few MCPyV-related reagents were available, due 
to its recent discovery in 2008.  Therefore, in Chapter 3 it was necessary to produce 
a range of MCPyV ST expression vectors and a stable cell line capable of inducible 
expression of MCPyV ST.  Furthermore, an initial aim of this project was to generate 
a library of proteins that were differentially expressed upon MCPyV ST expression, 
in an endeavour to identify specific cellular signalling pathways and virus-host 
interactions affected by MCPyV ST expression.  Therefore, a high throughput 
quantitative proteomics approach was utilised to identify multiple gene ontology 
pathways. 
One of the key overall aims of this study was to determine if MCPyV ST expression 
plays a role in the highly metastatic phenotype of MCC tumour cells.  Thus, 
quantitative proteomic analysis revealed that MCPyV ST expression affects the 
expression of numerous proteins important for microtubule organisation and 
dynamics.  Importantly, it has previously been shown that the microtubule 
cytoskeletal network plays an important role in cell shape and polarised cell 
motility322,328.   
Therefore, through proteomic analysis and motility assays, described in Chapter 3 
and 4, it was shown that MCPyV ST expression promotes cell motility, migration 
and invasion in multiple motility assays.  Furthermore, analysis revealed that 
MCPyV ST expression promotes microtubule destabilisation and is essential for 
MCPyV ST-induced cell motility.   
Data presented in Chapter 4, demonstrates that stathmin, a key microtubule-
associated protein, is upregulated upon MCPyV ST expression.  Interestingly, 
previously studies have shown that stathmin overexpression correlates with 
tumour formation, enhanced metastasis and poor patient prognosis340,354. 
Therefore in order to study stathmin in greater detail and the effects of stathmin 
upregulation on MCPyV ST-induced cell motility, siRNA studies demonstrated that 
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upregulation of stathmin by MCPyV ST is a requirement for MCPyV ST-induced cell 
motility and migration.   
Following this, a further aim was to address how upregulation of stathmin by 
MCPyV ST is able to promote enhanced cell motility.  Stathmins’ inherent activity is 
regulated through phosphorylation and data presented in Chapter 3, 4 and 5 
indicates that MCPyV ST expression promotes an increase in the cellular pool of 
unphosphorylated stathmin.  This finding is consistent with stathmins’ microtubule 
destabilising activity364,365, thereby suggesting that MCPyV ST expression promotes 
microtubule destabilisation by enhancing stathmin microtubule destabilising 
activity through dephosphorylation.   
It has long since been established that polyomavirus ST antigens contain binding 
sites required for interactions with cellular phosphatases, such as PP2A Aα and 
PP2A Aβ247.  Moreover, Griffiths and colleagues recently demonstrated that MCPyV 
ST interacts with the cellular phosphatase catalytic subunit PP4C226.  As stathmin 
activity is regulated by dephosphorylation by specific cellular phosphatases, it was 
necessary to determine if any known MCPyV ST interactions with these cellular 
phosphatases played a role in stathmin dephosphorylation.  Herein, data presented 
indicates that PP4C plays an important role in facilitating MCPyV ST-induced 
microtubule destabilisation and cell motility, through promoting the 
dephosphorylation of stathmin.  
In summary Chapters 3, 4 and 5 present a novel molecular mechanism by which 
MCPyV ST expression promotes cell motility, migration and invasion and is the first 
study to demonstrate this link.  Data here also eludes to the possibility of specific 
chemotherapy drugs which could aid in inhibiting this phenotype, thereby 
decreasing or preventing metastasis of MCC tumour cells.   
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2 Materials and Methods 
 
2.1  Materials 
 
2.1.1  MCC tumour samples 
Fresh MCC tumour samples were supplied by Professor Julia Newton-Bishop at St 
James’ Hospital, Leeds. Upon removal of samples from two patients undergoing 
surgery, these samples were immediately frozen on dry ice and stored at -80 °C.  
Tumour samples for immunohistochemistry tissue staining were kindly provided by 
Dr Neil Steven (University of Birmingham). 
 
2.1.2 Chemicals 
All chemicals and solvents (analytical grade) were provided by Sigma-Aldrich®, 
Melford Laboratories Ltd. and Life Technologies™, unless stated otherwise. 
Solutions were sterilised using 0.22 µm filters (Millex), or by autoclaving (121 °C, 30 
minutes, 15 psi).  All water used throughout, unless mentioned otherwise, was 
deionised water sterilised through an ELGA PURELAB ultra machine (ELGA). 
 
2.1.3 Enzymes 
All restriction enzymes were supplied by either Life Technologies™ or New England 
BioLabs Inc. Other enzymes and their suppliers are listed in Table 2.1.  
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Enzyme Supplier 
Platinum® Pfx DNA polymerase 
 
Life Technologies™ 
Taq DNA polymerase 
Superscript® II reverse transcriptase 
Proteinase K 
RNase out 
T4 DNA ligase New England BioLabs Inc. 
DNA-freeTM DNase I treatment kit Ambion® 
DNase I Amplification Grade Sigma-Aldrich® 
2x SensiMixTM SYBR No-ROX kit Quantace Ltd. 
Table 2.1.  List of enzymes and the corresponding suppliers. 
 
2.1.4 Antibodies 
Primary antibodies were obtained from a variety of suppliers, detailed in Table 2.2. 
Horseradish peroxidase (HRP) conjugated anti-mouse and anti-rabbit secondary 
antibodies were supplied by Dako™ and used for western blotting at concentration 
of 1:5000.    Alexa-fluor conjugated anti-mouse and anti-rabbit Immunoglobulin G 
(IgG) antibodies used for immunofluorescence microscopy were supplied by Life 
Technologies™.  An actin stain, Phalloidin was supplied by Life Technologies™ and 
used at a working concentration of 1:5000.  The 2T2 antibody (kindly provided by 
Dr Christopher Buck, National Cancer Institute, Bethesda, MD), which recognises 
the J-domain leader peptides present in both MCPyV ST and MCPyV LT was used at 
a dilution of 1:5 for western blot analysis. 
 
 
Chapter 2 
82 
  
Antibody  (supplier 
catalogue number) 
Origin Working dilution Supplier 
WB IF 
Anti-FLAG (F7425) Rabbit 1:1000 1:250  
 
 
 
 
Sigma 
Anti-β-actin (A2228) Mouse 1:5000 - 
Anti-GST (G1160) Mouse 1:3000 - 
Anti-HA (H9658) Mouse 1:3000 1:250 
Anti-Myc (M4439) Mouse 1:5000 1:250 
Anti-His (H1029) Mouse 1:1000 - 
Anti-GAPDH (ab8245) Mouse 1:10,000 - 
Anti-Glu-Glu 
(ab24627) 
Mouse 1:1000 - 
Anti-β-tubulin (2146) Rabbit - 1:200 
Anti-acetylated-
tubulin 
Mouse 1:5000 -  
Anti-GFP (632569) Mouse 1:5000 - Living Colors 
Anti-Lamin B (101-B7) Mouse 1:5000 - Calbiochem 
Anti-Statmin 1 Rabbit 1:1000 1:200 Abcam 
Anti-Stathmin 1 
(phospho S16) 
Rabbit 1:500 - Abcam 
Anti-Arp3 Rabbit 1:1000 -  
Anti-Cortactin Rabbit 1:1000 -  
Anti-STRAP Rabbit 1:1000 - GeneTex 
Anti-KIF14 Rabbit 1:1000 1:200  
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Anti-PKM2 Rabbit 1:1000 -  
Anti-PSPH Rabbit 1:1000 -  
Anti-PSAT1 Rabbit 1:1000 -  
Anti-PHGDH Rabbit 1:1000 -  
Anti-HK1 Rabbit 1:1000 -  
Anti-c-Myc Rabbit 1:1000 -  
Anti-AMPK Rabbit 1:1000 1:200 GeneTex 
Anti-Pirin Rabbit 1:1000 -  
Anti-ADAMTS1 Rabbit 1:1000 1:200  
Anti-TBCC Rabbit 1:1000 -  
Anti-JAM-B Rabbit 1:1000 -  
Anti-ZO-1 Rabbit 1:1000 1:200  
Anti-2T2 Mouse 1:5 - Dr C Buck 
Table 2.2.  List of primary antibodies, the corresponding suppliers and the working dilutions for 
either western blotting or immunofluorescence microscopy. 
 
2.1.5 Mammalian cell culture reagents 
All tissue culture media and culture supplements were supplied by either Life 
Technologies™, Lonza™, Sigma-Aldrich™ or Dundee Cell Products (SILAC media 
only). Selection antibiotics were provided by either InVivoGen™ or Life 
Technologies™ and LipofectamineTM 2000 was supplied from Life Technologies™. 
 
2.1.6 Oligonucleotides 
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Oligonucleotide primers for DNA sequencing and polymerase chain reaction (PCR) 
were supplied by Sigma-Aldrich®. A full list of primers used are shown in Table 2.3.    
Oligo(dT)12-8 was supplied by Promega, in order to perform reverse transcription. 
 
Primer Use Sequence (5’-3’) and restriction site 
Primer 1 PCR, 
cloning 
GGGGGTACCATGGATTTAGTC (KpnI) 
Primer 4 PCR, 
cloning 
GCTGGATTCTCTTCTTGAA (-) 
Primer 3 PCR, 
cloning 
GATATACCTCCCGAACACCATGAG (-) 
3’ STOP REV PCR, 
cloning 
GGGCCCGGGACTTGCTGAACTAGCAGAGCTTG (SmaI) 
pcDNA/FRT/TO-LT 
Forward 
PCR, 
cloning 
GGGGGTACCACCATGGATTTAGTCCTAAATAGGAAAG (KpnI) 
pcDNA/FRT/TO-LT 
Reverse 
PCR, 
cloning 
CGAGCGGCCGCTCACTTATCGTCGTCATCCTTGTAATCATGATCGA
ATGGAGGAGGGGTCTTCGGGGTG (NotI) 
pEGFP-C1-LT 
Forward 
PCR, 
cloning 
GGGCTCGAGATACCATGGATTTAGTCCTAAATAGGAAAG (XhoI) 
pEGFP-C1-LT Reverse PCR, 
cloning 
CGAGGTACCTCAGAATGGAGGAGGGGTCTTCGGGGTG 
Stathmin1 Forward qRT-PCR GAGTGTGGTCAGGCGGCTCG 
Stathmin1 Reverse qRT-PCR GAGAATCAGCTCAAAAGCCTGGC 
GAPDH Forward qRT-PCR GTGGTCGTTGAGGGCAATG 
GAPDH Reverse qRT-PCR TGTCAGTGGTGGACCTGAC 
Table 2.3.  List of primers used for various applications such as cloning or qRT-PCR including the 
sequences for both the forward and reverse primer pair. 
 
2.1.7 Plasmid constructs 
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Plasmid constructs were either purchased or supplied by other laboratories and are 
listed in Table 2.4. 
 
Construct Source 
pcDNA5-FRT-TO  Life Technologies™ 
pOG44  (pPGK/Flip/ObpA) Life Technologies™ 
pEGFP-C1 Clonetech Laboratories, Ic 
pcDNA3.1-FLAG-PP4C Marilyn Goudrealt, University of Toronto, 
Canada 
RL-PP4C-HA (transdomiant 
mutant) 
Tse-Hua Tan, National Health Research 
Institute, Taiwan 
pcDNA3.1-HA-PP2A Cα Peter Cron, University of Basel, Switzerland 
PcDNA5-EE-PP2A Aα Stefan Strack, University of Iowa, USA 
Table 2.4.  List of constructs purchased from suppliers for provided by collaborators 
 
2.2    Methods 
 
2.2.1    Extraction of DNA from MCC tumour sections 
Fresh tumour sections were lysed for 1 hour using digestion buffer [100 mM NaCl, 
10 mM Tris-HCl (pH 8.8), 2.5 mM EDTA, 0.5% SDS (pH 8), 0.1 mg/ml fresh 
Proteinase K]. DNA was extracted by carefully mixing the lysate with 
Phenol/Chloroform isoamyl alcohol (25:24:21) and precipitated by incubation for 1 
hour in cold Ethanol (66.6%) and 0.3 M Sodium Acetate (pH 5.2) at -80 °C, before 
pelleting in a microcentrifuge at 13,000 x g for 30 minutes.  Absolute ethanol was 
collected and the DNA pellet resuspended in 70% Ethanol.  DNA was pelleted and 
air dryed at room temperature, followed by resuspension in autoclaved, distilled 
H2O (dH2O) and storage at -20 °C. 
2.2.2      Molecular Cloning 
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2.2.2.1   Construction of recombinant vectors 
DNA was PCR amplified (Section 2.2.2.2) and separated by agarose gel 
electrophoresis (Section 2.2.2.3), then gel purified and ligated into the appropriate 
linearised double stranded DNA vector (Section 2.2.2.5 and Section 2.2.2.6).  This 
was done via a cloning vector, pCR Blunt (Life TechnologiesTM). Table 2.4 and Table 
2.5 display a list of recombinant vectors and the corresponding primers used for 
PCR amplification of their inserted fragments.  After amplification in chemically 
competent bacteria (Section 2.2.2.8) and purification of plasmid DNA (Section 
2.2.2.9), these constructs and inserts were verified by restriction digest analysis 
(Section 2.2.2.6).  All constructs were sequenced to validate the identity of the 
inserted fragments (Section 2.2.2.10). 
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Recombinant 
vector 
Parent 
vector 
Primer Sequence (5’-3’) Restriction 
Enzyme 
Primer 
name 
pEGFP-ST pEGFP-
c1 
(F)GGGGGTACCATGGATTTAGTC KpnI Small T F 
(R)GGGCCCGGGCTAGAAA SmaI Small T R 
pi293-ST pcDNA
5/ 
frt/To/
His 
(F)GGGGGTACCATGGATTTAGTC BamHI Small T F 
(R)CGAGCGGCGCCTCACTTATCGT
CGTCATCCTTGTAATCATGATGGA
AAAGGTGCAGATGCAGTAAGC 
NotI FLAG-
Small T R 
(R)GGGCCCGGGCTAGAAA EcoRI Small T R 
pEGFP-T 
antigen 
pEGFP-
c1 
(F)GGGCTCGAGATACCATGGATTT
AGTCCTAAATAGGAAAG 
XhoI EGFP-T F 
  (R)CGAGGTACCTCAGAATGGA
GGAGGGGTCTTCGGGGTG 
KpnI EGFP-T R 
pi293-T 
antigen 
pcDNA
5-FRT-
TO 
(F)GGGGGTACCACCATGGATT
TAGTCCTAAATAGGAAAG 
 
KpnI Tantigen 
F 
  (R)CGAGCGGCCGCTCACTTAT
CGTCGTCATCCTTGTAATCAT
GATCGAATGGAGGAGGGGTC
TTCGGGGTG 
NotI Tantigen 
R 
pi293-LTcDNA  (F)GGGGGTACCATGGATTTAGTC
CTAAATAGGAAAG 
KpnI LTcDNA F 
  (R)CGAGCGGCCGCTCACTTATCGT
CGTCATCCTTGTAATCATGATCGA
AGGAGGAGGGGTCTTCGGGGTG 
NotI LTcDNA R 
pEGFP-LTcDNA pEGFP-
c1 
(F)GGGCTCGAGATACCATGGATTT
AGTCCTAAATAGGAAAG 
XhoI EGFP-
LTcDNA F 
  (R)CGAGGTACCTCAGAATGGAGG
AGGGGTCTTCGGGGTG 
KpnI EGFP-
LTcDNA R 
Table 2.5.  List of recombinant constructs, the primer sequences used for cloning, restriction  
enzymes and the original parental vectors. 
 
2.2.2.2        Polymerase chain reaction (PCR) 
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PCRs were performed using a Mastercycler, epgradient (Eppendorf™) in thin-walled 
0.2 ml PCR tubes (Greiner™).   For cloning purposes Platinum® Pfx DNA polymerase 
was used due to the need for proofreading ability, otherwise Taq DNA polymerase 
was used. Reactions were performed in a total volume of 50 µl, containing the 
following components:  0.2mM of each primer, 1 x polymerase amplification buffer, 
1.5 mM MgSO4/MgCl2, 1-10 ng template DNA and 1 µl DNA polymerase.  The 
remaining volume consisted of deionised water.   Typical PCR amplifications were 
performed using an initial denaturing temperature of 95 °C for 5 minutes, followed 
by 35 cycles of; 95 °C for 1 minute, annealing temperatures in the range of 50-60 °C 
for 1 minute and an extension temperature of 68 or 72 °C, for 2 minutes. Following 
the final thermal cycling step, a period of 10 minutes at 68 or 72 °C respectively was 
performed to ensure that all polymerising templates were complete. All reactions 
were performed with the heated lid setting on, to prevent sample evaporation. 
After PCR amplification, products were analysed by agarose gel electrophoresis 
(Section 2.2.2.3). 
 
2.2.2.2.1    Overlap extension PCR (OE-PCR) 
To generate the MCPyV T antigen region the N-terminal/C-terminal fragments of 
the T antigen were gel purified (Section 2.2.2.4) and used in an overlap extension-
polymerase chain reaction (OE-PCR).  The 2 purified T antigen fragments were used 
as the template DNA in a single PCR reaction (Section 2.2.2.2) using only the 
outermost forward (Primer 1) and outermost reverse (3’STOP REV) primers.  The 
same PCR protocol was performed as in Section 2.2.2.2 however an annealing 
temperature of 51.2 oC was used. 
 
2.2.2.3       Agarose gel electrophoresis 
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Double stranded DNA fragments were separated by agarose gel electrophoresis, 
using 0.8-1.2% agarose gels, depending on the size of the DNA product.  Agarose 
was dissolved in 1 x TBE buffer [90 mM Tris-base, 2mM EDTA, 80mM boric acid] 
with 0.5µg/ml ethidium bromide.  A 10x solution of gel loading buffer [0.25% (w/v) 
Orange G dye, 30% (v/v) glycerol] was added to DNA samples at 1 x final 
concentration.  An appropriately sized DNA ladder (either 100 bp or 1 kb (Life 
Technologies™)), depending on DNA product size, was loaded alongside samples to 
indicate the size of the DNA product.  Electrophoresis was performed at 90-120V in 
1 x TBE buffer using a HE 99X Max horizontal electrophoresis tank (Hoefer™).  DNA 
bands were visualised under ultra-violet light using a transilluminator and images 
taken using the GeneGenius bio-imaging system (Syngene™). 
 
2.2.2.4 Gel purification of DNA 
DNA fragments were excised using a sterile scalpel following agarose gel 
electrophoresis and purified using the QIAquick gel extraction kit (Qiagen), 
according to the manufacturers instructions.  The weight of the DNA gel slice was 
recorded and then followed by incubation at 50 oC with 3 gel volumes of buffer QG, 
to melt the agarose.  Upon melting, one gel volume of isopropanol was added to 
the sample and mixed.  This mixture was then applied to a QIAuick column and 
centrifuged for 1 minute at 13,000 x g, room temperature.  DNA bound to the 
membrane was washed using 750 µl PE buffer and centrifuged at 13,000 x g for 1 
minute, room temperature.  DNA was eluted into a sterile eppendorf tube using   
30-50 µl TE buffer, followed by centrifugation at 13,00 x g for 1-2 minutes at room 
temperature.  Pure DNA was stored at -20 oC until further use.  
 
2.2.2.5 DNA ligation 
A standard ligation reaction was performed in a total volume of 20 µl, using 1 x T4 
DNA ligase buffer, 1 U of T4 DNA ligase (both Life TechnologiesTM), 10-100 ng of 
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linearised vector and varied molecular proportions of insert DNA.  Ligation 
reactions were performed at 16 oC for 1-2 hour.  Control reactions lacking either 
DNA insert or DNA ligase were also used for each reaction to determine the 
efficiency of the digest.   
 
2.2.2.6 Restriction enzyme digestion 
All DNA restriction digests were carried out according to the manufacturers 
protocol (New England BiolabsTM).  All reactions were prepared in a volume of 20 µl 
in the appropriate buffer for each restriction digest enzyme, with 1 U of restriction 
digest enzyme used per 1 µg of DNA to be digested.  Double digests, using two 
restriction digest enzymes were performed in a compatible buffer, to minimise DNA 
loss as a result of purification of DNA from sequential digests.  All digest reactions 
were performed at 37 oC for 2-4 hours or overnight at room temperature.  Resulting 
digests were terminated by heat inactivation at  65 oC for a minimum of 20 minutes.  
Resulting fragments were analysed by agarose gel electrophoresis (Section 2.2.2.3) 
and gel purified (Section 2.2.2.4).    
 
2.2.2.7 Preparation of chemically competent DH5α 
All cloning was carried out using Escherichia coli (E.coli) strain DH5α (Genotype: F-, 
Ψ80dlacZΔM15, Δ(lacZYA-argF)U169, deoR, recA1,  endA1, hsdR17(rk-, mk+), phoA, 
supE44, λ-, thi-1, gyrA19, relA1). 
Chemically competent E.coli was prepared using a rubidium chloride-based method 
and liquid cultures were grown in autoclaved Luria broth (LB) [1% (w/v) tryptone, 
0.5%(w/v) NaCl, 0.5% (w/v) yeast extract, pH 7.5]  and incubated at 37oC with 
shaking (200 rpm).  DH5α cells were streak plated on LB agar plates (1% NaCl, 1% 
Tryptone, 0.5% Yeast Extract and 1.5% Agar) followed by incubation at 37 oC.  One 
colony was used to inoculate 2 ml of LB media and incubated for 5-7 hours at 37oC 
with shaking. Following this 0.5 ml of the culture was used to inoculate 50 ml of LB 
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media and the cells were grown at 37 oC with shaking, until an OD600 of 0.3-0.6 was 
reached.  The cells were subsequently pelleted by centrifugation at 5,000 x g for 5 
minutes at 4 oC.  The pellet was resuspended in 40 ml ice-cold filter-sterilised TFB1 
buffer [30 mM KOAc, 10 mM CaCl2, 50mM MnCl2,100 mM RbCl, 15% (v/v) glycerol, 
adjusted to pH 5.8 with acetic acid]  and incubated for 5 minutes at 4 oC.  The cells 
were centrifuged at 5,000 x g for 5 minutes at 4oC followed by gentle resuspension 
of cells in 2 ml ice-cold filter-sterilised TFB2 buffer [10 mM MOPS, 75mM CaCl2, 10 
mM RbCl, 15% (v/v) glycerol, adjusted to pH 6.4 with KOH].  This was followed by 
incubation at 4oC for 15-60 minutes and subsequently cells were aliquoted and 
quick frozen on dry ice, followed by storage at -80oC.   
 
2.2.2.8 Transformation of chemically competent bacteria 
100 ng of a pre-chilled DNA expression construct was mixed with a 50 µl aliquot of 
chemically competent cells (either DH5α or BL21 Gold Cells (Stratagene)), and 
incubated for 5-30 minutes at 4 oC.  Mixtures were then incubated for precisely 30 
seconds at 42 oC then subjected to a rapid cool down for 2 minutes at 4 oC.  
Followed by addition of 250 µl LB media and incubation with shaking at 37 oC for 1 
hour.  Samples were then spread plated onto LB agar containing the appropriate 
selective antibiotic (either ampicillin or kanamycin) at a concentration of 50 µg/ml.  
These plates were then incubated overnight for approximately 16 hours at 37 oC.   
 
2.2.2.9  Plasmid purification 
2.2.2.9.1 Mini prep (small scale) plasmid purification 
A single transformed (Section 2.2.2.8) E.coli colony was used to inoculate 2 ml LB 
media, containing either ampicillin or kanamycin at 50 µg/ml, followed by shaking 
incubation at 37 oC overnight for 16 hours.  E.coli cells were centrifuged for 5 
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minutes at 5,000 x g and were resuspended in 100 µl autoclaved Solution I [25 mM 
Tris-HCL (pH 8.0), 10mM EDTA, 50mM glucose].  This was followed by addition of 
200 µl Solution II [200mM NaOH, 1% (w/v) SDS] and incubated for 5 minutes at 
room temperature to allow for cell lysis.  Followed by precipitation of DNA, proteins 
and SDS by addition of 150 µl Solution III [5 M potassium acetate, 30% (v/v) glacial 
acetic acid].  Samples were gently inverted and incubated for 20 minutes at 4 oC, 
followed by centrifugation at 4 oC for 10 minutes at 13,200 x g, to separate out 
precipitate and lysate.  Lysates containing plasmid DNA was extracted by addition 
of equal volumes of phenol:chloroform:isoamyl alcohol (25:24:21) solution, 
followed by centrifugation at 4 oC for 5 minutes at 13,200 x g.  The aqueous 
containing DNA layer was removed and 2 volumes of pre-chilled ethanol (4 oC) was 
added, followed by incubation for a minimum of 20 minutes at -20 oC, to allow 
precipitate of the DNA.  Following centrifugation at 13,200 x g the DNA pellet was 
washed using 70% (v/v) ethanol, air-dried and resuspended in 20 µl deionised water 
containing 10 µg/ml RNase A.  
 
2.2.2.9.2 Maxi prep (large scale) plasmid purification 
 
For large scale plasmid purification QIAGEN maxi prep kits and column were used 
according to the manufacturers protocol.  A single transformed (Section 2.2.2.8) 
E.coli colony was used to inoculate 2 ml LB media, containing either ampicillin or 
kanamycin at 50 µg/ml, followed by shaking incubation at 37 oC overnight for 16 
hours.  This 2 ml culture was then mixed with 200 ml LB media and incubated with 
shaking at 37 oC for 16 hours. The culture was then centrifuged at 4,500 x g for 20 
minutes at 4 oC.  The cell pellet was then resuspended in  10 ml Buffer P1 [10mM 
EDTA, 50Mm Tris-HCl (pH 8.0), 100 µg/ml RNase A] and 10 ml Buffer P2 [1% SDS, 
200nM NaOH], this mixture was then inverted 10 times and incubated at room 
temperature for 5 minutes.  Following this 10 ml of pre-chilled (4 oC) Buffer P3 [3 M 
potassium acetate, pH 5.5] was added, followed by immediate mixing (inverted 10 
times) and incubation at 4 oC.  Mixtures were centrifuged at 4 oC for 20 minutes at 
13,000 x g and the solution was added to a pre-equilibrated QIAGEN-tip 500 column 
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and allowed to drain by gravity, to allow binding of DNA.  The column was 
equilibrated with Buffer QBT [50 mM MOPS (pH 7.0), 750 mM NaCl, 0.15% (v/v) 
Triton X-100].  The column resin was subsequently washed twice with 30 ml Buffer 
QC [50mM MOPS (pH 7.0), 1 M NaCl, 15% (v/v) isopropanol], followed by DNA 
elution by addition of 15 ml Buffer QF [15% (v/v) isopropanol, 1.25 M NaCl, 50 mM 
Tris-HCl].  To precipitate the DNA, 10.5 ml isopropanol was added to the eluted 
solution and centrifuged at 4,500 x g for 30 minutes at 4 oC.  The DNA pellet was 
then subsequently air-dried and resuspended in 200 µl deionised water.  To 
determine the concentration and purity of the DNA recovered, 1 µl samples were 
analysed using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies) 
at 260 nm wavelengths.   
 
2.2.2.10  Sequencing of DNA 
All DNA sequencing was conducted by GATC, London. Plasmid DNA was sent at a 
concentration of 30 ng/ml in a total volume of 50 µl and corresponding primers at a             
10 pmol/µl in 30 µl.  Sequencing data was analysed using BioEdit sequence 
alignment editor and ClustalW (EBI, UK) against corresponding reference sequences 
obtained from the NCBI database. 
 
2.2.3  Mammalian cell culture 
 
2.2.3.1  Cell lines  
Human embryonic kidney (HEK) 293 FlpInTM (Life TechnologiesTM), were kindly 
supplied by Stuart Wilson (University of Sheffield, UK), the parental cell line for 
generation of the i293-ST.  The hepatocellular carcinoma cell line (HuH-7) and 
fibrosarcoma cell line (HT-1080) were provided by Professor Eric Blair (University of 
Leeds, UK) and used for immunofluorescence microscopy and invasion assays, 
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respectively.  Merkel cell carcinoma, MCPyV negative cell lines (MCC13) and a 
Merkel cell carcinoma, MCPyV positive cell lines (MKL-1) were obtained from the 
European Collection of Cell Cultures (ECACC).   
 
2.2.3.2 Cell line maintenance 
HEK 293 FlpInTM, i293-ST, i293-T antigen, iEGFP, iEGFP-ST, HuH-7 and HT-1080 cell 
lines were maintained in Dulbecco modified eagle medium (DMEM) (LonzaTM), 
supplemented with 5 U/ml penicillin and streptomycin and 10% (v/v) foetal calf 
serum (FCS), herein referred to as ‘’10% DMEM’’. HEK 293 FlpInTM cells were 
maintained in 10% DMEM supplemented with 100 µg/ml zeocin (Life 
Technologies™).  i293-ST, iEGFP and iEGFP-ST cells lines were maintained in 10% 
DMEM supplemented with 100 µg/ml Hygromycin B (Life Technologies™).  These 
cell lines were passaged every 3-4 days, whereby confluent cells layers were 
removed by kinetic force from the surface of a 75 cm3 tissue culture vessel (Sigma-
Aldrich®) and split in a 1:10 to 1:20 ratio into new flasks made up to a total volume 
of 20 ml using 10% DMEM and supplemented with the corresponding selective 
antibiotic.   
 
HuH-7 and HT-1080 cells were maintained in 10% DMEM and passaged every 3-4 
days, whereby the confluent cell layer was removed by trypsinisation and the cells 
were subsequently split 1:20 into new flask containing 10% DMEM.   MCC13 and 
MKL-1 cells were maintained in Roswell Park Memorial Institute (RPMI) media, 
supplemented with 5 U/ml penicillin and streptomycin and either 15% FCS or 10% 
FCS, respectively.  Herein referred to either ‘’15% RPMI’’ or ‘’10% RPMI’’ MCC13 
cells were passaged in the same fashion as HuH-7 cells but using 15% RPMI.  MKL-1 
cells are a non-adherent cell line, hence cells were first centrifuged at 1,500 x g for 
3 minutes and resuspended in 10% RPMI, and split at a 1:4 ratio every 4 days into 
new tissue culture flasks.   
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Long term storage of cell lines, required cells to be aliquoted into 1.8 ml 
Cryotubes™ (NUNC™) at 1 x 106 cells/ml.  Cells were resuspended in freezing media 
[90% (v/v) FCS, 10% (v/v) DMSO], Cryotubes were then stored at -80 oC for 24 hours 
in an isopropanol containing freeze flask and then transferred to liquid nitrogen for 
long term storage.  All cell lines were incubated in an InCu saFe Copper-Enriched 
Stainless Steel CO2 incubator (Panasonic), with 5% CO2 concentration, unless 
otherwise stated.   
 
2.2.3.3 Maintaining cells in SILAC media 
Media used to label i293-ST cells prior to SILAC based quantitative proteomic 
analysis was supplied by Dundee Cell Products and supplemented with 10% 
dialysed foetal calf serum (Dundee Cell Products).  i293-ST and i293-T antigen cells 
were passaged 7 times in both R0K0 DMEM (containing 
12C L-Arginine and 12C L-
Lysine), and R6K4 DMEM (containing 
12C L-Arginine and 12C L-Lysine), herein referred 
to as ‘’light DMEM’’ and ‘’heavy DMEM’’, respectively.  Upon each passage both 
light media and heavy media was supplemented with Hygromycin B (Life 
Technologies™) (as described in Section 2.2.3.5.2). 
 
2.2.3.4 Generating inducible cell lines 
To generate cell lines capable of inducible expression of either MCPyV ST, HEK 293 
FlpIn™ cells were co-transfected (Section 2.2.3.5.1) with iST-FLAG or iT-FLAG 
(respectively) and pPGK/Flip/ObpA (kindly supplied by M.Walsh, University of 
Sheffield, UK) at a 1:3 ratio, respectively using 0.5 µg of iST-FLAG and 1.5 µg 
pPGK/Flip/ObpA.  The cell line was selected and maintained by Hygromycin B 
resistance at concentration of 100 µg/ml.  Cells were monoclonally selected to 
ensure the resulting cell line was derived from a single cell/colony.   
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2.2.3.5 Mammalian cell culture based protocols 
2.2.3.5.1  Mammalian cell transfection 
A standard transfection protocol was followed for all assays unless stated 
otherwise.  Approximately 5 x 105 were seeded into each 6-well (35mm diameter) 
plate the day before transfection, to allow cells to grow to 70% confluency upon 
transfection.  All transfections used Lipofectamine™2000, according to the 
manufacturers protocol.  Per reaction (1 x 6-well), 3 µl Lipofectamine™ 2000 was 
diluted in 100 µl media (either DMEM or RPMI depending on the cell line) and 
mixed with 2 µg total plasmid DNA diluted in 100 µl media.  This mixture was 
incubated for 10 minutes at room temperature, during this time the media on the 
seeded cells was replaced with either 2 ml DMEM or RPMI (6-8 hour transfection) 
or 2.5% FCS containing DMEM or 2.5% FCS containing RPMI (overnight, 16 hour 
transfection).  Herein referred to as ‘’2.5% DMEM’’ or ‘’2.5% RPMI’’.  Following 
incubation the transfection mixture was then added to the cells in a drop-wise 
manner and cells were incubated at 37 oC for either 6-8 hours or 16 hours, 
depending upon the experiment.  Following this allotted time allowance the 
transfection containing media was replaced with the corresponding media for that 
cell line (either 10% DMEM, 10% RPMI, 15% RPMI, respectively) and allowed to 
express for 24, 48 or 72 hours depending upon experiment. 
 
2.2.3.5.2  Induction of inducible cell lines 
3 x 105 cells were seeded per 6-well dish (35mm diameter) in 2 ml 10% DMEM, cells 
seeded were either i293-ST, iEGFP or iEGFP-ST, depending upon experiment.  Upon 
adherence of cells to the culture dish surface (~6 hours), 4 µl doxyclycline hyclate 
(Life Technologies™) was added to 2 ml 10% DMEM and mixed, resulting in a final 
concentration of 2 µg/ml per well.  This induction media replaced the 10% DMEM 
on the seeded cells, cells were then allowed to grow to confluence over the course 
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of 48 hours in the presence of the induction media.  SILAC analysis required a large 
scale up of cells resulting in 5 x 175 cm3 tissue culture vessels (Sigma-Aldrich™) 
(Section 2.2.7).  Concurrent with this approximately 1 x 107 cells per flask were 
induced with 2 µg/ml doxycycline hyclate in a volume of 30 ml light DMEM (Section 
2.2.3.5.2), as explained previously. 
 
2.2.3.5.3 Stabilisation of microtubules    
Either i293-ST or MCC13 cells were seeded into 6 well plates at either 4 x 105, for 
western blot analysis (Section 2.2.5.4) or scratch assay analysis (Section 2.2.6.3) or  
2 x 105 on coverslips for immunofluorescence analysis (Section 2.2.4.1).  Following 
transfection (Section 2.2.3.5.1) or induction (Section 2.2.3.5.2) or both, cells were 
incubated with 2 ml media (10% DMEM, 10% RPMI or 15% RPMI, depending upon 
the cells line) containing 10  µM Paclitaxel™ (Sigma-Aldrich™) for 4 hours prior to 
harvest, scratch wound or fixation.   
 
2.2.3.5.4 Analysis of protein stability  
i293-ST cells were seeded at a density of 3 x 105 in duplicate for each condition 
(uninduced and induced) and time points for both control and cyclohexamide 
treated cells.  Cells were incubated with doxycycline hyclate for 48 hours prior (as 
described in Section 2.2.3.5.2) prior to treatment with 50 µg/ml cyclohexamide 
(Sigma™)  or 50 µg/ml DMSO (Sigma™) for control cells (as cyclohexamide was 
resuspended in DMSO).  Cells were harvested at the corresponding time points (0, 
2, 4, 6, 8 hours), as described in Section 2.2.5.1 and protein samples analysed via 
western blot analysis (Section 2.2.5.4). 
 
2.2.3.5.5 Analysis of translational inhibition  
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i293-ST cells were seeded at a density of 3 x 105 in duplicate for each condition 
(uninduced and induced) and time points for both control and rapamycin treated 
cells.  Cells were incubated with doxycycline hyclate for 48 hours prior (as described 
in Section 2.2.3.5.2) prior to treatment with 500 µM Rapamycin (Sigma™) for 5 
hours at 37 oC.  Control cells were treated with 500 µM DMSO (Sigma™).  Cells were 
harvested after incubation as described in Section 2.2.5.1 and protein samples 
analysed via western blot analysis (Section 2.2.5.4). 
 
2.2.3.5.6 siRNA based knockdown of protein expression  
i293-ST cells were seeded at a density of 3 x 105 and incubated overnight at 37 oC 
followed by induction for 24 hours with doxycycline hyclate (Section 2.2.3.5.2).  
Media was then replaced with DMEM and cells incubated for 6-8 hours with either 
a control scrambled siRNA or stathmin specific siRNA using 10 nM concentrations of 
each Flexi-Tube siRNA premix.   Transfection media was replaced with fresh 10% 
DMEM and left overnight.  The following day the same procedure was repeated, so 
cells were transfected two days in a row with siRNA for 6-8 hours.  In the context of 
scratch assays cells were transfected at 0 hours scratch and at 24 after scratch.  
MKL-1 cells were centrifuged at 1,200 x g for 3 minutes and resuspended in 10 ml 
RMPI.  5 X 105 cells were seeded into 6-well tissue culture dishes and left overnight 
and immediately incubated with scrambled siRNA and stathmin specific siRNA for  
6-8 hours.  Cells were centrifuged at 1,200 x g for 3 minutes and resuspended in 
10% RPMI and incubated overnight at 37 oC.  The following day the same procedure 
was followed, so that cells were incubated with Flexi-Tube siRNA on two 
consecutive days for 6-8 hours.   For invasion and migration transwell assays this 
was performed in triplicate and after both days of transfection cells were seed into 
the transwells.     
 
2.2.4 Immunofluorescence microscopy    
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Glass coverslips were sterilised in 100% ethanol and allowed to air-dry before 
placing in individual wells in a 6 well tissue culture plate.  Coverlips were treated 
with 0.01% poly-L-lysine solution (Life Technologies™) for 3-5 minutes at room 
temperature, followed by 3 washes with 2 ml phosphate buffered saline (PBS) 
(Lonza™).  Coverlsip were air-dried for a minimum of 3 hours before cell seeding.  
For all cell lines ~2 x 105 cells were seeded onto the coverslips in their respective 
media and incubated for ~16 hours at 37 oC.  Cells were either transfected (Section 
2.2.3.5.1) or induced (Section 2.2.3.5.2) or both.  Following the appropriate 
incubation depending upon the experiment, the media was removed and the cell 
monolayer washed 3 times in 2 ml PBS, followed by fixation in 2 ml PBS containing 
4% (v/v) paraformaldehyde for 15 minutes at room temperature, followed by 3 
washes with 2 ml PBS.  This was followed by cell permeabilisation in 2ml PBS 
containing 1% (v/v) Tritin X-100 for a further 15 minutes and washed a further 3 
times in 2 ml PBS.  Cells then underwent blocking for 1 hour at 37 oC in 2 ml 
blocking solution [PBS, 1% (w/v) bovine serum albumin (BSA)].  After blocking 
coverlsips were transferred to a humidity chamber to prevent cells drying out and 
incubated for 1 hour at 37 oC or overnight at 4 oC with an appropriate primary 
antibody (See Table 2.6 for dilutions) diluted in blocking solution.  Following 
incubation, cells were washed gently with PBS and incubated with the appropriate 
AlexaFluor conjugated secondary antibody for 1 hour at 37 oC.  Subsequently cells 
were washed gently 5 times with PBS and mounted on coverslides using 
VECTORSHIELD® with DAPI mounting media (Vector Laboratories) to stain the 
nucleus.  Cells were then visualised using the LSM510 META laser scanning inverted 
confocal microscope and the ZEN 2009 or ZEN 2011 image analysis software (Zeiss). 
 
2.2.4.1 Analysis of the actin cytoskeletal network 
The immunofluorescence microscopy protocol was followed as in Section 2.2.4.  An 
actin stain, Phalloidin (Life Technologies™) was used at a 1:5000 dilution in 1% BSA 
at room temperature for 30-60 minutes.  This stain was either used after cells had 
been washed following permeabilisation with 1% (v/v) Triton X-100, if primary or 
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secondary stains were not required.  Otherwise cells were exposed to Phalloidin 
after PBS washes following secondary antibody exposure.  Cells were then gently 
washed 5 times with PBS and mounted using VECTORSHIELD® with DAPI (Section 
2.2.4). 
 
2.2.5  Electrophoretic analysis of proteins 
 
2.2.5.1  Preparation of mammalian cell lysates 
Upon completion of cell culture based protocols, for experiments that required 
analysis of cellular protein composition, mammalian cells were removed from the 
tissue culture plates (usually a 6 well) by pipetting with 1 ml PBS.  Adherent cells 
such as MCC13, HuH-7 or HT-1080 were removed from the surface of the culture 
plate by scraping in 1 ml PBS.  The cells suspension was then centrifuged at 3,500    
x g at room temperature, followed by washing, 3 times in 1 ml PBS and further 
centrifugation, as per the previous step.  After which, the cell pellet was 
resuspended and lysed in 100 µl, 4 oC pre-chilled, 100 µl RIPA lysis buffer [150nM 
Tris-HCl, 50mM Tris base ultrapure, 1% NP40, pH 7.6, with 1 x protease inhibitor 
EDTA (Roche)].  This was immediately mixed and incubated on ice for 30 minutes, 
with mixing every 10 minutes.  Followed by centrifugation of the cell lysates in a 
pre-chilled centrifuge at 4 oC, 13,200 x g for 10 minutes.  The supernatant was then 
transferred to a clean Eppendorf and stored at -20 oC until further use. 
 
2.2.5.2 Determination of protein concentration 
 
All protein concentrations were determined using the DC Protein Assay Kit          
(BIO-RAD), according to the manufacturers protocol.  Briefly, using a microplate 
(96-well plate), 5 dilutions of a protein standard (BSA) was prepared with 
concentrations ranging from 0.2 mg/ml to 1.5 mg/ml.  This was used to prepare a 
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standard curve for each plate measurement.  The standard was prepared in the 
same buffer that the test protein samples were prepared in to ensure accuracy of 
the standard curve.  5 µl of each standard were pipetted into the micro plate in 
triplicate, as were the test samples in triplicate.   Following this 20 µl of Reagent S 
was mixed thoroughly with 1 ml Reagent A.  25 µl of the mixed solution was then 
added to each individual well, followed by 200 µl Solution B.  This was then mixed 
for at least 15 minutes and the absorbance read at 750 nm.  Protein concentrations 
of the test samples were determined by plotting a standard curve using the 
standard dilution series.    
 
2.2.5.3 Tris-glycine SDS-Polyacrylamide gel electrophoresis  
(PAGE) 
 
Polyacrylamide Tris-glycine gels (Table 2.6) were overlaid with a stacking gel [per 2 
ml: 300 µl acrylamide/bis acrylamide solution 37.5:1 (Severn Biotech Ltd), 1 ml 0.25 
M Tris-HCL (pH 6.8), 40 µl 10% (v/v) SDS, 600 µl dH2O, 10 µl ammonium persulfate, 
2 µl TEMED].  Polymerisation of the gels was initiated by the addition of ammonium 
persulfate and TEMED.   
 
Protein lysates (Section 2.2.5.1) for analysis, were mixed with 2 x protein 
solubilising buffer [50 mM Tris-HCl (pH 6.8), 2% (w/v) SDS, 20% (v/v) glycerol, 50 
µg/ml Bromophenol Blue and 10 mM DTT] and denatured by heating at 95 oC for    
3-5 minutes.  Heated samples were loaded onto polyacrylamide Tris-glycine gels of 
the appropriate percentage (see Table 2.6 for volumes).  Samples were loaded next 
to the appropriate pre-stained protein ladder (Life Technologies™), as an indicator 
of molecular (kDa).  Prior to ladder or sample loading gels and the SDS-PAGE 
apparatus were immersed in Tris-glycine running buffer [0.25 M Tris-base, 192 mM 
glycine, 0.1% (w/v) SDS].  Gels were run at 180 V for ~45 minutes or until the 
solubilising buffer reached the bottom to the gel.  All SDS-PAGE was carried out 
using a Bio-Rad™ Mini-PROTEAN 3 cell, set up according to the manufacturer’s 
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instructions.  Proteins were then analysed by western blot or coomassie stain 
(Section 2.2.5.4 and Section 2.2.5.5, respectively).   
 
 6% 8% 10% 12% 
dh2O 2.6 ml 2.3 ml 1.9 ml 1.6 ml 
Acrylamide/bisacrylamide 
37.5:1    
1.0 ml 1.3 ml 1.7 ml 2.0 ml 
1 M Tris-HCl (pH 8.8)   1.3 ml 1.3 ml 1.3 ml 1.3 ml 
10% (w/v) SDS    0.05 ml 0.05 ml 0.05 ml 0.05 ml 
10% (w/v) ammonium 
persulfate 
0.05 ml 0.05 ml 0.05 ml 0.05 ml 
TEMED 0.004 ml 0.003 ml 0.002 ml 0.002 ml 
Table 2.6.  Reagents and corresponding volumes required to prepare 6%, 8%, 10% and 12% SDS-
PAGE gels.  
 
 
2.2.5.4 Western blot analysis 
Proteins from SDS-PAGE gels (Section 2.2.5.3) were transferred onto Hybond C 
extra (nitrocellulose membrane) (Amerhsam Biosciences™, UK), using the Bio-Rad 
Mini Trans-Blot Electrophoretic Transfer Cell (wet blotting system), according to the 
manufacturers protocol.  Briefly, 4 pieces of Whatman 3 mm filter paper, 1 SDS-
PAGE gels and one Hybond C extra membrane were soaked in transfer buffer 
[25mM Tris-base, 190 mM glycine, 20% (v/v) methanol] and placed in a cassette in 
a specific order. Proteins were transferred from the gel to the membrane at 100 V 
for 1-2 hours (depending upon protein size), followed by incubation of the 
membrane in 5% blocking buffer [500 mM NaCl, 20 mM Tris, 0.1% (v/v) Tween-20, 
5% non-fat dried milk (Marvel)] at room temperature for 1 hour.  Subsequently, the 
membrane was incubated in the corresponding primary antibody (See table 2.2 for 
concentrations) diluted in 1 % blocking buffer [500 mM NaCl, 20 mM Tris, 0.1% 
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(v/v) Tween-20, 1% non-fat dried milk (Marvel)] overnight (~16 hours) at 4 oC.  This 
was followed by three washes for 10 minutes in 1 x TBS-tween solution (20 mM 
Tris, 0.1% Tween-20, 500 mM NaCl).  The membrane was then incubated in the 
appropriate secondary antibody (Section 2.1.4 and Table 2.2) diluted 1:5000 in 1% 
blocking buffer and incubated for 1 hour at room temperature.  Followed by three 
washes for 10 minutes each in 1 x TBS-tween solution.  Protein bands were then 
visualised by enhanced chemiluminescence using EZ-ECL enhancer solutions A and 
B kit (Geneflow™) (A:B in a ratio of 1:1) and exposed to  ECL™ hyperfilm 
(Amersham™).  Films were developed using a Konica SRX-101A developer.  All 
incubations were carried out using a roller mixer and washing steps on a washing 
platform. 
 
2.2.5.5 Coomassie stain analysis 
Proteins were visualised by soaking SDS-PAGE gels (Section 2.2.5.3) in coomassie 
stain [0.1% (w/v) Coomassie Blue R-250, 50% (v/v) methanol, 10% (v/v) acetic acid] 
for 1 hours at room temperature.  Followed by incubation with coomassie de-stain 
[25% (v/v) methanol, 10% (v/v)acetic acid] for 30 minutes, subsequently used de-
stain was replace with fresh de-stain and incubated for a further 30 minutes at 
room temperature.   
 
2.2.6  Analysis of mammalian cell motility 
 
2.2.6.1 Invasion and migration transwell assays 
Inducible cell lines, MCC13 and MKL-1 cells were seeded in duplicate (per condition) 
at a density of 3 x 105 cells per 6-well tissue culture plate.  Cells were incubated at 
37 oC overnight before transfection (Section 2.2.3.5.4) or Induction (Section 
2.2.3.5.2); all conditions had corresponding control wells also (e.g. 
uninduced/induced or pEGFP-C1/pEGFP-ST transfected).  The MKL-1 cell line was 
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transfected with siRNA to Stathmin on 2 consecutive days.  HT-1080 cells were also 
used as a positive control.  After 48 hours post induction/transfection, cells were 
counted using a haemocytometer and seeded in triplicate (per condition) at a 
density of 1 x 105 cell per well, on to pre-coated BD BioCoat™ Angiogenesis System: 
Endothelial Cell Migration or Endothelial Cell Invasion (BD Bioscience) tissue culture 
plates for the appropriate time allowance per experiment.  This was also replicated 
for an uncoated control plate.  The cells were then analysed for migration and 
invasion in triplicate, according to the manufacturers protocol.  750 µl FCS 
containing media was added as a chemoattractant in the bottom wells via the 
sample ports and the plates incubated for 22 hours at 37 oC.  After incubations, the 
culture medium was removed from the upper chambers and the insert plates were 
transferred to 24 well culture plates containing 4 µg/ml Calcein AM™ (BD 
Biosceince) in 500 µl PBS (per well).  The cells were incubated for a further 90 
minutes at 37 oC, 5% Co2.  The fluorescence of invaded and migrated cells was 
determined using a fluorescence plate reader at excitation wavelengths of between 
494-517 nM.  Each condition was measured in triplicate and from this the 
percentage of invasion/migration compared to the control plate could be 
calculated, as per the manufacturers instructions.      
 
2.2.6.2 Live cell imaging 
Inducible cells or MCC13 cells were seed at a density of 3000 cells per 96-well plate, 
and were incubated overnight (~16 hours), followed by either induction with 
doxycycline hyclate at 2 µg/ml (as described in Section 2.2.3.5.2) or transfected 
using 250 ng of plasmid DNA per well, at 37 oC .  Cells were incubated for 24 hours 
at 37 oC.  Subsequently, the induction/transfection media was removed and 
replaced with Ham’s F-12 media (Gibco™) supplemented with 10% FCS.  Cells were 
then analysed using an IncuCyte™ Live-Cell Imaging System (Essen BioScience), as 
per the manufacturers protocol.  Imaging was performed every 30 minutes over the 
course of 24 hours and cell motility was then tracked using Image J software.   
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2.2.6.3 Scratch wound-healing assay 
6-well tissue culture plates were incubated with 2 ml poly-L-lysine (Life 
Technologies™) for 5 minutes, followed by three washes with 2 ml PBS.  Treated 
tissue culture plates were then air-dried for a minimum of 3 hours prior to cell 
seeding.  Cells were seeded at 3 x 105 per 6-well (35mmm diameter) and incubated 
overnight at 37 oC.  Cells were then either induced (Section 2.2.3.5.2) or transfected 
(Section 2.2.3.5.1), or both.  In this case, cells were induced for 24 hours, then 
transfected for 6-8 hours, the transfection media was replaced with induction 
media.  After the corresponding time allowance cells were subjected to a manual 
straight line scratch with a p1000 pipette tip in a continuous straight line through 
the centre of the well.  The cell monolayer was gently washed twice in 2 ml PBS to 
remove floating/loose cells dislodged by the scratch, to ensure an even line and 
that cells did not re-adhere in the wound.  Images were taken under using a Zeiss 
light microscope (Zeiss) at 4 X magnification at 0, 24, 48 and 72 hours post-scratch 
for i293-ST cells and 0 and 24 hours post scratch for MCC13 cells.  Paclitaxel™ based 
scratch assays were incubated for 4 hours prior to a scratch with 10 µM Pacliatxel™, 
and controls incubated with 10 µM DMSO.  siRNA knockdown studies for stathmin 
were transfected at 0 and 24 hours post scratch.      
 
2.2.7  SILAC-based quantitative proteomics 
 
2.2.7.1  Cell fractionation assay 
Inducible cell lines (i293-ST and i293-Tantigen, in two separate experiments) were 
seeded and passaged until there was 15 x 75 cm2 tissue culture flask per condition 
(R0K0/induced and R6K4/uninduced).  For each condition cells were harvested and 
washed twice in 10 ml PBS, with centrifugation after each wash at 1,200 x g for 4 
minutes at 4 oC.  The cell pellet was resuspended in 5 ml ice cold Buffer A [10mM 
Hepes, pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 0.5 mM DTT] and incubated at 4 
oC for 15 
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minutes.  Upon cytoplasmic swelling, the cytoplasm was ruptured using a             
pre-chilled dounce-homogeniser (25 strokes), and the suspension was centrifuged 
at for 5 minutes at 228 x g at 4 oC.  Following this the supernatant was removed and 
stored at -80 oC as the cytoplasmic fraction.  The nuclear pellet was resuspended in 
3 ml Solution 1 [0.25 M sucrose, 10 mM MgCl2] and layered over a sucrose cushion 
of 3 ml Solution 2 [0.35 M sucrose, 0.5 mM MgCl2] and centrifuged for 10 minutes 
at 2,800 x g.  The sucrose cushion wash step was repeated three times, after which 
the nuclear pellet was resuspended in 3 ml Solution 2 and stored at -80 oC until 
further use.  All solutions contained 1 protease inhibitor tablet (Roche™). 
 
2.2.7.2  Sample preparation and proteomics analysis 
Following cellular fractionation (Section 2.2.7.1) the R0K0 and R6K4 samples were 
mixed for each cellular compartment in a 1:1 ratio (total protein concentration).  
The proteins were then separated by SDS-PAGE and ten gel slices per fraction were 
extracted and trypsin digested (in-gel digestion).  Extracted and purified proteins 
were analysed and identified using a LTQ-Orbitrap Velos mass spectrometer 
(University of Bristol Proteomics Facility).  Peptides were quantified and identified 
using MaxQuant366 based on 2-D centroid isotope clusters within each SILAC pair.  
The peak list was subsequently searched with the Mascot search engine (version 
2.1.04, Matrix Science, London) against the International Protein Index human 
protein database (version 3.6, forward and reverse database) of 80,412 proteins.  
For analysis and quantification of proteins levels a 2.0 fold cut-off was chosen and a 
2 peptide cut-off.  Pathway analysis was performed using the Database for 
Annotation, Visualisation and Integrated Discover (DAVID, version 6.7)367. 
 
2.2.8  Analysis of cellular proliferation 
 
2.2.8.1 Standard cell proliferation assay 
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i293-ST cells were seeded into 6-well plates in triplicate for each condition 
(uninduced and induced) and time point.  HEK 293 FlpIn™ cells were also seed in 
triplicate as a control.  Cells were induced with doxycycline hyclate at 2 µg/ml and 
incubated at 37 oC.  At the chosen time point (24, 48, 72 hours), cells were 
detached from the tissue culture plate surface via trypsinisation [0.25%  (v/v) 
trypsin, in PBS], washed in 1 ml PBS and centrifuged at 1,200 x g for 3 minutes at 
room temperature.  The cell pellet was then resuspended in 1 ml HBSS (Hank’s 
Balanced Salts) (Sigma™). Using a dilution of 5:0.2 ml cell suspension was added to 
0.3 ml HBSS and 0.5 ml Trypan Blue solution [(0.4% (w/v) (Sigma™)], mixed 
thoroughly and incubated at room temperature for 10 minutes.   Cells were then 
counted on a 0.1 mm depth haemocytometer (Nebauer Improved).   
 
2.2.9  Multicolour immunohistochemistry 
Tumour samples were provided by Dr Neil Steven (University of Birmingham) and 
immunohistochemistry analysis performed by Rachel Wheat (University of 
Birmingham) and Professor David Blackbourn (University of Surrey).  Primary MCC 
tumour samples and isotype control samples (tissue adjacent to the tumour) were 
Formalin-fixed, paraffin-embedded (FFPE), each 4 µm section was mounted onto 
charged microscope slides by drying overnight at 37 oC.  Followed by incubation at 
60 oC for 30 minutes and deparaffinised in Histo-Clear (National Diagnostics HS-
200), cleared in 100% ethanol and washed briefly in water.  Antigen retrieval 
treatment was conducted by heating the slides for 40 minutes at 99 oC in Wax 
Capture (W-Cap) TEC Buffer pH 8.0 (BioOptica 15-6315/F).  Samples were then 
blocked (for non-specific antibody binding) in blocking reagent [with 20% normal 
goat serum, 20% donkey serum, 0.1% BSA in PBS, (all serum was heat inactivated)] 
for 4 hours.  Samples were incubated with appropriate primary antibodies 
overnight in a humidified chamber at 40 oC, using anti-CK20 at 1:50 dilution (Dako) 
and anti-stathmin 1 at 1:250 dilution (Abcam).  Sections were first washed three 
times with PBS for 5 minutes each followed by sample incubation for 1 hour in 
mouse monocolonal isotype control antibody Dako X-0943 (Dako) for CK20 and a 
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rabbit polyclonal isotype control antibody (Abcom) for stathmin.  Subsequently 
sections were washed a further three times for 5 minutes each in PBS and 
incubated with the appropriate secondary antibody, labelled with fluorochromes.  
These were AlexaFluor 488 IgG2B and AlexaFluor 633 IgG2A (Life Technologies™) 
and Igg (H+L)-TRITC (Jackson ImmunoResearch).  The nucleus was counter-stained 
using bis-benzimide (Life Technologies™), and slides were then mounted with 
Immu-Mount (Thermo Scientific™).  Sections were analysed using a Zeiss LSM 510 
confocal microscope (Zeiss)368.  
 
2.2.10 Gene expression analysis by qRT-PCR 
2.2.10.1 RNA extraction 
i293-ST cells were seeded at a density of 4 x 105 in triplicate per condition 
(uninduced and induced) and induced for 48 hours at 37 oC with 2 µg/ml 
doxycycline hyclate.  Following incubation cells were directly lysed by addition of     
1 ml TRIzol reagent (Life Technologies™) per well, and mixed by pipetting in an 
RNase-free eppendorf , followed by incubation at room temperature for 5 minutes.  
Subsequently, 200 µl chloroform was added to each sample with vigorous mixing 
for 15 seconds and incubated at room temperature for 2-3 minutes.  Samples were 
centrifuged at 12,000 x g for 15 minutes at 4 oC and the upper RNA containing 
aqueous/colourless phase (~500 µl) was transferred to a fresh RNase-free 
eppendorf.   RNA was then precipitated by addition of 500 µl isopropanol and 
incubation at room temperature for 10 minutes before being centrifuged at 
12,0000 x g at 4 oC for 10 minutes.  The supernatant was carefully aspirated and the 
pellet washed in 1 ml 75% ethanol and briefly vortexed, followed by centrifugation 
at 7,500 x g for 5 minutes at 4 oC.  Supernatant was once again aspirated and the 
pellet air-dried for 5 minutes.  The pellet was resuspended in 49 µl DEPC-treated 
water and 1 µl RNaseOUT™ (Life Technologies™) and incubated at 57 oC for 10 
minutes. The RNA was immediately DNase I treated (Section 2.2.10.2) and reverse 
transcribed (2.2.10.3).  Any remaining RNA was stored at -80 oC until further use.    
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2.2.10.2 DNase I treatment 
A DNase I kit supplied by Ambion™ was used to remove contaminating DNA from 
RNA samples (Section 2.2.10.1) as per the manufacturers protocol.  0.1 volume of 
DNase reaction buffer and 0.5 µl Amplification Grade DNase I were added to each 
sample, gently mixed and incubated for 30 minutes.  The was followed by addition 
of 0.1 volume Stop solution, mixed thoroughly and heated at 70 oC for 10 minutes.   
Samples were then briefly chilled on ice and then long term storage at -80 oC.  The 
RNA concentration was measured on a NanoDrop and all samples diluted in RNase-
free water to a final concentration of 50 ng/µl.   
 
2.2.10.3 Reverse transcription 
Superscript™ II Reverse Transcriptase (Life Technologies™) was used to synthesise 
cDNA from the total extracted cellular RNA, according to the manufacturers 
protocol.   The initial sample mixture contained 1 µg DNase I treated RNA , 1 µl 
dNTP mix, 10 mM total or 0.25mM per dNTP, 1 µl Oligo(dT)12-18 primer and made 
up to a total volume of 12 µl.  Samples were then mixed and incubated at 65 oC for 
5 minutes and then quick-chilled on ice.  Following this, 4 µl 5X First-Strand buffer, 2 
µl 0.1 M DTT, 1 µl RNaseOUT™ and 1 µl Superscript™ II Reverse Transcriptase were 
added to each sample.  Samples were mixed gently and incubated at 42 oC for 50 
minutes, followed by enzyme inactivation at 70 oC for 15 minutes.   This was then 
followed by ethanol precipitation to remove dNTPs. 
 
2.2.10.4 Ethanol precipitation 
2 µl 3 M sodium acetate, pH 5.6 and 60 µl ice cold 100% ethanol was added to each 
cDNA sample (Section 2.2.10.3) and mixed gently, followed by incubation at 4 oC for 
10 minutes.  Samples were then centrifuged at 12,000 x g for 10 minutes at 4 oC and 
the supernatant discarded.  The pellet was then washed in 1 ml ice cold 100% 
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ethanol and further centrifuged at 12,000 x g for 10 minutes at 4 oC.  The 
supernatant was removed and the pellet air-dried briefly, followed by resuspension 
of the cDNA pellet n 20 µl nuclease-free water (Sigma™).  The cDNA concentration 
was determined by NanoDrop and subsequently diluted to 2 ng/ml in nuclease-free 
water. 
 
 
2.2.10.5 qRT-PCR reaction 
PCR reactions were set up Corbett tubes and a pre-chilled Corbett tube rack (both 
Corbett Life Sciences).  Each reaction PCR reaction was performed in duplicate using 
different primers (GAPDH as a reference and test primers, in this case stathmin).  
The PCR master mix contained the following for each reaction: 12.5 µl SensiMixPlus 
SYBR™ No-ROX (Quantace™), 2 µl primer mix (5 µM of both forward and reverse 
primers), 5.5 µl nuclease-free water and 5 µl cDNA (10 ng final amount).  The PCR 
reactions were performed using a Rotor-Gene™ Q 5plex MRM Platform (Qiagen™) 
using a 3 Step with Melt program.  A typical PCR cycle parameter consisted of 95 oC 
for 10 minutes and then 40 cycles of: 95 oC for 15 seconds, 60 oC for 30 seconds and 
72 oC for 20 seconds.  Quantitative analysis was then performed using the 
comparative CT method as previously described
369.   
 
2.2.11          Co-immunoprecipitation assay 
 
All co-immunoprecipitation assays were performed by Dr Andrew Macdonald and 
Hussein Abdul-Sada (both University of Leeds), as previously described370.  Briefly, 
HEK 293 FlpIn™ cells were transfected with the appropriate vectors and cellular 
lysates harvested after 48 hours.  Cell lysates were then incubated with either    
GFP-TRAP A beads (Chromotek) or Anti-FLAG M1 affinity gel (Sigma-Aldrich™) for 2 
hours at 4 oC, followed by washes with PBS.  Beads were then resuspended and 
analysed by immunoblotting (Section 2.2.5.4) with appropriate antibodies. 
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3. SILAC analysis identifies that MCPyV ST promotes host cell 
cytoskeletal alterations 
 
3.1 Introduction 
MCC is a highly aggressive form of skin cancer of neuroendocrine origin, with a 
propensity to spread through the dermal lymphatic system and a poor 5 year 
survival rate190,197.  It is now established that MCPyV is a causative factor in the 
formation of MCC and tumour pathology71.  The MCPyV genome is monoclonally 
integrated within the host genome in both primary and metastatic cancer forms, 
and has been observed for all MCC tumours positive for MCPyV.  Furthermore, all 
MCPyV LT sequences derived from MCC tumour cells contain a tumour specific 
deletion, rendering the virus replication defective upon integration71.  Due to the 
monoclonal integration pattern and acquisition of tumour specific mutations within 
the virus genome the notion that MCPyV may be a passenger virus has been 
dismissed.   
Recent evidence has demonstrated that expression of both MCPyV ST and LT are 
required for MCC tumour cell survival and cell proliferation, as depletion of the T 
antigens in MCPyV-positive MCC cells results in cell cycle arrest and cell death75.  In 
contrast to SV40, MCPyV ST expression alone can facilitate transformation and 
anchorage independent growth of rodent cells247.  This is currently a highly debated 
topic, as several studies involving MCPyV ST depletion and have shown 
contradictory results with regard to the requirement of MCPyV ST for cell 
proliferation277,371.   
Therefore it is essential to understand the mechanisms by which MCPyV ST can 
interact with the host cell and facilitate tumour formation and maintenance.  
MCPyV ST is thought to be a multifunctional protein with multiple cellular 
interactions.  Briefly, MCPyV ST has been shown to target the cellular ubiquitin 
ligase SCFFbw7, through an internal LSD domain and acts to stabilise the MCPyV LT 
antigen227, its expression also inhibits NF-κB-mediated transcription and the host 
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immune response226 and acts downstream of mTOR, deregulating cap-dependent 
translation, through hyperphosphorylation of 4E-BP1247.   
Despite the recent identification of these novel virus-host interactions, all have 
been attributed to transformation of MCC tumour cells though T antigen 
expression.  To date, no studies have investigated the role MCPyV T antigens may 
play in the highly aggressive and metastatic nature of MCC tumour cells.  The 
importance of this should not be underestimated, as metastasis of MCC tumour 
cells directly correlates with poor prognosis and patient survival rates284.  Therefore 
the initial aims of this project were to begin analysing and identifying possible 
cellular targets of MCPyV ST that may contribute to cellular transformation and 
metastasis. Initially MCPyV ST expression constructs and inducible cell lines had to 
be generated, which could then be used to conduct high-throughput quantitative 
proteomic analysis.  Stable isotope labelling by amino acids in cell culture (SILAC) 
coupled with LC-MS/MS and bioinformatial analysis was the used to identify 
important proteins that were differentially expressed upon MCPyV ST expression. 
This chapter discusses the initial experiments conducted to identify cellular proteins 
and pathways that are differentially expressed upon MCPyV ST expression.   
 
3.2  Using the 293 FlpIn™ system to generate a cell line capable of 
inducible expression of MCPyV ST 
 
Two samples of fresh MCC tumours were supplied by Professor Julia             
Newton-Bishop at St James’ University Hospital, Leeds. The first objective was to 
isolate cellular genomic DNA from these tumour sections using a standard 
protocol372.   Polymerase chain reaction (PCR) could then be applied to amplify the 
MCPyV ST antigen coding sequence (579 base pairs) with incorporated KpnI and 
SmaI restriction sites, followed by cloning into the respective vectors (pEGFP-C1 or 
pCDNA5-FRT-TO).    
While expression of EGFP-ST in mammalian cells is valuable for subcellular 
localisation and co-localisation studies the nature of a transient transfection poses 
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several problems.  Firstly, some human cell lines react poorly when subjected to 
serum starvation which may affect the inherent function of MCPyV ST.  
Furthermore, transfection does not result in 100% MCPyV ST expression in the cell 
population, thus posing problems when examining the fold change of protein levels 
on a global scale i.e. SILAC analysis.  Therefore, to address these problems, a cell 
line capable of inducible expression of MCPyV ST was developed.  Induction of this 
cell line is capable of achieving between 95-100% cell induction of the gene of 
interest, substantially higher than transfection.     
PCR was used to amplify the MCPyV ST coding region from MCC genomic DNA with 
incorporation of a C-terminal FLAG tag, for localisation and co-immunoprecipitation 
studies.  This produced a fragment containing a FLAG tag, and C-terminal and          
N-terminal restriction sites (BamI and NotI), resulting in a fragment of 624 base 
pairs. 
This MCPyV ST fragment was then sub-cloned into the mammalian expression 
construct, pCDNA5-FRT-TO, and termed iST-FLAG.  This expression construct 
contains a FLP Recombination Site (FRT) and facilitates Flp recombinase-mediated 
integration of the gene of interest into the host genome (HEK 293 FlpIn™ cell line).  
Figure 3.1 shows a schematic for the integration and expression of a gene of 
interest in the HEK 293 FlpIn™ system.   
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Figure 3.1. Schematic representation for the generation of a stably inducible cell line.  (i) and (ii) 
The pcDNA5/FRT/TO
TM 
 mammalian expression vector containing a gene of interest (GOI) in this case 
MCPyV-ST, is co-transfected with pPGK/Flip/ObpA into the HEK 293 FlpIn™.
 
The Flp recombinase 
expressed from the pPGK/Flip/ObpA vector facilitates a homologous recombination event between 
the FRT site in the pcDNA5/FRT/TO
TM
 expression vector and the FRT site in the HEK 293 Flp-In
TM 
cell 
genome. (iii) Integration of the pcDNA5/FRT/TO
TM 
expression vector confers antibiotic resistance to 
hygromycin. The Tet repressor (TetR) represses expression of the GOI (MCPyV ST).  Addition of 
tetracycline (Doxcycline hyclate at 2 µg/ml) results in induction of gene expression.   
 
iST-FLAG was then used to produce a stable inducible cell using the HEK 293 FlpIn™ 
system.  Briefly, transfection of iST-FLAG and a plasmid encoding a flip recombinase 
enzyme (pPGK/Flip/ObpA), resulted in a site specific recombination of MCPyV ST 
into the HEK 293 FlpIn™ genome.  This cell line was generated in a monoclonal 
fashion using Hygromycin B selection and was termed i293-ST.   
Multiple i293-ST clones were screened in order to establish the expression levels of 
MCPyV ST within each clone.  To induce the expression of MCPyV ST, cells were 
incubated with 2 µg/ml Doxycycline hyclate (Dox) for 24 and 48 hours.  It was also 
necessary to assess if clones that were left uninduced demonstrated expression of 
MCPyV ST.  This is an important point, as a control should show no ‘leaky’ 
expression of MCPyV ST in order to establish a reliable cell line for further 
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investigation.  Figure 3.2 (i) shows screening of multiple i293-ST clones for 
expression of MCPyV ST via immunoblotting at 48 hours post induction with Dox.  
All clones demonstrated expression of MCPyV ST, with clone 2 (herein referred to 
as i293-ST) subsequently being used for further analysis, after verification by DNA 
sequencing. 
It was also important to establish that the expression levels of MCPyV ST in the 
i293-ST were similar to the expression of MCPyV ST in the tumour setting, in order 
to draw the appropriate conclusions regarding MCPyV ST functions.   Using a 
MCPyV ST-specific antibody (2T2), capable of recognising the J-domain leader 
peptides in MCPyV T antigens, Figure 3.2 (ii) demonstrates that MCPyV ST protein 
levels in both i293-ST and MCPyV-positive MCC cells lines (MKL-1) are fairly 
consistent. The minor discrepancy between the molecular weight of MCPyV ST in 
Figure 3.2 (ii) can be attributed the C-terminal FLAG tag fused to MCPyV ST in  the 
i293-ST cells, whereas MKL-1 cells express wild type MCPyV ST. 
 
Figure 3.2.  Screening of i293-ST clones for the expression of MCPyV ST. (i) i293-ST clones were 
induced with Doxycyline hyclate for 48 hours and the cellular lysates (both uninduced and induced) 
were analysed by immunoblotting using an anti-FLAG polyclonal antibody to detect the presence of 
MCPyV ST.  Clone 2 as denoted by *, was taken forward for all future i293-ST experiments, unless 
stated otherwise.  (ii) i293-ST cells were induced and cellular lysates collected at 0 and 48 hours post 
induction.  MCPyV-negative and MCPyV-positive MCC cell lines (MCC13 and MKL-1, respectively) 
were lysed and analysed by immunoblotting using the 2T2-specifc antibody.   
 
 
In order to analyse the effect of MCPyV ST on the host proteome, SILAC-based 
quantitative proteomics was performed using the i293-ST inducible cell line.  This is 
a robust method to analyse protein levels on a global scale under various conditions 
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and in specific sub-cellular compartments.  Figure 3.3 shows a schematic 
representation of the experimental procedure required to conduct such analysis.   
 
Figure 3.3.  A schematic representation of the SILAC-based quantitative proteomic analysis 
approach.  Heavy and light labelled i293-ST cells remained uninduced or induced for 48 hours, 
respectively. Cells were subjected to fractionation into nuclear and cytoplasmic fractions, with 
confirmation of fraction purity by immunoblotting.  Corresponding fractions were mixed in a 1:1 
ratio before being separated by SDS-PAGE. 10 gel slices per lane were excised and trypsin digested, 
followed by sample analysis by LC-MS/MS to determine to relative abundance of proteins in light 
isotope containing cells compared to heavy labelled cells.  
 
Briefly, heavy and light labelled i293-ST cells were left uninduced or induced for 48 
hours, respectively. Figure 3.4 shows immunoblotting analysis demonstrating that 
MCPyV ST is only expressed in light-labelled cells which were induced with Dox. 
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Figure 3.4.  Expression of MCPyV ST in SILAC samples. i293-ST heavy and light labelled cells were 
left uninduced or induced for 48 hours, respectively. A 1 ml sample of cell suspension was collected 
from each prior to cell fractionation. Each sample was lysed and analysed by immunoblotting with a 
FLAG-specific antibody.   
 
Following this, cells underwent nuclear and cytoplasmic fractions in order to reduce 
the complexity of the samples and these samples were analysed by immunoblotting 
to ensure sample purity.  Figure 3.5 demonstrates that the cytoplasmic marker 
GAPDH in only present in the cytoplasmic fraction of both uninduced and induced 
samples.  Actin is also highly enriched in the cytoplasmic fraction, with a nuclear 
presence of actin accounted for by the presence of actin in the nuclear matrix373.  
While the nuclear marker Lamin B is present only in the nuclear fractions.    
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Figure 3.5.  Subcellular fraction analysis of SILAC lysates.  i293-ST heavy and light labelled cells were 
left uninduced or induced for 48 hours, respectively.  Cells were collected and subjected to 
cytoplasmic and nuclear fractions using an adapted protocol from the Lamond Laboratory.  A sample 
of each fraction for both uninduced and induced was analysed by immunoblotting using the 
cytoplasmic markers, GAPDH- and Actin-specific antibodies and a nuclear marker Lamin B-specific 
antibody. 
 
Corresponding fractions were mixed in a 1:1 ratio and separated by SDS-PAGE, with 
each lane divided into 10 gel fragments.  These fragments were then trypsin 
digested and submitted for LC-MS/MS analysis.  
 
3.3 Quantitative proteomic analysis identifies that cytoskeletal 
regulatory proteins are affected by MCPyV ST expression 
 
Following LC-MS/MS analysis, peptides were identified and quantified using 
MaxQuant366, with each peptide from the induced cells being expressed as a fold 
change in comparison to the endogenous proteins expressed in the uninduced cells.  
A large library of proteins were identified within both the cytoplasmic and nuclear 
data sets.  The cytoplasmic data set consisted of 2454 identified proteins, of which 
1626 demonstrated a 1.5 fold increase in MCPyV ST expressing cells, and of these 
273 showed more than a 2 fold increase.  The nuclear fraction identified 1908 
proteins, with 1307 showing a 1.5 fold increase upon MCPyV ST expression and of 
these 861 demonstrated more than a 2 fold increase.   
Interestingly, LC-MS/MS on both the cytoplasmic and nuclear fractions only 
identified a handful of proteins that were downregulated.  This feature has been 
demonstrated within the laboratory on numerous SILAC based LC-MS/MS analyses 
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and could be a result of the downregulation itself, resulting in few peptides and 
hence less likely to be identified during the process of LC-MS/MS.   
Due to the large number of proteins identified bioinformatical analysis of the data 
sets was conducted using the Database for Annotation, Visualization and Integrated 
Discovery (DAVID) v6.7 software367.  This analysis indicated that a significant 
number of highly differentially expressed proteins were those involved in gene 
ontology classes concerning cytoskeletal dynamics and regulation.  Table 3.1 
highlights the seven most prominent gene ontology groupings, many of which are 
cytoskeletal dominated.  In order to reduce the complexity to begin validating 
potentially crucial changes within the proteome, following identification of these 
specific gene ontology groupings, all peptide hits below 2 were dismissed as 
unreliable (as theye were only identified once), and could be an artefact the the 
experiment.  Furthermore, a 2.0 fold cut-off in protein fold change was chosen as a 
basis to begin investigating any potential changes in the proteome.   
 
Table 3.1.  Gene ontology groupings and pathways hits based on SILAC analysis of i293-ST cells.  
SILAC samples were analysed by LC-MS/MS.  Peptides were identified and quantified using 
MaxQuant, with peptide hits below 2 being discarded and a 2.0 fold cut-off for protein fold change 
between conditions being employed. Bioinformatical analysis was conducted using the DAVID v6.7 
software and highlighted a number of highly differentially expressed proteins upon MCPyV ST 
expression and the respective gene ontology grouping that these featured.     
 
Further analysis of the specific proteins within these gene ontology groupings 
highlighted that a significant proportion were involved in microtubule-associated 
cytoskeletal organisation, dynamics and regulation as shown in Table 3.2. In 
addition, the Appendices highlight other differentially expressed proteins in gene 
ontology groupings ranging from cancer cell metabolism, DNA replication and post-
translation modifications.   This further demonstrates the wide ranging effects of 
MCPyV ST expression on cellular pathways and the host proteome.   
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Protein IPI Accession 
no.  
Function Fold 
increase 
Peptide 
hits 
Tubulin-specific 
chaperone A 
IPI00217236 Tubulin-folding protein 7.23 10 
Microtubule-
associated protein, 
RP/EB family 
member 1 
IPI00017596 Regulates the microtubule 
dynamics by promoting 
nucleation and elongation 
2.92 13 
Microtubule-
associated protein 
1B (MAP1B) 
IPI00008868 Involved in cell polarisation, 
required for efficient cross 
talk between microtubules 
and actin cytoskeleton 
2.4 59 
Dystonin (DST) IPI00645369 Cytoskeletal linker protein, 
regulates keratinocyte 
polarity and motility 
2.0 155 
Stathmin 1 IPI00479997 Involved in the regulation of 
the microtubule cytoskeletal 
network 
8.33 11 
Microtubule-
associated protein 
4 
IPI00396171 Promotes microtubule 
assembly and disassembly 
3.72 32 
Kinesin-like protein 
14 (KIF14) 
IPI00299554 A microtubule motor protein 
essential for cell cytokinesis 
11.39 2 
 
Table 3.2.  MCPyV ST promotes the differential expression of proteins involved in          
microtubule-associated cytoskeletal organisation and dynamics.  Microtubule-associated 
regulatory proteins identified during i293-ST SILAC-based quantitative analysis.  Details include 
protein names, IPI accession number, functions, fold increase in MCPyV ST expressing cells 
compared to uninduced cells and peptide hits.   
 
This analysis represented a novel finding and in order to independently 
demonstrate that expression of MCPyV ST promotes upregulation of proteins 
involved in microtubule dynamics, immunoblotting was conducted.  Figure 3.6 
demonstrates that cells expressing MCPyV ST show an increase in microtubule 
associated proteins 48 hours post induction.  Proteins upregulated include 
stathmin, TBCC (tubulin folding cofactor C) and STRAP (serine/threonine receptor 
associated protein) and further supports the quantitative proteomic analysis.   
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Figure 3.6.  MCPyV ST expression promotes upregulation of proteins involved in microtubule 
cytoskeletal organisation and dynamics. (i) i293-ST cells were  uninduced or induced for either 24 or 
48 hours with Doxycycline hyclate.  Following induction, cells were lysed and analysed by 
immunoblotting using a range of microtubule associated- and FLAG-specific antibodies.  A GAPDH-
specific antibody was used as a measure of equal loading.  (ii) (iii) (iv) (v) and (vi) GAPDH was used as 
a measure of equal loading and densitometry analysis using Image J software enabled calculation of 
the percentage of relative densitometry of stathmin, dynamin, TBCC, KIF14 and STRAP, normalised 
to the loading control. Data analysed using three biological replicates per experiment, n=3. 
Statistical analysis employed was a two-tailed T-test with unequal variance. 
 
 
 
3.4 Stathmin is overexpressed in primary MCC tumour tissue 
 
One of the most highly upregulated microtubule-proteins upon MCPyV ST 
expression is stathmin, with an 8.33 fold increase in the cytoplasm.  Stathmin is an 
important regulatory protein in microtubule dynamics and has been associated 
with multiple human cancers, particularly those with a metastatic 
phenotype354,364,374.  Due to the highly aggressive nature of MCC tumours, the 
ability of MCPyV ST to promote upregulation of stathmin became of interest.   
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To further investigate stathmin in the context of MCC tumours, Rachel Wheat 
(University of Birmingham) and Professor David Blackbourn (University of Surrey) 
conducted multicolour immunohistochemistry analysis using formalin-fixed, 
paraffin-embedded (FFPE) sections of primary MCC tumours.  Tumour sections and 
isotyped-matched negative controls were incubated with the MCC tumour marker, 
cytokeratin 20 (CK20) and stathmin-specific antibodies. Figure 3.7 demonstrated 
that higher levels of stathmin expression were coincident with CK20 staining 
regions of the tumour.   This provides initial in vivo evidence that stathmin levels 
are increased in MCC tumour cells and supports the in vitro quantitative proteomic 
analysis conducted using i293-ST cells.   
 
Figure 3.7.  Primary MCC tumours upregulate the microtubule-associated protein, stathmin.  
Experiment performed by Rachel Wheat and Professor David Blackbourn.  Formalin-fixed, paraffin-
embedded (FFPE) sections of primary MCC tumours and an isotype negative control were stained 
with stathmin- and CK20-specific antibodies.  After washing, sections were incubated with Alexa 
Fluor labelled secondary antibodies and a nuclear stain, bis-benzimide.  Sections were analysed 
using a Zeiss LSM 510 confocal laser scanning microscope.   
 
 
3.5  MCPyV ST promotes redistribution of stathmin  
 
To further investigate the potential role of stathmin in MCPyV-induced 
transformation and metastasis of MCC tumour cells, immunofluorescence studies 
were conducted.  A MCPyV-negative MCC cell line (MCC13) was transfected with 
mammalian expression constructs, expressing either EGFP or EGFP-ST.  Cells were 
fixed and permeablised and the subcellular distribution of endogenous stathmin 
was analysed using a stathmin-specific antibody and GFP fluorescence was analysed 
by direct visualisation.   
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Initially, 293 FlpIn cells were transfected with either EGFP or EGFP-ST and the 
localisation of endogenous stathmin and β-tubulin (a marker for microtubule 
structures) determined.  However, as demonstrated in Figure 3.8, 293 FlpIn cells 
posses a distinct nucleus but there is very little cyctoplasm to visualise.  Therefore, 
any changes in the cyctoplasmic localisation of stathmin or the distribution of the 
MT structure would be underterminable.  
 
 
Figure 3.8.  Cystoplasmic visualisation is impaired in 293 FlpIn cells.  293 FlpIn cells were 
transfected with either EGFP or EGFP-ST mammalian expression vectors.  Cells were fixed and 
permeabilised 24 hours after transfection.  DAPI-containing mounting medium was used to visualise 
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the nucleus.  GFP fluorescence was analysed by direct visualisation whereas endogenous stathmin 
and β-tubulin was analysed by indirect immunofluorescence using a stathmin- and β-tubulin-specific 
antibody. Images were taken using a Z-stack protocol, where 10 slices evenly spaced throughout the 
cell were imaged and then combined by maximum intensity fluorescence to generate a single image 
per channel. 
 
As such, MCC13 cells were transfected as they posses a great nuclear to 
cyctoplasmic ratio, thus visualisation of any redristrubition occurring within the 
cyctoplasm would be distinguishable.  Figure 3.9 demosntrates that MCC13 cells 
expressing EGFP, show that endogenous stathmin has a diffuse cytoplasmic 
staining.  However, in MCC13 cells expressing EGFP-ST, stathmin in redistributed in 
a halo-like pattern, colocalising with a small proportion of MCPyV ST, indicating a 
possible interaction.   Interestingly, this cytoplasmic halo-like staining pattern is 
indicative of microtubule destabilisation341,359,375.  Interestingly, MCPyV ST staining 
is not present in the nucleus, as seen in Figure 3.9.  This could be a result of MCPyV 
ST binding to stathmin at increasing stathmin concentrations, resulting in its 
relocalisation.  
 
Figure 3.9.  MCPyV ST promotes redistribution of endogenous stathmin.  MCC13 cells were 
transfected with either EGFP or EGFP-ST mammalian expression vectors.  Cells were fixed and 
permeabilised 24 hours after transfection.  DAPI-containing mounting medium was used to visualise 
the nucleus.  GFP fluorescence was analysed by direct visualisation whereas endogenous stathmin 
was analysed by indirect immunofluorescence using a stathmin-specific antibody. Images were 
taken using a Z-stack protocol, where 10 slices evenly spaced throughout the cell were imaged and 
then combined by maximum intensity fluorescence to generate a single image per channel. 
 
3.6  MCPyV ST promotes microtubule destabilisation 
 
Chapter 3 
126 
  
Stathmin is a known microtubule-associated protein, whose activity regulates 
microtubule dynamics365.  Therefore, to investigate the effect of MCPyV ST 
expression on the microtubule network, immunofluorescence analysis was 
conducted.  MCC13 cells were transfected either EGFP or EGFP-ST expression 
constructs, followed by fixation and permeabilisation after 24 hours.  Cells were 
then incubated with a β-tubulin-specific antibody, a marker for the microtubule 
network.  Cells were imaged using a Z-stack protocol, with 10 image slices through 
the cell taken.  These images were then combined through ‘Maximum intensity 
fluorescence’ allowing a clear and concise view of the microtubule network 
throughout the cell to be observed. Figure 3.10 demonstrates that cells expressing 
EGFP show a dense, stable network of microtubule filaments throughout the cell. 
However, cells expressing EGFP-ST demonstrate a destabilised microtubule 
network, congregated around the nucleus, in a similar manner as stathmin 
expression in MCPyV ST expressing cells.  
 
Figure 3.10. MCPyV ST promotes microtubule destabilisation and stathmin redistribution.  MCC13 
cells were transfected with EGFP or EGFP-ST expression constructs.  24 hours after transfection cells 
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were fixed and permeablised, followed by staining with (endogenous β-tubulin- (i)) and (endogenous 
stathmin- (ii)) specific antibodies.  The nucleus was stained with DAPI-containing mounting medium 
and GFP fluorescence analysed by direct visualisation.  
 
To further confirm that MCPyV ST promotes redistribution of stathmin and results 
in microtubule destabilisation, immunofluorescence analysis was conducted using        
MCPyV-negative MCC cells and MCPyV-positive MCC cells (MCC13 and MKL-1, 
respectively).   
Figure 3.11 (i) demonstrates that stathmin is redistributed in a halo-like manner in 
MCPyV-positive MKL-1 cells, while the MCPyV-negative MCC13 cells show a diffuse 
cytoplasmic stathmin localisation. The results in Figure 3.11 (ii) also show a 
destabilised microtubule network in MKL-1 cells, as depicted by the localisation of 
β-tubulin around the nucleus. In comparison the MCC13 cells show a dense and 
stable microtubule network.  This highlights that the presence of MCPyV in MCC 
tumour cells, concurrent with MCPyV ST expression, results in a redistribution of 
stathmin promoting destabilisation of the microtubule network. 
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Figure 3.11.  MCPyV-positive MCC cells (MKL-1) demonstrate microtubule destabilisation and 
stathmin redistribution.  MCC13 and MKL-1 cells were analysed by immunofluorescence using 
stathmin- (i) and β-tubulin-specific antibodies (ii).  The nucleus was stained with DAPI-containing 
mounting medium.  
 
3.7 MCPyV ST affects stathmin phosphorylation levels and 
microtubule stability 
 
As previous immunofluorescence analysis indicated the rearrangement of the 
microtubules was indicative of destabilisation, the inherent stability of the 
microtubules was assessed by immunoblotting using a marker for stable 
microtubules, namely an acetylated tubulin-specific antibody376.  i293-ST cell lysates 
were analysed at 0, 24 and 48 hours post induction with Doxycyline hylate.  Figure 
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3.12 (i) and (ii) demonstrates that upon increased expression of MCPyV ST over 
time, there is a statistically significant decrease in acetylated tubulin levels.  This 
demonstrates that MCPyV ST expression promotes a decrease in stable microtubule 
structures. 
As previously discussed, there is a tight association between stathmin and 
microtubule dynamics, whereby stathmin phosphorylation promotes microtubule 
assembly and its subsequent depshosphorylation promotes microtubule 
disassembly and catastrophe.  MCPyV ST promotes the upregulation of stathmin, 
therefore the phosphorylation status of stathmin in MCPyV ST expressing cells was 
investigated.   Using i293-ST cells, uninduced and induced lysates were analysed by 
immunoblotting with a phospho-stathmin-specific antibody (Serine 16). The results 
in Figure 3.12 (iii) and (iv) indicate that upon MCPyV ST expression there is a 
statistically significant decrease in stathmin phosphorylation. 
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Figure 3.12.  MCPyV ST expression affects the cellular levels of phosphorylated stathmin and 
acetylated tubulin.  (i) i293-ST cells were left uninduced or induced and cell lysates harvested at 0, 
24 and 48 hours post-induction.  Lysates were analysed by western blot using acetylated tubulin-, 
FLAG-, β-tubulin- and GAPDH-specific antibodies.  (iii) i293-ST cells were left uninduced or induced 
for 48 hours after which cellular lysates were analysed by western blot using stathmin-, 
phosphorylated (Ser16) stathmin-, FLAG- and GAPDH-specific antibodies.  (ii) and (iv) GAPDH was 
used as a measure of equal loading and densitometry analysis using Image J software enabled 
calculation of the percentage of relative densitometry of either acetylated tubulin or phosphorylated 
stathmin, normalised to the loading control. Data analysed using three biological replicates per 
experiment, n=3. Statistical analysis employed was a two-tailed T-test with unequal variance. 
 
To verify that the observed differences in acetylated tubulin and phosphorylated 
stathmin were not a result of chemical induction, western blot analysis was 
performed, as seen in Figure 3.13.  HEK 293 FlpIn™ were treated in the presence or 
absence of Doxycyline hyclate for 48 hours and the cellular lysates analysed. The 
results demonstrate that chemical induction does not affect the post translational 
modifications of either protein.  Serine 16 (Ser16) was chosen as a marker for 
phosphorylated stathmin, as it it one of the dominant phosphorylated residues, as 
Chapter 3 
131 
  
mentioned previously.  Dephosphorylation of stathmin at Ser16, has been shown to 
induce significantly greater activation of stathmin, thus an increase in MT 
depolymerisation.  As such, Ser16 is an appropriate measure of stathmin 
dephosphorylation and function in terms of these experiements.   
 .   
 
Figure 3.13. Doxycyline hylcate induction does not affect protein levels.  (i) HEK 293 FlpIn™ cells 
were incubated for 48 hours in the presence or absence of doxycycline hyclate.  Lysates were 
isolated and immunoblot analysis performed using stathmin-, phosphorylated stathmin- and 
acetylated tubulin-specific antibodies.  GAPDH was used as a measure of equal loading and allowed 
the relative densitometry of stathmin (ii), phosphorylated stathmin (iii) and acetylated tubulin (iv) to 
be calculated using Image J software.  Data analysed using three biological replicates per 
experiment, n=3. Statistical analysis employed was a two-tailed T-test with unequal variance. 
 
To confirm these results, experiments were repeated comparing MCC13 and MKL-1 
cells.  Lysates were collected and immunoblotting performed using stathmin-, 
phosphorylated stathmin- and acetylated tubulin-specific antibodies.  Figure 3.14 
highlights that in cells expressing MCPyV ST a statistically significant increase in 
stathmin and a reduction in both acetylated tubulin and phosphorylated stathmin 
was seen, compared to control cells.  This demonstrates that a MCPyV-positive cell 
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line, coincident with MCPyV ST expression, shows both microtubule destabilisation 
and a reduction in stathmin phosphorylation. 
 
Figure 3.14. MCPyV-positive MKL-1 MCC cells shows microtubule destabilisation and altered 
phosphorylated stathmin levels. MKL-1 cells and MCC13 cells were isolated and the lysates 
analysed by western blotting using stathmin-, phosphorylated stathmin-, acetylated tubulin-, 2T2-, 
GFP- and GAPDH-specific antibodies.  The 2T2 antibody recognises MCPyV T antigens and is used to 
detect the presence of MCPyV ST.  GAPDH was used as a measure of equal loading and densitometry 
analysis using Image J software enabled calculation of the percentage of relative densitometry of 
stathmin (ii), phosphorylated stathmin (iii) and acetylated tubulin (iv), all normalised to the loading 
control.  Data analysed using three biological replicates per experiment, n=3. Statistical analysis 
employed was a two-tailed T-test with unequal variance. 
 
To verify that the observed results were due to MCPyV ST expression, MCC13 cells 
were transfected with either EGFP or EGFP-ST and the cell lysates analysed by 
immunoblotting with acetylated tubulin- and phosphorylated stathmin-specific 
antibodies.  Figure 3.15 demonstrates that upon MCPyV ST expression there is a 
significant increase in stathmin expression and a decrease in both acetylated 
tubulin and phosphorylated stathmin levels.  Clearly indicating that MCPyV ST 
expression is responsible for this phenotype.  
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Figure 3.15.  MCPyV ST expression promotes microtubule destabilisation in MCC13 cells. (i) MCC13 
cells were transfected with either EGFP or EGFP-ST.  After 24 hours lysates were analysed by 
immunoblotting using a stathmin-, phosphorylated stathmin-, and acetylated tubulin-specific 
antibody.  GAPDH was used as a measure of equal loading and allowed the relative densitometry of 
stathmin (ii), phosphorylated stathmin (iii) and acetylated tubulin (iv) to be calculated using Image J 
software.  Data analysed using three biological replicates per experiment, n=3. Statistical analysis 
employed was a two-tailed T-test with unequal variance. 
 
Furthermore to ensure that these results were not due to the presence of an EGFP 
fusion tag, this experiment was repeated with MCC13 cells transfected with either 
EGFP or an untagged-ST expression construct.  Figure 3.16 verifies that the 
observed increase in stathmin and decrease in acetylated tubulin and 
phosphorylated stathmin is a result of MCPyV ST expression and not the presence 
of a tagged epitope.  Moreover, this data confirms that the conclusions drawn with 
regard to MCPyV ST expression in i293-ST cells is physiologically relevant with 
regards to the MCC tumour cell lines. 
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Figure 3.16.  An EGFP tag does not affect MCPyV ST function.  (i) MCC13 cells were transfected with 
either EGFP or native-ST (untagged) and 24 hours later the cell lysates isolated.  Lysates were 
analysed by immunoblotting using stathmin-, phosphorylated stathmin-, and acetylated tubulin-
specific antibodies.  GAPDH was used as a measure of equal loading and allowed the relative 
densitometry of stathmin (ii), phosphorylated stathmin (iii) and acetylated tubulin (iv) to be 
calculated using Image J software.  Data analysed using three biological replicates per experiment, 
n=3. Statistical analysis employed was a two-tailed T-test with unequal variance. 
 
3.8 MCPyV ST affects the distribution of the actin cytoskeletal 
network 
 
Quantitative proteomic analysis also revealed that the gene ontology grouping 
‘cytoskeletal regulation, organisation and dynamics’ consisted of a number of actin 
cytoskeletal proteins that were also upregulated upon MCPyV ST expression.  
Therefore to investigate if MCPyV ST promotes alterations within the actin 
cytoskeletal network, immunofluorescence analysis was performed.  HEK 293 
FlpIn™ cells were transfected with either EGFP or EGFP-ST for 24 hours.  The actin 
cytoskeletal network was analysed using the actin stain, Phallodin. HEK 293 FlpIn™ 
cells, rather than MCC13 cells, were used for this analysis as untransfected MCC13 
cells show significant actin cytoskeletal protrusions.  This is likely due to gain of 
function mutations in MCPyV-negative MCC cells. Thus HEK 293 FlpIn™ cells were 
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used to analyse the effect of MCPyV ST on the actin network, as untransfected HEK 
293 FlpIn™ demonstrate few, if any, actin cytoskeletal protrusions and form 
ordered and stable actin networks.        
Figure 3.17 demonstrates that EGFP expressing cells contain an ordered and stable 
actin cytoskeletal network.  In contrast, EGFP-ST expressing cells show the actin 
network is altered in a manner characteristic of protrusion formation e.g. filopodia 
and invadepodia.  Two distinct distributions of the actin cytoskeletal network were 
observed upon MCPyV ST expression.  Firstly, a diffused nature with multiple 
protrusions on all sides of the cell surface membrane and secondly, a more 
polarised distribution of protrusions concentrated on one side of the cell.  The 
difference seen in the architecture of the actin network in MCPyV ST expressing 
cells may be a result of cells becoming polarised in order to facilitate cell motility.  
However, what is clear is that MCPyV ST expression promotes the formation of cell 
protrusions, likely filopodia or invadepodia which may be involved in cell motility 
and migration.   
Figure 3.17.  MCPyV ST promotes a rearrangement of the actin cytoskeletal network.  HEK 293 
FlpIn™ cells were transfected with either EGFP or EGFP-ST mammalian expression vectors.  Cells 
were fixed and permeabilised and incubated for 30 minutes with an actin stain, Phallodin.            
DAPI-containing mounting medium was used to visualise the nucleus.   
Chapter 3 
136 
  
3.9 Discussion 
 
The oncogenic MCPyV ST protein has been shown to be sufficient to promote 
anchorage independent growth of rodent cells and facilitate transformation247.  
However, no studies have addressed the mechanism by which MCC tumour cells 
readily metastase, and the possible role the MCPyV T antigens may play in this 
phenotype.  Herein, quantitative proteomic analysis has demonstrated an 
upregulation of a large proportion of cytoskeletal proteins upon MCPyV ST 
expression.  SILAC-based analysis, coupled with LC-MS/MS and bioinformatical 
analysis is an effective way of studying the host cell proteome, and has recently 
been applied in increasing areas of microbiology research377.  Furthermore, 
reducing sample complexity allows analysis of subcellular trafficking between 
various cellular compartments, to understand in greater detail the virus-host 
interactions. 
Data presented here, demonstrates that MCPyV ST promotes the upregulation of 
specific cytoskeletal and actin proteins, crucial to their regulation, organisation and 
dynamics.  Bearing in mind the highly aggressive nature of MCC and the               
well-established links between cell motility and cytoskeletal dynamics, this 
suggested a possible link between this phenotype and MCPyV ST expression.  
Moreover, MCC distant metastases results in poor patient survival rates, therefore 
addressing the mechanism by which this occurs may present novel targets for 
chemotherapy regimens.  
MCC tumour formation is effectively an indirect result of the monoclonal 
integration of the MCPyV genome into the host chromosome, which results in 
defective viral replication and leaves the MCPyV unable to generate infectious 
virions.  Interestingly, this indirect promotion of metastases is not without 
precedent in the viral world.  Other tumour-associated viruses, such as HPV 16, 
EBV, HBV and SV40 have all demonstrated the capacity to promote metastasis, 
through expression of viral oncoproteins.  These mechanisms vary but include 
alteration of cellular adhesion complexes, manipulation of matrix 
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metalloproteinases, gene expression modulation and cytoskeletal 
reorganisation299,378,379.   
Furthermore, results demonstrate that MCPyV ST expression correlates with an 
upregulation of stathmin. This has been shown in both i293-ST cells and         
formalin-fixed paraffin-embedded sections of primary MCC tumours.  Interestingly, 
stathmin overexpression is a feature of multiple cancer types and has been shown 
to correlate with tumour growth, poor patient prognosis and a high metastatic 
potential340,354. This has been confirmed by RNA interference studies that 
demonstrate that stathmin levels can drastically reduce the motility of various 
tumour cells340,356-358.  As such, the data presented here, suggests that MCPyV ST 
may contribute to the metastatic phenotype of MCC tumour cells through 
alterations in crucial cytoskeletal regulatory proteins, specifically by promoting the 
overexpression of stathmin. 
Due to the known association between stathmin and microtubule dynamics, and 
the importance of the microtubule network in facilitating cell motility, the structure 
of the microtubules in MCPyV ST expressing cells was investigated. Data presented 
herein, demonstrates that MCPyV ST expression promotes a rearrangement of the 
microtubule network, in a peri-nuclear halo-like ring, indicative of microtubule 
destabilisation341,375.  MCPyV-positive MCC cells, coincident with MCPyV ST 
expression, also show a destabilised microtubule network compared to          
MCPyV-negative MCC cells, further confirming that microtubule destabilisation is a 
result of MCPyV ST expression.  Moreover, through the use of a marker of stable 
microtubule, namely acetylated tubulin, results demonstrated there was a 
significant decrease in stable microtubule structures upon MCPyV ST expression.    
Moreover, the activity of stathmin is regulated by phosphorylation at multiple 
serine residues, whereby dephosphorylation promotes stathmins’ tubulin binding 
ability, thereby promoting microtubule destabilisation346,364,365.  Therefore in order 
to account for the ability of MCPyV ST to promote microtubule destabilisation, the 
phosphorylation status of stathmin was investigated. Findings here demonstrate 
that upon MCPyV ST expression there is an increase in the pool of 
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unphosphorylated stathmin.  This suggests that MCPyV ST expression promotes 
stathmin dephosphorylation, thereby resulting in MCPyV ST-induced microtubule 
destabilisation.  
This data represents the first quantitative proteomics study into MCPyV and MCC 
biology and provides a novel line of enquiry into cytoskeletal biology which may be 
an underlying mechanism in MCC metastasis.   
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4. MCPyV ST promotes cell motility, migration and invasion by 
facilitating microtubule destabilisation 
 
4.1  Introduction 
 
The spread of malignant cells from the primary solid tumour to remote sites within 
the body is one of the biggest problems facing cancer treatment, and results in 
more than 90% of cancer associated-deaths286.   Despite the clinical important of 
metastasis, the molecular mechanisms by which this phenotype is acquired have 
yet to be fully elucidated285.  This poses a significant problem in real terms for 
cancer prognosis and treatment of patients and is an area of cancer biology that 
needs much research.    
As previously discussed, MCC is regarded as the most aggressive form of skin cancer 
and is associated with poor patient prognosis and quick progression to distant 
metastases201.  Thus it is important to address the underlying molecular 
mechanisms by which this phenotype arises in MCC tumour cells.  
It is clear that cell motility, migration and invasion are key aspects that facilitate 
dissemination of cancer cells from the primary tumour.  It has long since been 
established that the actin cytoskeletal network is crucial in the process of cell 
motility and migration321, however recent evidence also highlights the emerging 
role of the microtubule network in both regulating and facility cell motility322.  
While the microtubule (MT) cytoskeletal network is pivotal for intracellular vesicle 
transport, organelle positing and mitotic spindle formation324-327, it is also 
important for the control of cell shape and polarised cell motility322,328.   
Microtubules form a dense cytoplasmic network and are composed of hollow tubes 
of αβ-tubulin heterodimers.  These tubulin heterodimers can self-assemble and 
disassemble, a process known as dynamic instability329.  This process is tightly 
regulated and is controlled by two classes of MT-associated proteins (MAPs), known 
as MT stabilising and MT destabilising proteins324,329.   
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One such MT destabilising protein is stathmin, also known as oncoprotein-18, and is 
a key regulator of MT dynamics340-342.  Stathmin has demonstrated both indirect 
sequestration of tubulin dimers and direct binding of protofilaments present at 
growing MT tips346, both of which facilitate MT destabilisation.  
Quantitative proteomic analysis highlighted that a large proportion of differentially 
expressed proteins upon MCPyV ST expression were involved in microtubule 
organisation, regulation and dynamics.  Bearing in mind the link between 
microtubules and cell motility and combined with the fact that MCC is highly 
metastatic, investigations were conducted into the ability of MCPyV ST to promote 
cell motility, migration and invasion.  Various methods of cell motility assays were 
performed using a range of cell lines, including the physiologically relevant MCPyV-
negative (MCC13) and MCPyV-positive (MKL-1) MCC cell lines.  This chapter 
focusses on MCPyV ST ability to promote microtubule destabilisation, possibly 
through stathmin activity, which in turn promotes a more motile and migratory 
phenotype.  
 
4.2 MCPyV ST promotes cell motility, migration and invasion in 
i293-ST cells 
 
To assess if expression of MCPyV ST affects cell motility and migration, a variety of 
motility and invasion assays were performed.  Initially, HEK 293 FlpIn™ cell 
movement was assessed using live cell imaging and tracking through the use of an 
IncuCyte kinetic live cell imaging system.  Cells were transfected with either EGFP or 
EGFP-ST, and cells imaged over the course of 24 hours, at 30 minute intervals to 
determine cell movement. It has previously been demonstrated within the 
Whitehouse Laboratory that the EGFP fusion does not affect MCPyV ST function226.  
Using Image J analysis software, transfected cells were tracked and the distance 
moved calculated, as can be seen in Figure 4.1.   
Separate line traces (blue, red, yellow, cyan and green) were used to demonstrate 
the path of movement of individual cells over a 24 hour period.  The results 
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demonstrate that HEK 293 FlpIn™ cells transfected with EGFP-ST show a 
statistically significant increase in cell motility in comparison to cells expressing 
EGFP.  Moreover, live cell imaging also demonstrated that HEK 293 FlpIn™ cells 
grow in a colony, however upon MCPyV ST expression cells rapidly dissociate from 
the rest of the colony, unlike EGFP expressing cells (depicted in supplementary 
movies on the attached CD-ROM) This once again suggests that MCPyV ST 
expression promotes a more motile and migratory phenotype.    
 
Figure 4.1. MCPyV ST expression promotes cell motility in HEK 293 FlpIn™ cells.  (i)  Cells were 
transiently transfected with either EGFP or EGFP-ST and 12 hours after transfection cell motility was 
analysed using an IncuCyte kinetic live cell imaging system.  Images were taken over the course of 24 
hours every 30 minutes and cell movement tracked using Image J software.  Red, blue, cyan, yellow 
and green line tracks depict the path of cell movement over the time course.  (ii) The average 
distance moved by transfected cells was measured in μM (n=50). Data analysed using three 
biological replicates per experiment, n=3. Statistical analysis employed was a two-tailed T-test with 
unequal variance. 
 
To verify this finding, a scratch-wound healing assay was performed using i293-ST 
cells to compare wound healing capabilities as a result of MCPyV ST expression.  
i293-ST cells were left uninduced or induced for 48 hours, the confluent cell 
monolayer was then subjected to a scratch wound.  The cellular growth back into 
the wound was then recorded every 24 hours for a course of 3 days as 
demonstrated in Figure 4.2.  The results clearly indicate that cells expressing MCPyV 
ST migrate more quickly into the wound, compared to uninduced cells, and fully 
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occlude the wound after 72 hours. Once again confirming that MCPyV ST 
expression significantly increases the motility and migration of cells.   
 
Figure 4.2. Scratch-wound healing analysis indicates that MCPyV ST expression promotes cell 
motility and migration in i293-ST.   Cells were seeded onto poly-L-lysine coated 6 well plates and 
left uninduced or induced for 24 hours, followed by generation of a scratch-wound across the cell 
monolayer.  Cells were imaged every 24 hours over the course of 3 days, using a Zeiss light 
microscope at 4x magnification.  (ii) The size of the wound was measured at 0 and 72 hours          
post-scratch.  (iii) Image J analysis was conducted to determine the area remaining at 72 hrs post 
scratch.  The area is expressed as a percentage of the original area of the sratch-wound at 0 hrs. All 
scratch assays were performed in triplicate. Data analysed using three biological replicates per 
experiment, n=3. Statistical analysis employed was a two-tailed T-test with unequal variance.   
   
To further investigate the role MCPyV ST plays in promoting cell motility and 
migration, the growth characteristics were analysed using matrigel- and    
fibronectin-based transwell migration and invasion assays.  The invasive human 
fibrosarcoma cell line, HT-1080, was used a positive control for cell migration and 
invasion.  The effect of MCPyV ST expression was observed in both the i293-ST 
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inducible cell line and HEK 293 FlpIn™ transfected with either EGFP or EGFP-ST.  
After 24 hours cells were seeded at the same cell density onto the matrigel or 
fibronectin coated transwells, along with an uncoated control plate and incubated 
for 22 hours.  Cells were then incubated with a Calcein AM dye and the percentage 
of cells which moved through the transwell, compared to the uncoated control 
plate was calculated and is displayed in Figure 4.3.   
Figure 4.3 demonstrates that cells expressing MCPyV ST, whether by induction with 
Dox or transfection show significantly increased migratory and invasive properties, 
in comparison to uninduced or EGFP expressing cells, respectively.  
 
Figure 4.3.  MCPyV ST expression promotes cell motility, migration and invasion.  i293-ST cells 
were left uninduced or induced for 24 hours, while HEK 293 FlpIn™ cells were transfected with 
either EGFP or EGFP-ST.  Cells were seeded onto precoated matrigel- or fibronectin-based transwell 
migration and invasion tissue culture wells.  Cells were incubated at 37 
o
C for 22 hours and 
subsequently labelled with Calcein AM fluorescent dye for 90 minutes.  The fluorescence was 
measured between 494-517 nM and the relative percentage of cells moved through the transwell 
was calculated as a percentage of the uncoated control plate (set at 100%). Data analysed using 
three biological replicates per experiment, n=3. Statistical analysis employed was a two-tailed T-test 
with unequal variance. 
 
In addition, to confirm that the observed increase in cell motility, migration and 
invasion was not a result of increased cell proliferation, the growth characteristics 
of MCPyV ST expressing cells was analysed.  Cell proliferation assays were 
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performed, comparing the growth of MCPyV ST expressing cells in both i293-ST 
cells and HEK 293 FlpIn™ cells transfected with either EGFP or EGFP-ST expressing 
cells.  Cells were grown in 10% serum, as per the motility assays, and the 
proliferative rate assessed over a 3 day period using a dye exclusion protocol using 
Trypan Blue solution.  Figure 4.4 demonstrates that there is no statistically 
significant difference in the growth rate of cells expressing MCPyV ST, in 
comparison to the respective negative counterparts.  This confirms that MCPyV ST 
is capable of promoting cells to adopt a more motile, migratory and invasive 
phenotype without increasing cell proliferation.   
 
Figure 4.4.  MCPyV ST expression does not promote cell proliferation in i293-ST and HEK 293 
FlpIn™ cells.  i293-ST cells were  uninduced or induced for 24 hours, while HEK 293 FlpIn™ cells were 
transfected with either EGFP or EGFP-ST expression constructs.  2x10
5
 cells were seeded into 6 well 
plates in DMEM containing 10% FCS (same as all motility experiments) and the cell number counted 
every 24 hours for a period of 3 days (n=3).  
 
4.3 MCPyV ST promotes cell motility, migration and invasion in 
MCC13 cells  
 
The i293-ST cell line is a useful and robust tool in order to conduct initial 
investigations and analysis into the role of MCPyV ST in tumourigenesis and 
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metastasis.  However, in order to demonstrate that MCPyV ST expression promotes 
cell motility, migration and invasion in a physiologically relevant tumour setting, it 
was necessary to repeat these experiments using MCC13 and MKL-1 cell lines. 
To confirm the accuracy of the previous findings live cell imaging was performed 
using the MCPyV-negative cell line, MCC13.  MCC13 cells were transfected with 
either EGFP or EGFP-ST expression vectors and imaged every 30 minutes over the 
course of 24 hours.  Figure 4.5 demonstrates that MCC13 cells expressing MCPyV ST 
show a statistically significant increase in the distance moved by cells.  One point to 
note is that the average distance moved between EGFP and EGFP-ST in MCC13 cells 
is less than between EGFP and EGFP-ST expressing HEK 293 FlpIn™ cells.  This is 
likely due to the MCC13 cell line being derived from a primary MCC tumour, and as 
mentioned previously MCC tumours are highly metastatic, suggesting gain of 
function mutations within MCPyV-negative MCC cells that result in increased cell 
motility.  Despite this it is clear that in a physiologically relevant cell line such as 
MCC13, MCPyV ST can promote a significant increase in cell motility.   
 
Figure 4.5.  MCPyV ST expression promotes cell motility in MCC13 cells.  (i) Cells were transfected 
with either EGFP or EGFP-ST and 12 hours after cell motility was analysed using an Incucyte kinetic 
live cell imaging system.  Images were taken over the course of 24 hours every 30 minutes and cell 
movement tracked using Image J software.  Red, blue, cyan and green line tracks depict the path of 
cell movement over the time course.  (ii) The average distance moved by transfected cells was 
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measured in μM (n=50). Data analysed using three biological replicates per experiment, n=3. 
Statistical analysis employed was a two-tailed T-test with unequal variance. 
Furthermore, matrigel-based migration assays were repeated using MCC13 cells 
transfected with either EGFP or EGFP-ST. Following the same procedure as 
previously described, transfected MCC13 cells were seeded onto the transwells and 
allowed to migrate over the course of 22 hours. This was followed by cell staining 
and the number of cells that migrated was calculated as a percentage of the 
uncoated control plate.  Figure 4.6 demonstrates MCPyV-ST expression results in a 
statistically significant increase in the percentage of cells migrating in comparison to 
MCC13 cells expressing EGFP. This once again confirms that MCPyV ST expression 
promotes a more migratory phenotype in both HEK 293 FlpIn™ and MCC13 cells. 
 
Figure 4.6.  MCPyV ST expression promotes cell motility, migration and invasion in MCC13 cells.  
Cells were transfected with either EGFP or EGFP-ST and seeded onto precoated matrigel- or 
fibronectin-based transwell migration and invasion tissue culture wells. HT-1080 fibrosarcoma cells 
were used as a positive control for migration. Cells were incubated at 37 
o
C for 22 hours and 
subsequently labelled with Calcein AM fluorescent dye for 90 minutes.  The fluorescence was 
measured between 494-517 nM and the relative percentage of cells moved through the transwell 
was calculated as a percentage of the uncoated control plate (set at 100%).  Data analysed using 
three biological replicates per experiment, n=3. Statistical analysis employed was a two-tailed T-test 
with unequal variance. 
 
4.4 Taxane compounds inhibit MCPyV ST-mediated microtubule 
destabilisation 
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Microtubule reorganisation plays an important role in cell motility, migration and 
invasion324,328. Therefore, to assess if MCPyV ST-mediated microtubule 
destabilisation could be inhibited, immunofluorescence was conducted in the 
presence of Paclitaxel.  MCC13 cells were transfected with either EGFP and       
EGFP-ST, then 4 hours prior to cell fixation cells were incubated with Paclitaxel 
(Figure 4.7 (ii)). Microtubule structures were then analysed using a β-tubulin-
specific antibody.  Figure 4.7 shows that MCPyV ST expressing cells exposed to 
Paclitaxel, show rigid, stable bundles of microtubules, in contrast to MCPyV ST 
expressing cells without Paclitaxel (Figure 4.7 (i) and Figure 3.9). Paclitaxel 
treatment has no effect on the stable microtubule structures in EGFP expressing 
cells, and is consistent with EGFP expressing cells alone (previously shown in Figure 
3.9). Another taxane compound termed Docetaxel (a derivative of Pacliatxel) was 
also used, to similar effect (results not shown). This data highlights that exposure to 
the chemotherapeutic drug, Paclitaxel, is able to inhibit MCPyV ST-mediated 
microtubule destabilisation. 
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Figure 4.7.  Paclitaxel treatment inhibits MCPyV ST-mediated microtubule destabilisation.  MCC13 
cells were transfected with either EGFP or EGFP-ST.  20 hours after transfection cells were incubated 
without Paclitaxel (i) or with Paclitaxel (ii) for 4 hours, followed by fixation and permeabilisation.  
Immunofluorescence was conducted using a β-tubulin-specific antibody.   The nucleus was stained 
with DAPI-containing mounting medium and GFP fluorescence was analysed by direct visualisation. 
Paclitaxel was used at a concentration of 10 μM. 
 
4.5 Microtubule destabilisation is crucial for MCPyV ST-mediated 
cell motility and migration 
 
Paclitaxel treatment proved successful in the inhibition of MCPyV ST-mediated 
microtubule destabilisation, therefore in order to establish if microtubule 
destabilisation was a prerequisite for MCPyV-ST cell motility, scratch-wound healing 
assays were performed.  i293-ST cells were left uninduced or induced for 24 hours 
and incubated with or without Paclitaxel for 4 hours prior to scratch-wound 
generation and the wound imaged every 24 hours for 3 days.   In parallel, MCC13 
cells were transfected with either EGFP or EGFP-ST and incubated for 4 hours prior 
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to scratch-wound generation, with or without Paclitaxel.  The results in Figure 4.8, 
clearly demonstrate that cells expressing MCPyV ST in the absence of Paclitaxel 
show enhance cell motility and migration, which is statistically significant.  
However, in the presence of Paclitaxel MCPyV ST expressing cells no longer show 
enhanced motility, instead migrate at a similar rate as uninduced i293-ST or EGFP 
transfected MCC13 cells. This data confirms that the ability of MCPyV ST to 
destabilise the microtubule network is crucial for MCPyV ST-mediated cell motility 
and migration and that this cell motility phenotype can be inhibited by the use of 
taxane-based drugs. 
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Figure 4.8. Paclitaxel treatment inhibits MCPyV ST-mediated cell motility and migration.  (i) i293-
ST cells were left uninduced or induced for 24 hours, upon which cells were incubated with or 
without Paclitaxel for 4 hours.  Cells were then subjected to a scratch-wound and analysed every 24 
hours over the course of 3 days.  (iii)  MCC13 cells were transfected with either EGFP or EGFP-ST for 
24 hours, followed by incubation with Paclitaxel for 4 hours.  The cell monolayer was then subjected 
to a scratch-wound and analysed over the course of 24 hours. The size of the wound was measured 
at 0 and 72 hours for i293-ST cells (ii) and 0 and 24 hours for MCC13 cells (iv) post scratch. (v) and 
(vi)  Image J analysis was conducted to determine the area remaining at either 72 hrs or 24 hrs post 
scratch, repectively.  The area is expressed as a percentage of the original area of the sratch-wound 
at 0 hrs.   All scratch assays were performed in triplicate.  Data analysed using three biological 
replicates per experiment, n=3. Statistical analysis employed was a two-tailed T-test with unequal 
variance. 
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To verify this data, and to analyse the levels of stathmin, phosphorylated stathmin 
and acetylated tubulin, western blot analysis was conducted using these samples.  
Figure 4.9 demonstrates that Paclitaxel treatment did not affect the ability of 
MCPyV ST to promote upregulation of stathmin or affect the levels of 
phosphorylated stathmin.  However, Paclitaxel treatment did significantly increase 
the levels of acetylated tubulin in MCPyV ST-expressing cells, a marker of stabilised 
microtubules. 
 
Figure 4.9.  Paclitaxel inhibits MCPyV ST ability to promote microtubule destabilisation and 
stathmin dephosphorylation.  (i) i293-ST cells were left uninduced or induced for 24 hours followed 
by incubation with or without Paclitaxel.  Lysates were analysed by immunoblotting using a 
stathmin-, phosphorylated stathmin-, and acetylated tubulin-specific antibody.  GAPDH was used as 
a measure of equal loading and allowed the relative densitometry of stathmin (ii), phosphorylated 
stathmin (iii) and acetylated tubulin (iv) to be calculated using Image J software.  Data analysed using 
three biological replicates per experiment, n=3. Statistical analysis employed was a two-tailed T-test 
with unequal variance. Data analysed using three biological replicates per experiment, n=3. 
Statistical analysis employed was a two-tailed T-test with unequal variance. 
 
To further confirm MCPyV ST-induced microtubule destabilisation is required for 
increased cell motility and migration in MCC tumour cells, MCPyV ST was depleted 
using a lentiviral-based knockdown system. The MCPyV-positive MKL-1 cell line was 
transduced with either lentivirus-based vectors expressing either shRNAs targeting 
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either ST alone, both LT and ST (PanT) or a scrambled negative control247,371.  Figure 
4.10 shows that MCPyV ST knockdown leads to a reduction in stathmin levels and 
increased levels of phosphorylated stathmin and acetylated tubulin.  This indicates 
that upon MCPyV ST knockdown microtubules are stabilised.    
 
Figure 4.10.  MCPyV ST is required for microtubule destabilisation in MKL-1 cells.   MKL-1 cells 
were transduced with lentivirus-based vectors expressing shRNAs targeting ST alone, both LT and ST 
(Pan T) and a scrambled negative control.  Cells lysates were isolated and analysed by western blot 
using stathmin-, phosphorylated stathmin-, acetylated tubulin- and 2T2-specific antibodies. GAPDH 
was used as a measure of equal loading and densitometry analysis using Image J software enabled 
calculation of the percentage of relative densitometry of stathmin (ii), phosphorylated stathmin (iii) 
and acetylated tubulin (iv), all normalised to the loading control.  Data analysed using three 
biological replicates per experiment, n=3. Statistical analysis employed was a two-tailed T-test with 
unequal variance. 
 
Furthermore, the effect of MKL-1 lentiviral knockdown of ST and PanT was assessed 
in matrigel-based transwell assays, specific for non-adherent cells as demonstrated 
in Figure 4.11.  The results show that MCPyV ST depletion results in a statistically 
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significant decrease in cell migration, with cells migrating at a much reduced rate in 
comparison to scrambled-control cells.  This once again confirms that MCPyV ST 
expression is crucial for microtubule destabilisation, which in turn promotes are 
more motile and migratory phenotype.  
.  
Figure 4.11.  MCPyV ST is required cell motility and migration in MKL-1 cells.  MKL-1 cells were 
transduced with lentivirus-based vectors expressing shRNAs targeting ST alone, both LT and ST (Pan 
T) and a scrambled negative control.  HT-1080 fibrosarcoma cells were used as a positive control for 
migration.  Cells were seeded onto transwells and incubated for 22 hours, followed by labelling with 
Calcein AM fluorescent dye for a further 90 minutes.  Fluorescence was measured between 494-517 
nM and the relative percentage of cells moved through the transwell was calculated as a percentage 
of the uncoated control plate (set at 100%).  Data analysed using three biological replicates per 
experiment, n=3. Statistical analysis employed was a two-tailed T-test with unequal variance. 
 
4.6 Stathmin depletion inhibits MCPyV ST-mediated cell motility, 
migration and invasion 
 
Paclitaxel is widely used in chemotherapy regimes and can inhibit MCPyV               
ST-mediated microtubule destabilisation and motility as discussed previously.  
However, a caveat in using Paclitaxel for scratch motility assays is that taxane-based 
compounds may affect cell division and therefore could prevent the growth of cells 
into the scratch-wound.  To overcome this issue and to more closely study the role 
of stathmin within this phenotype, scratch-wound assays were performed using 
i293-ST depleted of stathmin.  i293-ST cells were left uninduced or induced for 24 
hours and then transfected with either a scrambled control or stathmin-specific 
siRNA.  Upon transfection a scratch-wound was generated, 24 hours after the initial 
transfection cells were transfected again for a further 6 hours.  Cells were imaged 
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every 24 hours for the course of 3 days.  Western blots analysis of the same 
samples confirmed that stathmin was successfully depleted in cells with a 
significant decrease in stathmin levels at 72 hours post transfection, as seen in 
Figure 4.12 (i) and (ii). Similar rates of cell motility were observed in i293-ST 
induced cells transfected with a scrambled-control compared to i293-ST induced 
cells, as seen in Figure 4.12 (iii) and (iv).  This clearly demonstrates that the 
scrambled control as no effect on cell motility and upregulation of stathmin upon 
MCPyV ST expression (Figure 4.12 (i)).  However, cells induced for MCPyV ST 
expression and depleted of stathmin, show a statistically significant decrease in cell 
motility and migration in scratch-wound analysis (Figure 4.12 (iii) and (iv)).    
Importantly, these results indicate for the first time that the microtubule-associated 
protein, stathmin, is required for MCPyV ST-mediated cell motility. 
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Figure 4.12.  Stathmin is required for MCPyV ST-mediated cell motility and migration.  (i) i293-ST 
cells were transfected with either stathmin-specific siRNA or a scrambled control siRNA, and after 24 
hours left uninduced or induced.  Cell lysates were isolated at 0, 24, 48 and 72 hours and analysed 
by western blot using stathmin- and GAPDH-specific antibodies.  (ii) GAPDH was used as a measure 
of equal loading and densitometry analysis using Image J software enabled calculation of the 
percentage of relative densitometry of stathmin, normalised to the loading control.  (iii) i293-ST cells 
were seeded onto poly-L-lysine coated 6 wells and transfected with either stathmin-specific siRNA or 
a scrambled control siRNA and left uninduced or induced.  24 hours later cells were subjected to a 
scratch-wound and analysed every 24 hours for 3 days.  (iv) The size of the wound was measured at 
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0 and 72 hours.  All scratch assays were performed in triplicate, n=3.  (v) Scratch wound analysis 
using Image j software to calculate the area of the gap remaining at 72 hrs.  All numbers expressed 
as a percentage of the area remaining.  Statistical analysis employed was a two-tailed T-test with 
unequal variance.  
 
Furthermore, subsequent analysis of stathmin depletion in the context of       
matrigel-based migration assays was conducted, in order to determine the 
potential of stathmin upregulation on MCPyV ST-enhanced cell motility and 
migration. MKL-1 cells were transfected with either a scrambled-control or 
stathmin-specific siRNA on two consecutive days and seeded onto matrigel-coated 
transwells or uncoated control wells.  Figure 4.13 clearly demonstrates that 
stathmin depletion in cells positive for MCPyV show a statistically significant 
decrease in motility and migration through the transwells.  This confirms that 
stathmin is a crucial component for MCPyV ST-mediated cell motility and migration.   
     
 
Figure 4.13.  Stathmin is required for MCPyV ST-mediated cell migration in transwell assays.     
MKL-1 cells were transfected with either stathmin-specific siRNA or a scrambled control siRNA.  (i) 
24 hours later cells were seeded onto precoated matrigel-based transwell migration culture tissue 
wells.  Cells were incubated for 22 hours and then labelled for 90 minutes with Calcein AM 
fluorescent dye.  The fluorescence was measured between 494-517 nM and the relative percentage 
of cells moved through the transwell was calculated as a percentage of the uncoated control plate 
(set at 100%).  (ii) MKL-1 cells transfection with stathmin-specific or scrambled siRNA and the cellular 
lysates isolated at 0, 24, 48 and 72 hours after transfection.  Lysates were analysed by 
immunoblotting using a stathmin- and GAPDH specific antibodies.  Data analysed using three 
biological replicates per experiment, n=3. Statistical analysis employed was a two-tailed T-test with 
unequal variance. 
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4.7 Discussion 
 
There is a strong association between stathmin overexpression and enhanced 
metastasis in numerous cancer types340,354, hence the role of MCPyV ST in 
promoting cell motility was investigated. Data herein, demonstrates that MCPyV ST 
expression promotes cell motility, migration and invasion and this was confirmed 
using a range of cell lines, such as i293-ST cells and MCC13 and MKL-1 MCC cell 
lines.  For accuracy, a range of motility assays and techniques were employed, from 
live cell imaging and tracking to 2D scratch-wound healing assays and 3D migration 
and invasion transwell assays.  All motility assays used demonstrated that MCPyV 
ST expression promoted a statistically significant increase in cell motility.  This 
suggests a possible role of the MCPyV ST oncoprotein in facilitating MCC metastasis 
and provides evidence for further investigation into the underlying mechanisms.  
Indeed, other tumour-associated viruses have been shown to promote metastasis, 
such as HPV 16, EBV, HBV and SV40299,378,379. 
Therefore, in order to establish the requirement of MCPyV ST in promotion of 
microtubule destabilisation and cell motility a group of chemotherapeutic drugs 
were employed, known as taxanes. Taxanes such as Paclitaxel and Docetaxel bind 
directly to the microtubule structures and prevent tubulin heterodimer dissociation 
from the filament, hence stabilising the micortubules380.  Treatment of cells with 
Paclitaxel was able to inhibit MCPyV ST-mediated microtubule destabilisation and 
cell motility. This is significant as it demonstrates that MCPyV ST is required for 
microtubule destabilisation and that microtubule destabilisation is fundamental in 
facilitating enhanced cell motility and migration.   
Furthermore, lentiviral-based siRNA knockdown of MCPyV ST demonstrated that 
MCPyV ST is absolutely required for microtubule destabilisation, as depletion 
resulted in restoration of wild type levels of acetylated tubulin and phosphorylated 
stathmin.  Moreover, stathmin depletion in MKL-1 cells, significantly reduced the 
potential of cells to migrate in transwell assays. Once again clearly demonstrating 
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the fundamental role MCPyV ST plays in promoting microtubule destabilisation and 
in turn cell motility, migration and invasion.   
Quantitative proteomic analysis suggested that MCPyV ST affects the expression of 
multiple proteins involved in microtubule organisation and dynamics.  Interestingly, 
microtubule dynamics has now been shown to play a role in cell shape and 
polarised cell motility324,328. Chapter 3 highlighted that MCPyV ST expression 
promotes the upregulation of stathmin and also facilitates a decrease in the pool of 
unphosphorylated stathmin. Unphosphorylated stathmin promotes the 
microtubule destabilising activity of this protein and subsequent analysis confirmed 
that MCPyV ST expression resulted in destabilisation of the microtubule network.  
This data strongly implicated stathmin in MCPyV ST induced microtubule 
destabilisation.   
In an effort to circumvent the caveats associated with Paclitaxel treatment and 
subsequently analyse the role of stathmin in the context of MCPyV ST-induced cell 
motility, stathmin depletion studies were conducted. Findings herein, demonstrates 
that siRNA depletion of stathmin in scratch-wound healing and matrigel based 
assays and demonstrated that stathmin expression is required for the ability of 
MCPyV ST to promote cell motility and migration.  This data is supported by RNA 
interference studies that demonstrate that stathmin levels can drastically reduce 
the motility of tumour cells355-358. Moreover, this is the first time that stathmin has 
been shown to be required for viral-enhanced cell motility and demonstrates the 
novel mechanisms by which tumour virus can manipulate the host cell.  
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5. Cellular phosphatases are required for MCPyV ST-enhanced cell 
motility and migration 
 
5.1 Introduction 
 
Microtubule dynamics is an important aspect of cell motility and polarisation, and is 
a process that is heavily regulated by the action of microtubule-associated proteins 
(MAPs)324,329. A master regulator of microtubule destabilisation is the MAP protein, 
stathmin. Stathmin regulates microtubule destabilisation through two mechanisms, 
termed indirect and direct.  Stathmin possess two binding sites of equal size and 
affinity for tubulin heterodimers, and forms the T2S complex, thus sequestering 
tubulin heterodimers and reducing the substrate for growing MT structures346.  
Stathmin can also act in a direct manner, through binding protofilament structures 
present at the growing MT tips, thereby inhibiting the interactions required to 
maintain its structure and function346.   
Importantly, stathmin overexpression is a feature of multiple cancer types and has 
been shown to correlate with tumour growth, poor patient prognosis and a high 
metastatic potential340,354. Furthermore, RNA interference studies have 
demonstrated that reducing stathmin levels can drastically reduce the motility of 
various tumours355-358. Stathmin is regulated by phosphorylation, whereby 
phosphorylation at one or more serine residues (Ser16, Ser25, Ser38, and Ser63) 
weakens stathmin’s tubulin binding ability and leads to an increase in free tubulin 
within the cells, required for MT growth346.  Conversely, dephosphorylation by 
cellular phosphatases, promotes stathmin MT destabilising ability and can 
contribute to transformation346,359. As such it has been suggested that the 
phosphorylation status of stathmin can directly impact on cell motility, migration 
and invasion.   
Similar to SV40, MCPyV ST has been shown to interact with multiple cellular 
phosphatases, including PP2A Aα, PP2A Aβ and PP4C226,247.  Therefore in order to 
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assess the role of these cellular phosphatases in MCPyV ST-mediated microtubule 
destabilisation and stathmin phosphorylation status, experiments were performed 
using cellular phosphatase transdominant mutants and MCPyV ST mutants, 
incapable of interacting with specific cellular phosphatases.  This chapter assesses 
the role of MCPyV ST binding to specific cellular phosphatases, particularly PP4C, in 
relation to microtubule destabilisation.  Further studies were also conducted to 
address the mechanism by which MCPyV ST promotes the upregulation of 
stathmin, either by transcriptional or translation enhancement or by increasing 
stathmin protein stability.  Moreover the interactions of MCPyV ST, stathmin and 
PP4C were addressed in order to establish a novel mechanism of action of MCPyV 
ST-induced cell motility.   
 
5.2 ST binding mutants identify specific cellular phosphatases 
required for MCPyV ST-mediated microtubule destabilisation 
 
The function of stathmin is regulated by phosphorylation which in turn regulates 
microtubule stability346,381. Previous findings demonstrate that MCPyV ST 
expression increases the levels of unphosphorylated stathmin, which increases 
microtubule destabilisation.  Findings from the Whitehouse laboratory and other 
research groups have shown that MCPyV ST interacts with multiple cellular 
phosphatase subunits including PP2A Aα, PP2A Aβ and PP4C226,247.   
To determine if these cellular phosphatases were important in MCPyV ST-mediated 
microtubule destabilisation, two previously generated MCPyV ST mutants were 
employed.  The R7A mutant fails to interact with PP2A Aα, while the ∆95-111 fails 
to interact with both PP4C and PP2A Aβ.  Significantly, it has previously been shown 
that both mutants retain the inherent functions associated with MCPyV ST, as both 
stimulate the expression of the MCPyV early promoter, to similar levels as those 
seen with wild-type MCPyV ST226. Initially, MCC13 cells were transfected with either 
EGFP, EGFP-ST, EGFP-R7A or EGFP-∆95-111, followed by fixation and 
permeabilisation.  Cells were then incubated with a β-tubulin-specific antibody to 
analyse the microtubule structure (Figure 5.1).  The R7A binding mutant, which fails 
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to interact with PP2A Aα, retains the ability to promote microtubule destabilisation, 
similar to EGFP-ST, suggesting that the MCPyV ST-PP2A Aα is not required for 
microtubule destabilisation.  However, the ∆95-111 mutant shows a stable 
microtubule network, similar to EGFP.  Indicating that abolishing MCPyV ST 
interaction with PP4C and or PP2A Aβ prevents MCPyV ST-mediated microtubule 
destabilisation.  
 
Figure 5.1.  Cellular phosphatases are required for MCPyV ST-mediated microtubule 
destabilisation in MCC13 cells.   Cells were transfected with either EGFP, EGFP-ST, EGFP-R7A or 
EGFP-∆95-111 mammalian expression constructs. 24 hours after transfection cells were fixed and 
permeablised, followed by analysis using an endogenous β-tubulin-specific antibody to visualise the 
microtubule network.  GFP fluorescence was visualised by direct visualisation and the nucleus was 
stained with DAPI-containing mounting medium. 
 
To verify these results, western blot analysis was conducted using MCC13 cell 
lysates transfected with EGFP, EGFP-ST, EGFP-R7A and EGFP-∆95-11 and the levels 
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of phosphorylated stathmin, stathmin and acetylated tubulin analysed.  Figure 5.2 
demonstrates that EGFP-R7A and EGFP-ST show statistically similar increases in 
stathmin and a decrease in acetylated tubulin and phosphorylated stathmin, 
indicative of microtubule destabilisation.  However, EGFP-∆95-111 demonstrates a 
phenotype similar to EGFP, whereby an increase in acetylated tubulin and 
phosphorylated stathmin levels is observed.  Importantly, this suggests that the 
association of MCPyV ST with PP2A Aα is not required for microtubule 
destabilisation.  Conversely, these results indicate a possible mechanism by which 
MCPyV ST may act through binding to either PP4C and/or PP2A Aβ which facilitates 
MCPyV ST-mediated microtubule destabilisation. 
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Figure 5.2. Cellular phosphatases are required for MCPyV ST-mediated microtubule destabilisation 
and affect microtubule stability.  Cells were transfected with either EGFP, EGFP-ST, EGFP-R7A or 
EGFP-∆95-111 mammalian expression constructs. (i) 24 hours after transfection cell lysates were 
harvested and analysed by immunoblotting using stathmin-, phosphorylated stathmin-, acetylated 
tubulin-, EGFP- and GAPDH-specific antibodies.  GAPDH was used as a measure of equal loading and 
densitometry analysis using Image J software enabled calculation of the percentage of relative 
densitometry of stathmin (ii), phosphorylated stathmin (iii) and acetylated tubulin (iv), all normalised 
to the loading control. Data analysed using three biological replicates per experiment, n=3. 
Statistical analysis employed was a two-tailed T-test with unequal variance. 
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5.3 ST binding mutants identify specific cellular phosphatases 
required for MCPyV ST-enhanced cell motility 
 
From previous results the binding of MCPyV ST to the cellular phosphatases PP4C 
and/or PP2A Aβ is required for microtubule destabilisation.  As such scratch-wound 
healing assays were performed to determine if these cellular phosphatases are 
required for MCPyV ST-enhanced cell motility.  Wound healing analysis was 
conducted in HEK 293 FlpIn™ cells, transfected with either EGFP, EGFP-ST,        
EGFP-R7A or EGFP-∆95-111.  After transfection a scratch wound was generated and 
cells imaged every 24 hours for 3 days.  The results in Figure 5.3 clearly 
demonstrate that cells expressing R7A migrate at a similar rate as EGFP-ST 
expressing cells.  However, EGFP-∆95-111 expressing cells show a statistically 
significant reduction in cellular growth back into the wound (similar to EGFP). 
              
Figure 5.3.  Cellular phosphatases are required for MCPyV ST-mediated cell motility in HEK 293 
FlpIn™ cells.  Cells were seeded onto poly-L-lysine coated 6 well plates and transfected with either 
EGFP, EGFP-ST, EGFP-R7A or EGFP-∆95-111 mammalian expression constructs.  (i) 24 hours after 
transfection a scratch wound was generated and cells imaged every 24 hours over the course of 3 
days, using a Zeiss light microscope at 4x magnification.  (ii) The size of the wound was measured at 
0 and 72 hours post-scratch.  All scratch assays were performed in triplicate. Data analysed using 
three biological replicates per experiment, n=3. Statistical analysis employed was a two-tailed T-test 
with unequal variance. 
 
To verify this result, scratch wound analysis was performed using MCC13 cells 
transfected with either EGFP, EGFP-ST, EGFP-R7A or EGFP-∆95-111.   Cellular 
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growth back into the wound was analysed over the course of 24 hours.  Figure 5.4 
shows similar results as observed in the HEK 293 FlpIn™ cell line analysis, whereby 
EGFP-∆95-111 expression does not enhance cellular growth back into the wound.  
This data indicates that PP4C and/or PP2A Aβ are required for MCPyV ST-induced 
cell motility and migration, possibly through dephosphorylation of stathmin.  
 
Figure 5.4.  Cellular phosphatases are required for MCPyV ST-mediated cell motility in MCC13 
cells.  Cells were seeded onto poly-L-lysine coated 6 well plates and transfected with either EGFP, 
EGFP-ST, EGFP-R7A or EGFP-∆95-111 mammalian expression constructs.  (i) 24 hours after 
transfection a scratch wound was generated and cells imaged every 24 hours over the course of 3 
days, using a Zeiss light microscope at 4x magnification.  (ii) The size of the wound was measured at 
0 and 72 hours post-scratch.  Data analysed using three biological replicates per experiment, n=3. 
Statistical analysis employed was a two-tailed T-test with unequal variance. 
   
In addition, these results were confirmed by live cell tracking of MCC13 cells 
transfected with either EGFP, EGFP-ST, EGFP-R7A or EGFP-∆95-111.  Cells were 
imaged over the course of 24 hours every 30 minutes and the path of movement by 
each cell marked in blue, cyan, green and red. Figure 5.5 demonstrates that MCC13 
cells transfected with ∆95-111 show a statistically significant decrease in cell 
motility in comparison to EGFP-ST or EGFP-R7A expression cells.    Taken together, 
this data indicates that PP4C and/or PP2A Aβ are required for MCPyV ST-induced 
cell motility and migration, possible through dephosphorylation of stathmin which 
would promote microtubule destabilisation.  
Chapter 5 
168 
  
 
Figure 5.5. Live cell tracking shows that cellular phosphatases are required for MCPyV ST-mediated 
cell motility in MCC13 cells.  Cells were transiently transfected with either EGFP, EGFP-ST, EGFP-R7A 
or EGFP-∆95-111.  (i) 12 hours after transfection cell motility was analysed using an IncuCyte kinetic 
live cell imaging system.  Images were taken over the course of 24 hours every 30 minutes and cell 
movement tracked using Image J software.  Red, blue, cyan and green line tracks depict the path of 
cell movement over the time course.  (ii) The average distance moved by transfected cells was 
measured in μM (n=50). Data analysed using three biological replicates per experiment, n=3. 
Statistical analysis employed was a two-tailed T-test with unequal variance. 
 
5.4 PP4C is important for microtubule organisation and dynamics 
 
It is clear that the ability of MCPyV ST to bind specific cellular phosphatases is 
important for microtubule dynamics and stability, therefore to further define the 
role of these phosphatases in MCPyV ST-mediated cell motility, transdominant 
mutants of PP2A and PP4 were employed.  The PP4-RL is a phosphatase dead 
mutant of PP4, whereby arginine 236 has been replaced with a leucine169.  The 
PP2AcH118N, is a catalytically inactive dominant negative mutant of the PP2A 
catalytic subunit, with a mutation within the active site incorporating a His118  
residue382. 
Immunofluorescence analysis was performed using MCC13 cells co-transfected with 
either EGFP or EGFP-ST and in the presence of either the wild-type or the 
transdomiant PP2A.  Cells were stained with a β-tubulin-specific antibody and the 
microtubule network analysed.  Figure 5.6 demonstrates that transfection with 
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wild-type PP2A has little effect on the microtubule structures in either EGFP or 
EGFP-ST expressing cells, with MCPyV ST showing distinct microtubule 
destabilisation.  However, co-expression of the control EGFP with the catalytically 
inactive PPAcH118N mutant, results in distinct destabilisation of the microtubule 
structures.  This suggests that PP2A transdomiant overexpression is important for 
microtubule dynamics and that its inhibition can result in microtubule 
destabilisation.  As previously dicussed MCPyV ST binds PP2A, thus expression of an 
inactive PP2A isoform may prevent MCPyV ST interacting with or facilitating the 
dephosphorylation of downstream substrates, thereby resulting in subsequent MT 
destablilation. As such, no further conclusions regarding the role of PP2A in MCPyV 
ST-mediated microtubule destabilisation could be drawn. 
 
Figure 5.6. PP2A Aα is important for microtubule stability in control cells.  MCC13 cells were 
transfected with either EGFP or EGFP-ST in the presence of either wild type or inactive PP2A.  Cells 
were fixed, permeablised and analysed by immunofluorescence using a β-tubulin-specific antibody.  
GFP fluorescence was analysed by direct visualisation and the nucleus identified using                  
DAPI-containing mounting medium.  WT (wild type), TD (transdomiant). To detect the expression of  
both PP2A Aα WT and PP2A Aα TD, a glu-glu-specific and a HA-specific antibody were used for 
analysis, respectively. 
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Therefore, in order to further investigate the role of the MCPyV ST-PP4C 
interaction, these experiments were repeated using MCC13 cells transfected with 
either EGFP or EGFP-ST in the presence of either wild-type or transdomiant PP4. 
Figure 5.7 demonstrates that co-expression of wild-type PP4 with EGFP results in 
stable microtubule structures, however co-expression with MCPyV ST once again 
demonstrates microtubule destabilisation. Furthermore, co-expression of a 
transdomiant PP4 with EGFP results in stable microtubules structures, in 
comparison to transfection with a transdominant PP2A.  This demonstrates that 
PP4 is not crucial for microtubule dynamics in healthy cells.   Importantly though, 
co-expression of EGFP-ST and the catalytically transdominant PP4-RL mutant does 
not result in microtubule destabilisation, indicative of MCPyV ST expression alone.  
This is a crucial point and indicates that PP4C is pivotal for MCPyV ST-mediated 
microtubule destabilisation and that subsequent inhibition of PP4C can inhibit this 
MCPyV ST-induced phenotype.   Importantly, this demonstrates a novel molecular 
mechanism by which the MCPyV ST-PP4C interaction, perhaps by facilitating the 
dephosphorylation of stathmin, leads to microtubule destabilisation and enhanced 
cell motility. 
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Figure 5.7.  Expression of a transdominant PP4C mutant inhibits MCPyV ST-mediated microtubule 
destabilisation.  MCC13 cells were transfected with either EGFP or EGFP-ST in the presence of wild 
type or inactive PP4C mammalian expression constructs.  24 hours after transfection cells were 
fixed, permeablised and stained with an endogenous β-tubulin-specific antibody.  GFP fluorescence 
was analysed by direct visualisation and the nucleus stained using DAPI-containing mounting 
medium.   
 
 
To verify these results, immunoblotting was performed using MCC13 cell lysates 
transfected with either EGFP or EGFP-ST in the presence of wild type or 
transdominant PP4.  Cell lysates were analysed using stathmin-, phosphorylated 
stathmin- and acetylated tubulin-specific antibodies (Figure 5.8).  In EGFP-ST 
expressing cells, co-expression of PP4-RL resulted in a notable increase in 
phosphorylated stathmin and acetylated tubulin levels, in comparison to EGFP-ST 
expressing cells cotransfected with wild type PP4.  These results are similar to those 
seen with EGFP-∆95-111, suggesting that PP4C may be important of MCPyV           
ST-mediated microtubule destabilisation. 
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Figure 5.8. Expression of a transdominant PP4C mutant promotes microtubule destabilisation.  
MCC13 cells were transfected with either EGFP or EGFP-ST in the presence of wild type or inactive 
PP4C mammalian expression constructs.  (i) 24 hours after transfection cell lysates were harvested 
and immunoblotting performed using stathmin-, phosphorylated stathmin-, acetylated tubulin-, 
EGFP- and GAPDH-specific antibodies.  GAPDH was used as a measure of equal loading and 
densitometry analysis using Image J software enabled calculation of the percentage of relative 
densitometry of stathmin (ii), phosphorylated stathmin (iii) and acetylated tubulin (iv), all normalised 
to the loading control. Data analysed using three biological replicates per experiment, n=3. 
Statistical analysis employed was a two-tailed T-test with unequal variance. 
 
To further investigate the role of PP4C in MCPyV ST-mediated cell motility,       
scratch-wound healing assays were performed using uninduced and induced      
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i293-ST cells transfected with either wild type or inactive PP4.  Figure 5.9 
demonstrates that expression of the catalytically inactive PP4 inhibits cellular 
growth back into the wound in MCPyV ST expressing cells, in comparison to 
expression of the wild type construct which shows typical MCPyV ST-induced cell 
motility and migration.  
         
Figure 5.9.  Expression of a transdominant PP4C mutant inhibits MCPyV ST-mediated cell motility 
in i293-ST cells.  (i) Cells were seeded onto poly-L-lysine coated 6 well plates and transfected with 
either wild type or the catalytically inactive PP4-RL expression constructs.  24 hours after 
transfection a scratch wound was generated and cells imaged every 24 hours over the course of 3 
days, using a Zeiss light microscope at 4x magnification.  (ii) The size of the wound was measured at 
0 and 72 hours post-scratch.  Data analysed using three biological replicates per experiment, n=3. 
Statistical analysis employed was a two-tailed T-test with unequal variance. 
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These results were then confirmed using MCC13 cells transfected with either EGFP 
or EGFP-ST in the presence of either wild type or inactive PP4 (Figure 5.10). Once 
again these results demonstrate that expression of the inactive PP4-RL in EGFP-ST 
expressing cells inhibits cellular growth.  Taken together, these results suggest that 
PP4C is important for MCPyV ST-mediated microtubule destabilisation and in turn 
increases cell motility.  
            
Figure 5.10.  Expression of a transdominant PP4C mutant inhibits MCPyV ST-mediated cell motility 
in MCC13 cells.  (i) Cells were seeded onto poly-L-lysine coated 6 well plates and transfected with 
either EGFP or EGFP-ST in the presence of either wild type or the catalytically inactive PP4-RL 
expression constructs.  24 hours after transfection a scratch wound was generated and cells imaged 
over the course of 24 hours, using a Zeiss light microscope at 4x magnification.  (ii) The size of the 
wound was measured at 0 and 24 hours post-scratch.  All scratch assays were performed in 
triplicate.    Data analysed using three biological replicates per experiment, n=3. Statistical analysis 
employed was a two-tailed T-test with unequal variance. 
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5.5 MCPyV ST interacts with stathmin  
 
Previous results have demonstrated that PP4C is required for MCPyV ST-induced 
microtubule destabilisation and cell motility.  This may also be due to the 
interaction between MCPyV ST and PP4C, and through this interaction MCPyV ST 
may increase the levels of unphosphorylated stathmin. As previously mentioned 
the Whitehouse laboratory have shown that MCPyV ST binds the cellular 
phosphatase catalytic subunit PP4C226.  Therefore, results herein examined whether 
MCPyV ST interacts with stathmin and also whether stathmin binds PP4C.  Dr 
Andrew Macdonald and Hussein Abdul-Sada performed co-immunoprecipitation 
assays in HEK 293 FlpIn™ cells, transfected with either EGFP, EGFP-ST, empty-FLAG, 
or FLAG-PP4C mammalian expression constructs.  MCPyV ST immunoprecipitations 
were then performed using GFP-TRAP beads, while PP4C cell lysates were 
immunoprecipitated using FLAG-affinity agarose beads. The subsequent 
precipitated proteins were identified using a stathmin-specific antibody and Figure 
5.11 demonstrates that stathmin binds both PP4C and MCPyV ST.  Importantly, this 
indicates that these interactions may facilitate an increase in unphosphorylated 
stathmin, resulting in microtubule destabilisation and in turn enhancement of cell 
motility, migration and invasion.   
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Figure 5.11.  Stathmin interacts with both MCPyV and PP4C.  (i) HEK 293 FlpIn™ cells were co-
transfected with EGFP or EGFP-ST mammalian expression constructs.  Cell lysates were incubated 
with GFP-TRAP affinity beads and immunblotting performed on precipitates using a control GFP-, 
stathmin and GAPDH-specific antibodies.  (ii)  HEK 293 FlpIn™ cells were co-transfected with empty-
FLAG or FLAG-PP4C mammalian expression constructs. Cell lysates were incubated with FLAG affinity 
agarose beads and the precipitate analysed by western blot using a control FLAG-, stathmin- and 
GAPDH-specific antibodies.  (These experiments were performed by Hussein Abdul-Sada).   
 
5.6 MCPyV ST may enhance stathmin translation 
 
The previous findings indicate that MCPyV ST expression promotes the upregulation 
of stathmin and through an interaction of MCPyV ST with cellular phosphatases 
(particularly PP4C) stathmin is dephosphorylated. This leads to an increase in the 
pool of unphosphorylated stathmin and promotes microtubule destabilisation, 
enhancing cell motility and migration.  However, the level at which stathmin 
protein levels are regulated needs to be addressed. Initially, qRT-PCR analysis was 
conducted using uninduced and induced i293-ST cells, in order to establish if 
MCPyV ST enhances stathmin at the transcriptional level. Figure 5.12 clearly shows 
that despite there being a slight increase in stathmin mRNA levels in MCPyV ST 
cells, this is insignificant, and suggests that MCPyV ST does not increase stathmin 
transcript levels.  
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Figure 5.12.  MCPyV ST does not promote enhanced transcription of stathmin.  (i) Using uninduced 
and induced i293-ST cells, total RNA was extracted after 24 hours and reversed transcribed to 
produce a cDNA library.  The relative stathmin levels were analysed by qRT-PCR using GAPDH as a 
reference.  The relative fold increase was calculated using ∆∆cT values and statistical analysis by a 
non-paired t-test.  The data from 3 independent studies is presented as a fold change against the 
uninduced control.  (ii) MCPyV ST expression was confirmed by western blot using the same samples 
and analysed using the 2T2-specific antibody that detects MCPyV T antigen expression. Data 
analysed using three biological replicates per experiment, n=3. Statistical analysis employed was a 
two-tailed T-test with unequal variance. 
 
This result suggests that MCPyV ST promotes an increase in stathmin levels at a 
post-transcriptional level.  Therefore to assess if stathmin protein stability is 
affected by MCPyV ST expression, immunoblotting was performed on induced   
i293-ST cell lysates in the absence or presence of cyclohexamide.  Figure 5.13 
demonstrates that there is a slight, but insignificant increase in the half-life of 
stathmin in cells incubated with cyclohexamide.  As a positive control, p53 showed 
reduced protein levels in the presence of cyclohexamide over time.  Therefore, 
these results suggest that MCPyV ST does not actively increase the protein stability 
of stathmin.  
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Figure 5.13.  MCPyV ST does not enhance stathmin protein stability.  i293-ST cells were left 
uninduced or induced in the presence or absence of cyclohexamide and samples harvest at 0, 2, 4 
and 6 hours post cyclohexamide treatment. (i)  Cell lysates were analysed by western blot using 
stathmin-, FLAG- and GAPDH-specific antibodies.  (ii) Relative stathmin protein levels were 
quantified using Image J software, between unindued and induced cells in the presence of CHXl, and 
is shown as a percentage of relative densitometry compared to the loading control, GAPDH. Data 
analysed using three biological replicates per experiment, n=3. Statistical analysis employed was a 
two-tailed T-test with unequal variance. 
 
Previous findings have indicated that MCPyV ST acts downstream in the mammalian 
target of rapamycin (mTOR) signaling pathway, deregulating cap-dependent 
translation by maintaining the hyperphosphorylated state of the translation 
initiation factor, 4E-BP1247.  Therefore, to establish if MCPyV ST enhances stathmin 
expression through this mechanism, immunoblotting was performed comparing 
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uninduced and induced i239-ST cells in the absence or presence of rapamycin.  
Rapamycin specifically binds FK-binding protein 12 (FKBP12) and through this 
complex is able to inhibit mTOR signaling.  mTOR activation results in the 
phosphorylation of 4E-BP1 and subsequently prevents 4E-BP1 binding to eIF4E, 
thereby allowing eIF4E to form at the cap of mRNA molecules, resulting in ribosome 
recruitment and translation.  As mentioned MCPyV ST expression preserves the 
hyperphosphorylated state of 4E-BP1, even under rapamycin treatment, to 
stimulate cap-dependent translation. 
The results in Figure 5.14 demonstrate that in the absence or presence of 
rapamycin the induced levels of stathmin remain the same, suggesting that even 
though rapamycin treatment inhibits mTOR activation and subsequent translation, 
this does not affect the translation of stathmin. This indicates that induced stathmin 
levels are unaffected by rapamycin, due to the ability of MCPyV ST to maintain the 
hyperphosphorylated state of 4E-BP1.  Moreover, this suggests that MCPyV ST may 
enhance stathmin expression levels through an enhancement of cap-dependent 
translation.  
 
 
Figure 5.14.  MCPyV ST dysregulation of cap-dependent translation is required for enhanced 
stathmin expression.  (i) i293-ST cells were left uninduced or induced for 24 hours, followed by 
incubation with rapamycin for 4 hours.  Cells lysates were harvested and analysed by western blot 
using stathmin-, phosphorylated 4E-BP1, and GAPDH-specific antibodies.  (ii) Relative stathmin levels 
were quantified using Image J software, and is shown as a percentage of relative densitometry 
compared to the loading control, GAPDH.  
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5.7 Discussion 
 
In terms of MCC treatment and metastasis prevention, understanding the 
mechanism by which MCPyV ST promotes microtubule destabilisation and cell 
motility is a key factor for possible therapeutic regimes.  This Chapter discusses the 
role MCPyV ST has in promoting the upregulation of stathmin and its subsequent 
dephosphorylation.  To date few studies have directly implicated any specific 
cellular phosphatases in stathmin dephosphorylation.  However studies have 
indicated that okadaic acid treatment inhibits protein phosphatases type 1, type 2A 
and type 2B, and drastically elevated the levels of phosphorylated stathmin, 
thereby implicating these phosphatases in stathmin regulation383.  Interestingly, 
MCPyV has been shown to interact with a number of cellular phosphatases such as 
PP2A Aα, PP2A Aβ and PP4C226,247.   
Data herein demonstrates a likely role for PP4C in MCPyV ST-mediated microtubule 
destabilisation and enhancement of cell motility.  Cell motility assays conducted 
using either a MCPyV ST mutant incapable of binding PP4C or an inactive PP4C 
mutant showed a significant reduction in cell motility upon MCPyV ST expression in 
both i293-ST cells and MCC13 cells.  Immunoblotting and immunofluorescence 
analysis further confirmed that inhibition of the PP4C-MCPyV ST interaction 
resulted in a significant increase in microtubule stability.  Interestingly, PP4C has 
previously been shown to affect microtubule organisation at the centrosome 
through recruitment of katanin p60 and regulation of NEDL1384.   
 
Moreover, further analysis herein demonstrates a novel interaction of MCPyV ST 
and stathmin and a further novel interaction between stathmin and PP4C.  Work is 
now ongoing to determine is a tertiary complex involving stathmin, PP4C and 
MCPyV ST is formed and to assess whether the interaction between stathmin and 
PP4C is enhanced by the presence of MCPyV ST. 
 
Data presented herein, allows a model of MCPyV ST-mediated cell motility to be 
established.  Whereby, the interaction between MCPyV and stathmin may facilitate 
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an interaction between PP4C and stathmin.  This may direct PP4C dephosphatase 
activity towards stathmin, subsequently increasing the pool of unphosphorylated 
stathmin.  High unphosphorylated stathmin levels therefore promote microtubule 
destabilisation which in turn promotes enhanced cell motility of MCPyV ST 
expressing cells.   
 
In summary, while the role of MCPyV ST in the proliferation of MCC tumour cells is 
controversial within the field, findings here highlight the pivotal role PP4C plays in 
MCPyV ST-induced microtubule destabilisation and cell motility. Importantly, two 
novel interactions have been characterised which allow a model of MCPyV ST-
induced cell motility to be established.  This data suggests novel virus-host 
interactions which may allow for therapeutic intervention and chemotherapy 
regimes to be established.   
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6. Final discussion and future perspectives 
MCC is a skin cancer of neuroendocrine origin and arises from Merkel cell situated 
within the basal layer of the epidermis.  Merkel cells are mechanoreceptor cells, 
stimulated by light touch and form the Merkel-cell neurite complex, one of the four 
main mammalian sensory receptors179.  MCC is a highly aggressive skin cancer with 
a propensity to spread through the dermal lymphatic system and is associated with 
a poor 5 year survival rate and early establishment of distant metastases186,187.  It 
has now been established that MCPyV is the causative agent in the MCC tumour 
development and is monoclonally integrated in 80-90% of both primary and 
metastatic tumour forms71.  Furthermore, all MCPyV LT sequences derived from 
MCPyV-positive tumour cells demonstrate tumour specific mutations that render 
the virus replication defective71.  Due to the monoclonal integration pattern and 
acquisition of tumour specific mutations, the notion that MCPyV may be a 
passenger virus has been dismissed.  
MCC tumour formation is effectively an indirect result of monoclonal integration of 
the MCPyV genome within the host chromosome, resulting in impaired viral 
replication.  Interestingly, indirect promotion of metastasis is not without 
precedence, as several  tumour-associated viruses, such as HPV, EBV and SV40 have 
all demonstrated the capacity to promote metastasis.  The mechanisms vary, but 
include alteration of cellular adhesion complexes, matrix metalloproteinase 
production, gene expression modulation and cytoskeletal reorganisation299,378,379.   
Since the discovery of MCPyV, several studies have highlighted a role for the MCPyV 
T antigens, in viral replication and tumour formation227,247,281.  It has also been 
demonstrated that expression of MCPyV ST is sufficient to promote anchorage 
independent growth of rodent cells and facilitate transformation247.  However, to 
date, no studies have addressed the underlying molecular mechanisms that 
promote MCC metastasis nor the potential role of the MCPyV T antigens in this 
phenotype.   
Therefore, using a cell line capable of inducible expression of MCPyV ST, high 
throughput quantitative SILAC-based proteomic analysis was conducted to enable 
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differentially expressed proteins to be identified upon MCPyV ST expression.    
SILAC-based analysis coupled with LC-MS/MS and bioinformatical analysis is an 
effective way in which to study the host cell proteome, and has recently been 
established as a highly informative tool for studying virus-host interactions377.    
Furthermore, this technique is capable of reducing the sample complexity and 
allows analysis of subcellular trafficking between various cellular compartments.   
Through this approach, the bioinformatical analysis highlighted that MCPyV ST 
promotes the differential expression of numerous proteins involved in cytoskeletal 
processes, particularly those associated with microtubule regulation, organisation 
and dynamics.  While it has been established that the microtubule network is 
pivotal for intracellular vesicle transport, organelle positioning and mitotic spindle 
formation324,326,327, there is also an emerging role of the microtubule network in the 
control of cell shape and polarised cell motility322,328.   
Following identification of crucial pathways altered upon MCPyV ST expression, it 
was necessary to determine if any key proteins involved in microtubule dynamics 
were upregulated.  Importantly, the bioinformatical analysis highlighted that one of 
the most upregulated proteins, was the microtubule-associated protein, stathmin.  
To confirm this result, stathmin protein levels were examined and MCPyV ST 
expression was shown to correlate with upregulation of stathmin in both i293-ST 
and MCPyV-positive MCC cells, in addition to formalin-fixed, paraffin embedded 
sections of primary MCC tumours.   
Previous studies have demonstrated that stathmin overexpression is a feature of 
multiple cancer types and has been shown to correlate with tumour growth, poor 
patient prognosis and a high metastatic potential340,354.  Furthermore, this has been 
confirmed by RNA interference studies that demonstrate that decreased stathmin 
levels can drastically reduce the motility of various tumour cells355,358.   As such, the 
data presented here, suggests that MCPyV ST may contribute to the metastatic 
phenotype of MCC tumour cells through alterations in crucial cytoskeletal 
regulatory proteins, specifically by promoting the overexpression of stathmin. 
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Despite this, the mechanism by which stathmin promotes metastasis and tumour 
development is still poorly understood, however it is known that stathmin is a key 
regulator of the microtubule network and has inherent microtubule destabilising 
abilities.  Furthermore, recent findings have been able to distinguish the indirect 
and direct manner in which stathmin can promote both microtubule destabilisation 
and promote catastrophe, through the use of distinct stathmin mutants340,385.  
Using mutation studies it has been shown that overexpression of wild type stathmin 
and a mutant containing only the tubulin sequestering activity resulted in a 
significant decrease in stable acetylated microtubules and an enhancement of cell 
motility355.  This suggests that there is a strong link between stathmin 
dephosphorylation, microtubule destabilisation and enhanced cell motility.   
Findings presented here, demonstrate that MCPyV ST expression promotes cell 
motility, migration and invasion and this was confirmed using a range of cell types, 
such as i293-ST, MCC13 and MKL-1 cells.  For accuracy a range of motility assays 
and techniques were employed, from live cell imaging and tracking, to 2D scratch-
wound healing assays and 3D migration and invasion transwell assays.  All motility 
assays used demonstrated that MCPyV ST expression, coincident with stathmin 
upregulation, promoted a statistically significant increase in cell motility, and 
further highlighted the important role of MCPyV ST in metastasis.   
In contrast,  recent data has suggested that certain cell types with stathmin 
overexpression and altered microtubule dynamics has been shown to be 
insufficient to promote cell motility in 2D would closure assays355,385,386.  However, 
the underlying molecular mechanisms have yet to be identified and it has been 
speculated that there may be a link with specific molecular mechanisms that 
regulate cell shape and morphology387,388.  This is interesting as previous studies 
have demonstrated that a less phosphorylated stathmin mutant can promote 
alterations in cell morphology and promote a rounded cell shape with amoeboid-
like protrusions, thus allowing enhanced cell motility through bleb-like propulsion 
mechanisms340.  These findings suggest that stathmin overexpression may result in 
a more dynamic and flexible microtubule network.  Moreover, as the microtubule 
network forms a crucial regulatory component of healthy cells, any alterations may 
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induce changes in other arms of the cytoskeletal network which may contribute to 
additional morphological changes and enhance cell motility.  In particular, depletion 
of stathmin has been shown to affect the activation of the Rho-Rho associated 
coiled-coil forming serine/threonine kinase signalling pathway, an important 
regulator of actin cytoskeletal remodelling, though phosphorylation of cofilin and 
myosin light chains, and the microtubule network358.   
Interestingly, herein bioinformatical analysis highlighted that other gene ontology 
groupings consisting of more general cytoskeletal changes were altered upon 
MCPyV ST expression.  Importantly, initial findings demonstrated that there were 
significant alterations in the actin cytoskeletal network structure upon MCPyV ST 
expression, consistent with filopodia or lamelipodia formation. The actin 
cytoskeletal network has long since been established as crucial mediator of cell 
motility321, and is an important aspect of MCPyV ST biology that is currently under 
investigation.   
Furthermore, findings here demonstrate that upon expression of MCPyV ST the 
pool of unphosphorylated stathmin is significantly increased.  Unphosphorylated 
stathmin activity has been shown to promote microtubule destabilisation and 
catastrophe, along with enhanced cell motility340,354,364,365.  Herein, it has been 
demonstrated that MCPyV ST expression promotes destabilisation of the 
microtubule network and a decrease in stable acetylated tubulin levels, further 
confirming the importance of stathmin in regulating microtubule dynamics. The 
role of stathmin as a microtubule destabilising protein has long since been 
established, however to date, few cellular phosphatases have been directly 
implicated in regulating stathmin phosphorylation.  It has been demonstrated that 
treatment with okadaic acid results in inhibition of cellular phosphatases, leading to 
a significant increase in phosphorylated stathmin389.  This indicates a role for 
protein phosphatases type 1, type 2A and type 2B in stathmin dephosphorylation.  
Furthermore, it has been suggested through the use of in vitro dephosphorylation 
assays, that stathmin dephosphorylation occurs through the sequential activity of 
multiple cellular phosphatases389.   
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It has been demonstrated that MCPyV ST has specific binding sites which facilitate 
interactions with multiple cellular phosphatases, including PP2A Aα, PP2A Aβ and 
PP4C226,247.  Interestingly, these cellular phosphatases have been previously 
implicated in microtubule regulation and dynamics375,383,390, thereby suggesting a 
possible link between these phosphatases and MCPyV ST-mediated microtubule 
destabilisation.  Moreover, PP4C has previously been shown to affect the correct at 
timely organisation of the microtubules at the centromsome, through the 
regulation of NDEL1 and the recruitment of katanin p60384.  Data presented here, 
indicates the likely role of the cellular phosphatase PP4C in MCPyV ST-induced 
microtubule destabilisation and in the promotion of cell motility, whereby 
expression of an inactive PP4C mutant is capable of inhibiting MCPyV ST-mediated 
microtubule destabilisation.  
Furthermore, these findings highlight a novel interaction between PP4C and 
stathmin and for the first time an interaction between MCPyV ST and stathmin.  
This allows a model of MCPyV ST-mediated cell motility to be established. Whereby 
expression of MCPyV ST promotes the upregulation of stathmin, in a                    
post-transcriptional manner, believed to be a result of MCPyV ST deregulation of 
cap-dependent translation, through preservation of the hyperphosphorylated state 
of the translation initiation factor, 4E-BP1.  Evidence here suggests that the ability 
to MCPyV ST to interact with stathmin, may facilitate an interaction between 
stathmin and PP4C, and the subsequent dephosphorylation of stathmin.  This in 
turn results in an increase in the cellular pool of unphosphorylated stathmin, 
thereby promoting stathmins’ microtubule destabilising properties and enhanced 
cell motility and migration.  
Historically, identification of MCC tumours was particularly difficult and often 
mistaken for small-cell carcinoma of the lung, which presents as a visibly similar 
tumour190.  However, recently, a robust MCC detection system has been developed, 
and requires positive CK20 staining along with neuroendocrine biomarkers such as 
chromatogranin and somatostatin194.  Despite this improved detection system, the 
management and treatment of MCC is a concerning issue and there is no specific 
therapeutic regime available.  Current regimes used to treat MCC are those used for 
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small-cell carcinoma of the lung, however none have shown to increase the survival 
of MCC patients203.  Therefore, it essential to understand the molecular biology of 
this disease in order to enable optimal treatment and care for patients. 
The discovery of a novel polyomavirus associated with MCC, provides an important 
aspect in understanding MCC tumour formation and development and may provide 
potential therapeutic targets and novel virus-targeted chemotherapy regimes.  The 
recent study into MCPyV has highlighted the important role of MCPyV LT in the 
upregulation of survivin, which is essential for the survival of MCPyV-positive MCC 
cells281.  Furthermore, this study demonstrated that treatment with a small 
molecule inhibitor of the survivin promoter, YM155, activates cell death pathways, 
specifically in MCPyV-positive cell lines and delayed formation of MCC xenografts in 
mice models.   
Herein, results demonstrate that MCPyV ST-mediated cell motility, a result of 
microtubule destabilisation, may be a possible therapeutic target for the treatment 
of MCC.  The group of chemotherapeutic drugs known as taxanes, have been widely 
used for a number of years, in combination with other therapeutics, in order to 
treat a variety of different cancers types.  Taxanes are microtubule inhibitors which 
directly bind to the microtubule structures and stabilise them, thus may be of 
benefit in the treatment of MCC.  Findings presented here demonstrate that 
treatment with taxane compounds inhibits both MCPyV ST-mediated microtubule 
destabilisation and MCPyV ST-induced cell motility.   Moreover, these drugs are 
already in use in the clinic, thus could potentially be used to treat MCC patients 
within a few years, in an endeavour to prevent metastasis of MCC tumour cells 
from the primary carcinoma.  However, there are significant side effects associated 
with Paclitaxel treatment and it is usually reserved as an end-stage drug.  
Furthermore its use is restricted on a patient by patient basis, due to the acquisition 
of multi-drug resistance (MDR) to one or more of these compounds.       
However, in the last few years newly developed Paclitaxel derivatives have entered 
clinical trials, such as the nanoparticle paclitaxel (FDA approved Abraxane®), which 
has proved its efficacy in both breast and non-small cell lung cancer clinical trials.  
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Furthermore, three new taxanes have been isolated from the Japanese Yew, and 
may provide treatment for early diagnosed cancer patients391.  Thus it would be 
encouraging to determine if these newly developed taxanes are able to prevent 
MCPyV ST-mediated microtubule destabilisation.  .    
Furthermore, in order to overcome taxane MDR, novel microtubule-targeting 
compounds have since been developed.  The class of compounds referred to as, 
epothilones, isolated from myxobacterium Sorangium cellulosum, can be used to 
treat taxane resistant cell lines and xenograft tumours391,392.   Once again, it would 
be useful to determine if these class of compounds have the same inhibitory effects 
on MCPyV ST-induced cell motility compared to taxanes.   
The upregulation of stathmin, is key to the ability of MCPyV ST to promote cell 
motility and may provide novel therapeutic targets for the treatment of MCC 
patients.  Interestingly, gene profiling of melanoma cells identified that the 
microRNA, miR-193b, specifically targets stathmin and that ectopic expression of 
miR-193b decreases stathmin protein levels and reduces the ability of melanoma 
cells to migrate356.  This demonstrates that the use of RNAi-based therapies may be 
a viable solution to decreases stathmin levels upon MCPyV T antigen expression.  
More specifically, findings herein demonstrate that siRNA depletion of stathmin 
inhibits MCPyV ST-induced cell motility and migration in MCPyV-positive cells lines.  
This indicates that RNAi-based therapies, delivering stathmin-specific siRNAs 
through the use of virus-based delivery systems or biodegradable nanoparticles, 
may be a successful new chemotherapeutic regime in order to prevent cell motility 
and metastasis associated with MCC.  Furthermore, the development of small 
molecule inhibitors that prevent MCPyV ST interacting with PP4C and/or stathmin, 
may prevent stathmin dephosphorylation and MCPyV ST-induced cell motility.   
While the role of MCPyV ST in the promotion of cell proliferation is controversial, 
data herein highlights the fundamental role of MCPyV ST in enhancement of cell 
motility and migration.  This is the first study to demonstrate that MCPyV ST 
promotes the differential expression of cytoskeletal proteins, with specific regard to 
the upregulation of stathmin.  Furthermore, these findings highlight the essential 
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role of MCPyV ST and stathmin in MCPyV ST-mediated microtubule destabilisation 
and cell motility.  Importantly, the interaction between MCPyV ST and the cellular 
phosphatase catalytic subunit PP4C has been implicated and provides a novel 
molecular mechanism for MCPyV ST-mediated cell motility.  Moreover, this 
provides an explanation for the highly metastatic nature of MCC and demonstrates 
that stathmin may be a useful biomarker for MCC prognosis and in the future a 
viable therapeutic target for MCC treatment.  
Moreover, a fundamental aspect of cancer development and metastasis involves 
specific alterations within the host cell metabolism, and is now regarded as a 
‘Hallmark of Cancer’.  Cancer cell metabolism is the broad category, used to 
described specific adaptations within metabolic pathways that allows cancer cell to 
consume more glucose and produce a large quantity of lactose, a process known as 
aerobic glycolysis393.  While this process may generate less ATP than conventional 
mitochondrial respiration, the process is much more rapid394,395.  Thus providing the 
necessary energy required by cancer cells for increased cell proliferation, 
adaptation to the environment and provides energy for processes such as 
metastasis. 
Although not a focus of this thesis, the quantitative proteomic approach used 
herein highlighted that MCPyV ST expression also promotes alterations in the host 
cell metabolism, including pathways such as, glucose, serine, lactate and lipid 
synthesis. Importantly, key proteins in these pathways were upregulated upon 
MCPyV ST expression, such as pyruvate kinase, lactate dehydrogenase and serine 
synthesis enzymes.   Previous studies have demonstrated that overexpression of 
these proteins has been shown to facilitate aerobic glycolysis and promote the 
accumulation of upstream metabolic intermediates.  Thereby contributing to a shift 
in metabolism toward amino acid, nucleotide and lipid synthesis, all required in 
increasing amounts for maintenance and growth of cancer cells394,396.   
While the study of virus-host interactions in terms of the host cell metabolism has 
not been widely explored, there is precedence for metabolic alterations during viral 
infection.  Dramatic intermediary metabolic alterations have been demonstrated 
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during infection of human cell lines with human cytomegalovirus (HCMV), in a 
similar manner as those seen in tumour cells397.  Such changes could be attributed 
to pathogenesis and potentially implicate HMCV as a subtle cofactor in human 
malignancy. Furthermore, the human tumour-associated virus hepatitis C virus 
(HCV), has been implicated in the upregulation of host cell lipid metabolism through 
inhibition of AMP-activated protein kinase398,399.   
Despite the controversy within the MCPyV field regarding the role of MCPyV ST in 
cell proliferation, data herein suggests that MCPyV ST expression alone does not 
enhance cell proliferation or alterations in the cell cycle.  However, findings do 
suggest that MCPyV ST expression may promote alterations of specific metabolic 
processes that allow survival of cells in low nutrient conditions.  Conditions that are 
experienced by cancer cells in an expanding primary tumour environment286.   
However, this in itself represents a dichotomy as a switch to a cancer cell 
metabolism phenotype is generally consistent with an increase in cell proliferation.  
Interestingly, while data here indicates that MCPyV ST alone does not facilitate 
increased cell proliferation, the expression of both MCPyV LT and ST results in a 
significant increase in cell growth.  Importantly, research in the Whitehouse 
laboratory using a quantitative proteomic approach to investigate the role of 
MCPyV LT in the cellular proteome revealed that MCPyV LT expression promotes 
the differential expression of proteins involved in cell cycle control at G1-S phase.  
This suggests that MCPyV LT may directly promote increased cell proliferation 
through facilitating a switch from G1 to S phase and is consistent with the 
polyomavirus literature, whereby LT promotes progression to S phase to stimulate 
viral DNA replication227.  Alternatively, it may also be a result of the combined 
expression of both MCPyV T antigens that provide the necessary cellular pathway 
alterations in order to facilitate enhanced cell proliferation. This notion of 
cooperative T antigen activity is supported by evidence indicating that MCPyV ST 
expression promotes the stability of LT, and facilitates enhanced viral replicative 
functions227.   
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As previously mentioned, quantitative proteomic analysis highlighted the 
upregulation of pyruvate kinase (PK), a crucial candidate enzyme in facilitating the 
switch from normal host cell metabolism to aerobic glycolysis.  PK catalyses the last 
reaction in glycolysis and is essentially irreversible, thus lowering the activity of PK 
results in decreased pyruvate synthesis and accumulation of upstream metabolic 
intermediates396.   
The principle form of PK expressed in healthy non-cancerous cells is PKM1, however 
it has been demonstrated that cancer cell predominantly express an alternatively 
spliced isoform of PK, referred to as PKM2396.  PKM2 is a master regulator of 
glycolysis and is less activate thereby promoting aerobic glycolysis and 
accumulation of upstream metabolites.  To ensure the preferential splicing of 
PKM2, cancer cells have evolved a number of mechanisms involving enhanced 
expression of heterogenous nuclear ribonucleoproteins and polypyrimidine-tract-
binding protein.  Interestingly, analysis highlighted the upregulation of both of 
these protein subsets, suggesting that MCPyV ST expression may promote the 
preferentially splicing of PKM2.  
Importantly, other tumour-associated viruses have been shown to enhance PKM2 
expression, such as human papillomavirus-16 (HPV)400.  This suggests that 
upregulation of PKM2 by specific viral proteins may be a widely used mechanism by 
which to facilitate enhanced aerobic glycolysis thus enhancing cell proliferation and 
metastasis.      
As PMK2 is a master regulator of aerobic glycolysis and facilitates macromolecular 
synthesis, it also presents an attractive target for therapeutic intervention in cancer 
patients.  However, to date, this enzyme has not been targeted for virus-induced 
cancers.  In 2007, a seven amino acid peptide inhibitor of PKM2, referred to as    
TLN-232/CAP-232, underwent Phase II clinical trials in metastatic renal 
carcinoma401. The results were encouraging and the treatment well tolerated.  
More recently, in 2012, a large library of synthetic compounds were screened and 
two small water-soluble molecule inhibitors, with specific PKM2 selectivity were 
identified401. Furthermore, the compounds shikonin and alkannin also inhibit PKM2, 
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resulting in a 50% reduction in PKM2 levels, without affecting expression of 
PKM1401.  Consequently, these compounds could be used to inhibit glucose 
consumption, promote anaerobic glycolysis and exhibit the potential to be used as 
novel anti-cancer drugs.  
Furthermore, a range of PKM2 activators have been developed including, DASA-58 
and TEPP-46, both of which promote the tetramerisation of PKM2.  Thus shifting 
metabolism towards anaerobic glycolysis and respiration thought the TCA cycle, 
and consequently have been shown to inhibit tumour growth400.  Further 
characterisation of the MCC metabolic phenotype, may provide novel anti-viral and 
chemotherapeutic targets, such as PKM2, which may aid in the treatment of MCC 
and improve overall patient prognosis. 
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7.  Appendices 
7.1 Quantitative proteomics highlights that MCPyV ST promotes 
alterations in multiple cellular processes 
 
Table 7.1.  Bioinformatical analysis highlighting gene ontology groupings differentially expression 
upon MCPyV ST expression.  Proteins differential expressed upon MCPyV ST are highlighted under 
each gene ontology heading.  The uniprot accession number, protein name, fold increase in induced 
cells and peptides hits are referred to. 
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